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Towards Risk-Based 
Benefits and Harms
Benefits and harm
s
In virtually all European mammographic screening programs, age is the only risk factor to 
deﬁne the target group for population-based mammographic screening programs. This is 
also true for the Netherlands, where women aged 50 to 75 are invited for biennial mammo-
graphic screening. Age is one of the strongest risk factors for breast cancer, but not the only 
risk factor. Incorporation of additional risk factors to deﬁne and stratify the target group can 
potentially optimize breast cancer screening: more beneﬁts with less or the same harms. 
During her doctoral research Theodora Maria Ripping evaluated the beneﬁts and harms of 
mammographic screening stratiﬁed for multiple risk factors: socio-economic status (SES), 
family history of breast cancer, co-morbidity and breast density. In this thesis, she shows that 
the investigated risk factors aﬀect the risk of averting breast cancer death (beneﬁt) and/or 
the risk of false-positive screening outcomes and interval cancer (harms). Furthermore, she 
presents her search for the optimal method to quantify the extent of overdiagnosis and to 
express the percentage of overdiagnosis. 
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PART 1
PART I - CURRENT BENEFIT-HARM BALANCE

CHAPTER 1
General Introduction
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Part 1
15General introduction
Worldwide, breast cancer is the most common cause of cancer death in women. Breast 
cancer screening and treatment can benefit women who will develop breast cancer 
by averting their death from breast cancer. However, breast cancer screening can also 
harm women by detecting breast cancers that would not become symptomatic dur-
ing a woman’s lifetime (overdiagnosis) and by recalling women without breast cancer 
for further diagnostic follow-up (false-positives). Nowadays, the benefits and harms of 
screening are well recognized, even though the benefit-harm balance is still debated. As 
a consequence, the question arises: how can women benefit from breast cancer screen-
ing without causing too much harm?
BENEFITS
The main benefit of breast cancer screening is the prevention of breast cancer deaths. 
Mammographic screening detects breast cancers at an earlier stage with better treatment 
options, and thereby prevents death from breast cancer.1 In the 1970s and ‘80s, eight 
trials showed that mammographic screening is effective in reducing the breast cancer 
mortality. This led to the introduction of population-based mammographic screening pro-
grams in most European countries2 and mammographic screening recommendations in 
North America3-5. After the introduction of mammographic screening, evaluation of the ef-
fectiveness of mammographic screening continued using observational studies6 – includ-
ing incidence-based mortality7, case-control and trend studies8 – and modeling studies. 
Even though many studies have quantified the extent of breast cancer mortality reduc-
tion by mammographic screening, it is still topic of discussion. For example, one review on 
the breast cancer screening trials indicated that the breast cancer mortality achieved by 
screening is only 10% after 13 years of follow-up9, while another review of the same trials 
shows a breast cancer mortality reduction of 20%10. A review of observational studies from 
Europe shows higher breast cancer mortality reductions for mammographic screening: 
25% based on incidence-based mortality studies and 31% based on case-control studies.6 
HARMS
The major harms of screening are overdiagnosis and false-positives. These two harms 
are included in most benefit-harm balances of mammographic screening. Mammographic 
screening has, however, more harms, including interval cancers. In this thesis, we will fo-
cus on these three harms: overdiagnosis,  false-positives and interval cancers.
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Part 1 Overdiagnosis
Overdiagnosis is the detection of cancers that would not present symptomatically dur-
ing one’s lifetime in the absence of screening.11 It is the reverse side of early detection 
by screening: early detection can lead to benefit, but can also result in detection of pre-
clinical breast cancers that would not become clinically relevant during a woman’s lifetime 
and are thus overdiagnosed.  
Overdiagnosis is regarded as the major harm of mammographic screening. First be-
cause overdiagnosis transforms healthy women into cancer patients, a change that would 
not take place without screening. The second and main harmful consequence of overdi-
agnosis is treatment of overdiagnosed cancers, so-called overtreatment. Overtreatment 
does not necessarily have to be a consequence of overdiagnosis. Currently, it is, however, 
a direct consequence of overdiagnosis because overdiagnosed cancers cannot yet be dis-
tinguished reliably from life-threatening cancers. 
The extent of overdiagnosis is a topic of debate with estimates varying from 0% to 
57% (or even to 75%12).11,13 The main drivers of the uncertainty surrounding the extent 
of overdiagnosis are the lack of agreement on the definition of overdiagnosis and the un-
availability of good data and methodology to estimate overdiagnosis.
False-positives
A woman experiences a false-positive result when she is recalled after screening for fur-
ther diagnostic follow-up, while she has no breast cancer. It occurs when a radiologist is 
unable to decide on basis of a mammogram alone whether a suspicious finding is cancer 
or when a radiologists refers women with high suspicion of breast cancer that cannot be 
confirmed. Further diagnostic follow-up is required and can be non-invasive, such as ad-
ditional imaging, or invasive, such as a biopsy. 
False-positives, in particular those requiring invasive work-up, have a negative impact 
on psychological state14-16 and are therefore regarded as a harm of breast cancer screen-
ing. Furthermore, false-positives may affect screening attendance: a review showed that 
women from the US were more likely to return after a false-positive result16, while false-
positives had a negative impact on screening attendance in women from the Nether-
lands17 and Europe.16
A false-positive result is a harmful consequence of screening that can be quantified 
per screening round. Nevertheless, to balance the benefits and harms of screening, it is 
more informative to express the risk of a false-positive for the same time period as the 
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benefits of screening and the harm of overdiagnosis: a screening lifetime. The extent of 
this, so-called, cumulative risk of false-positives varies by setting, with the US having much 
higher risks than Europe and Australia18, and by personal characteristics19, such as family 
history of breast cancer20. 
Interval cancers
Interval cancers are breast cancers that are detected between two subsequent screening 
examinations. Interval cancers can be missed at mammography due to readers’ errors or 
masking of the detectable cancer, i.e. so-called false-negatives. Most interval cancers are, 
however, mammographically occult or not detectable at mammography.21,22 
In contrast to false-positives and overdiagnosis, detection of an interval cancer is not 
a side effect of screening, but a limitation of screening.22 Without breast cancer screening, 
overdiagnosis and false-positives would be non-existent, while an interval cancer would 
still be detected as cancer. Nevertheless, interval cancers are regarded as a harm of mam-
mographic screening because women with an interval cancer did not benefit from early 
detection and treatment. 
As with false-positives, the cumulative risk of interval cancers over a screening lifetime 
is most relevant for the benefit-harm balance of breast cancer screening. Overall, interval 
cancers comprise about a quarter of all cancers detected in women participating in a bien-
nial screening  program.22 The extent of the cumulative risk of interval cancer is, however, 
likely to vary by screening interval and personal characteristics, such as breast density23.
BALANCE
The balance between the benefits and harms of mammographic screening is of crucial im-
portance: mammographic screening is only justified when its benefits outweigh its harms. 
This has been questioned. As a consequence, several groups have reviewed and balanced 
the benefits and harms of mammographic screening.10,24 Furthermore, other groups and 
organization have also created a balance in order to provide guidance and/or give recom-
mendations.3-5,9,25
The benefit-harm balances of mammographic screening differ drastically in their es-
timates of the benefits and harms and its balance. For example, the Nordic Cochrane 
Review concluded that “for every 2000 women invited for screening throughout 10 years, 
one will avoid dying of breast cancer and 10 healthy women, …, will be treated unneces-
sarily” as result of overdiagnosis.9 In contrast, EUROSCREEN concluded that the number 
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Part 1 of overdiagnosed cases was smaller than the number of breast cancer deaths prevented, 
i.e. “the chance of saving a woman’s life by population-based mammographic screening 
of appropriate quality is greater than that of over-diagnosis”.26 
Although the benefit-harm balances differ in their estimates and screening recom-
mendations, they all acknowledge that mammographic screening benefits some women 
and harms a number of other women. As a consequence, there is room for improvement 
in the benefit-harm balance of mammographic screening.27 Such improvement may be 
achieved by risk-based screening, also called ‘personalized screening’, where women are 
assigned to a screening regimen based on their breast cancer risk’.27,28  
Table 1.1 Effect of (risk) factors on the different aspects influencing the benefits and 
harms of mammographic screening 
 
(Risk) factors 
Affects*: 
Breast cancer 
risk 
Performance of 
mammographic 
screening Treatment 
Competing 
mortality/ 
death of all 
causes 
First-degree family 
history of breast 
cancer 
Yes Not likely Not likely Not likely 
Socio-economic 
status 
Yes Not likely Likely Likely 
Co-morbidity Not likely Not likely Yes Yes 
Breast density Yes Yes Not likely Not likely 
 
* Breast cancer risk influences a woman’s chance to benefit from screening: women with a higher 
risk of breast cancer also have a higher chance to benefit from screening. Performance of 
mammographic screening influences the benefit and risk of adverse screening outcomes (false-
positives and interval cancer). Adequate treatment after detection of breast cancer can influence 
both the benefit and harm of overdiagnosis. Lastly, competing causes of death will affect the benefit 
from screening. 
 
BENEFITS AND HARMS BY RISK FACTORS
A key assumption to risk-based screening is that the benefits (breast cancer deaths pre-
vented) and harms (false-positives, false-negatives and overdiagnosis) of screening vary 
by the risk for breast cancer. In this context, we selected four (risk) factors: a family his-
tory of breast cancer, socio-economic status (SES), co-morbidity and breast density. These 
four factors are expected to affect the benefit-harm balance of mammographic screening 
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in different ways, namely via breast cancer risk, mammographic screening performance, 
treatment after diagnosis and competing mortality (see Table 1.1).
Family history
A family history of breast cancer means that a woman has one or more relatives who 
were diagnosed with breast cancer. The strength of family history depends mainly on 
the presence or absence of genetic mutations (BRCA 1 and 2), relation with the affected 
relative, and the relative’s age at diagnosis. For example, women with one or two of the 
well-known breast cancer genes , i.e. BRCA 1 and BRCA 2, have a strong family history of 
breast cancer based on their breast cancer risk and are offered breast cancer screening 
outside the Dutch national screening program.29 The relation with the affected relative, 
sometimes in combination with the age of diagnosis, is more commonly used for women 
without a known genetic mutation and a family history. Often, there is a distinction made 
between first-degree family relatives (mother, sister(s) and daughter(s)) and second-de-
gree family relatives (grandmothers and aunt(s)). In this thesis, we will focus on women 
with a first-degree relative with a history of breast cancer.
In Western countries, about 15% of the population has a first-degree relative with a 
history of breast cancer.30-32 Women with a family history have about a two-fold risk of 
breast cancer compared to women without a family history.33,34 This risk is altered by the 
number of relatives33,34 and the age of breast cancer diagnosis of the relative(s)34: women 
with more relatives and younger age at diagnosis have a higher risk of breast cancer. Fur-
thermore, women with a family history have an increased risk to die from breast cancer, 
and therefore, mammographic screening may have a greater absolute benefit in women 
with a family history than in those without. Previous research has, however, also indicated 
mammographic screening may cause more harm in women with a family history: women 
with a family history have a higher risk of a false-positive result20,30,35,36  and interval cancer37. 
Until now, quantification of the benefits and harms of mammographic screening in 
family history groups remains limited: no observational studies have estimated the ab-
solute benefit of screening, overdiagnosis or the cumulative risk of interval cancers and 
false-positives in the screened age range. Only modeling studies have balanced the ben-
efits and harms of mammographic screening for risk-based screening including a family 
history.38-40 These studies indicated that risk-based screening may result in more favorable 
benefit-harm balances.38-40 Modeling studies do, however, rely on data and assumptions 
that may be incorrect38, and therefore, observational studies estimating the benefits and 
harms of screening are required.  
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Part 1 Socio-economic status
Socio-economic status (SES) refers to the social and economic position of an individual 
in the society. Although most people have a feeling what SES means and can classify in-
dividuals in high or low SES groups, SES itself is difficult to explain: it is not a uniform 
concept and it has different measures. SES can be measured using (a combination of) 
education, (family) income, occupation, (un)employment, affluence of communities, ur-
ban/rural, and crowded household condition. The most common measures of SES are, 
however, education, income and occupation, which are related to different domains of 
SES, i.e. class, state and power.41 In this thesis, we will use an SES indicator based on in-
come, unemployment and education, which was developed by the Netherlands Institute 
of Social Research (SCP-score).42
SES is related to many risk factors for breast cancer including reproductive factors (age 
at menarche, mother’s age at first birth) and lifestyle factors (use of hormone replace-
ment therapy, alcohol consumption).43,44 Overall, women with a high SES have ‘more’ risk 
factors for breast cancer than women with a low SES, e.g. women with a high SES have a 
higher age at first birth, consume more alcohol and are more likely to use hormone re-
placement therapy.43,45 As a consequence, breast cancer incidence and mortality in women 
over 50 years of age is higher in women with a high than low SES.44,46 Survival from breast 
cancer is, however, also higher in women with a high SES compared to women with a low 
SES, which may be explained by differences in screening uptake, tumor characteristics, 
and/or treatment.47,48 
So far, the benefits and harms of mammographic screening have not been estimated 
in women with a high and low SES, except for one study from the US that investigated the 
effect of median household income on the cumulative risk of false-positives.20 However, 
knowing that SES reflects a number of risk factors, insight in the benefit-harm balance for 
women with a high SES may provide valuable information for risk-based screening.
Co-morbidity
Co-morbidity is the co-existence of multiple chronic diseases in one individual. More par-
ticular for breast cancer, co-morbidity is the presence of another life-shortening chronic 
disease, such as cardiovascular disease or diabetes, next to breast cancer.  There are more 
than one hundred diseases that can affect the mortality and may influence survival from 
breast cancer. In this thesis, co-morbidity refers to the group of co-morbid conditions that 
have been shown to affect breast cancer survival, i.e. the diseases included in the Charl-
son’s Co-morbidity Index.49
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As for breast cancer, the incidence of most chronic diseases increases with age. For 
example, in the Netherlands, the percentage of women with breast cancer and one or 
more co-morbid diseases increases from less than 9% in women below 50 years of age 
to 20% in women aged 50-69 and to 41% in women aged 70-79.50 Unlike family history 
and SES, co-morbidity is not a risk factor or a proxy of a group of risk factors for breast 
cancer, but co-morbidity is likely to affect the benefit, and possibly also the harms51, of 
screening. Women with co-morbid diseases have a higher all-cause mortality and breast 
cancer specific mortality52, even when breast cancers are diagnosed early.53,54 Early detec-
tion by mammography seems, however, to confer a decreased risk of breast cancer death 
among women with mild to moderate co-morbidity.55 In contrast, (older) women with se-
vere or multiple co-morbidities seem to have no survival advantage from early diagnosis 
by screening.55,56 
Currently, a number of screening guidelines from the US recommend that a woman’s 
life expectancy and co-morbidity should be considered when recommending mammo-
graphic screening.4  This is supported by modeling studies, which indicate that screening is 
more cost-effective for the healthiest women.57 However, more observational studies are 
required to understand the benefits and harms of mammographic screening in women 
with co-morbidities.5
Breast density
Breast density is a measure to describe the tissue of the breast. Breasts have fatty tissue 
and non-fatty tissue, i.e. glandular tissue (milk ducts and lobules) and connective tissue. 
On a mammogram, fatty tissue is black, while non-fatty tissue and breast tumors are white. 
If there is much non-fatty tissue (>75%), the breasts will have a large amount of white area 
on the mammogram and are called ‘dense’. Breast density can be classified qualitatively 
using the Wolfe scale and quantitatively using the BI-RADS breast density scale. In this 
thesis, breast density is assessed visually and classified using the Wolfe scale.58
Breast density is a risk factor for breast cancer: women with dense breasts have about 
a two-fold risk of being detected with breast cancer compared to women with non-dense 
breasts.59,60  The effect of breast density is, however, not restricted to the risk for breast 
cancer: breast density also influences the test characteristics of the mammographic ex-
amination. Because non-fatty tissue and breast tumors appear both as white structures 
on a mammogram, dense breasts can mask tumors.60 As a consequence, breast density is 
expected to make mammographic screening less effective and to increase the risk of false-
positives and interval cancers.61
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Part 1 Currently, there is much interest in the use of breast density in risk-based screening, 
because breast density is a strong risk factor for breast cancer and it can be assessed from 
a mammogram. Besides, due to the limited performance of mammographic screening, 
breast density may require screening with additional modalities which is already recom-
mended in multiple states in the US that have adopted the Breast Density Law. There is, 
however, still discussion about the most appropriate way to use breast density in risk-
based screening. More information on the benefits and harms of mammographic screen-
ing in women with dense breasts could support decision making. 
THESIS OUTLINE
The main objective of this thesis is to contribute to  an optimization of the benefit-harm 
balance of mammographic screening via better understanding of the benefit-harm bal-
ance in risk-based screening and quantification of the harm overdiagnosis. In order to 
increase the understanding of the benefit-harm balance in risk-based screening, we will 
investigate the benefits and harms of mammographic screening for four factors, i.e. fam-
ily history, SES, co-morbidity and breast density. Furthermore, we will contribute to the 
quantification of the harm overdiagnosis by investigating the optimal method to estimate 
and communicate overdiagnosis. A schematic overview of this thesis is given in Figure 1.1.
In part I, we discuss several benefit-harm balances which were published by groups or 
organizations (Chapter 2). In this chapter, we show that the benefit-harm balances differ 
drastically in their estimates of the benefits and harms and their conclusions. We give 
some explanations for these differences and provide recommendations for further work.
In part II of this thesis, we study the effect of mammographic screening on breast 
cancer mortality, i.e. the main benefit of screening. In Chapter 3, we investigate whether 
the relative effect of mammographic screening differs between women with a high and 
low SES. For this purpose, we executed a case-control study in the Nijmegen population 
(The Netherlands). Chapter 4 and 5 use the same approach to study the effect of mammo-
graphic screening on breast cancer mortality stratified by co-morbidity and breast density, 
respectively.
Next to the benefits, we also study the major harms of mammographic screening. In 
part III, we estimate the cumulative risk of false-positive results and interval cancers strati-
fied by risk factors for breast cancer. Chapter 6 presents the cumulative risks for women 
with and without a first-degree family history and Chapter 7 focuses on the cumulative 
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PART II
BREAST CANCER
MORTALITY REDUCTION
PART IV
OVERDIAGNOSIS
PART III
FALSE-POSITIVES + 
INTERVAL CANCERS
PART I - CURRENT BENEFIT-HARM BALANCE
PART V - RISK-BASED BENEFIT HARM BALANCE
Figuur 1.1. - Thesis outline
risk for women with a high and low SES. Because the existing methods to estimate the 
cumulative risks were not optimal for our setting, we also investigated which method is 
most optimal to estimate the cumulative risk of each screening outcome in the Nether-
lands and the US (Chapter 8).
The third and major harm of screening, i.e. overdiagnosis, is investigated in part IV. 
The major focus is to improve the methodology used to estimate overdiagnosis and con-
tribute to comparable overdiagnosis estimates. We start by  explaining why it is more 
suitable to estimate overdiagnosis in birth cohorts than periods (Chapter 9). Then, we 
use two approaches to estimate overdiagnosis in the Netherlands: adjustment for the 
effect of screening (Chapter 10) and extrapolation of pre-screening trends (Chapter 11). 
Furthermore, we give an overview of all methods to estimate overdiagnosis in the review 
presented in Chapter 12. In order to contribute to comparable overdiagnosis estimates 
by screening, we also propose a definition for overdiagnosis by screening in Chapter 13.
This thesis is concluded with part V in which we integrate our results in a general dis-
cussion (Chapter 14). We present the benefit-harm balance of each (risk) factor studied 
and discuss the future of breast cancer screening. 
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ABSTRACT
Breast cancer screening aims to reduce mortality, but the screening process introduces 
harm as well as benefit. Over the past several decades, mammographic breast cancer 
screening has been the subject of controversy with questions focusing on whether the 
benefits outweigh the harms. In light of this debate, this chapter evaluates evidence re-
views from North America and Europe that have been used to guide decision-making or 
have served as the basis for recommendations for screening mammography. It provides 
a detailed explanation of methodological differences between the reviews that partly ex-
plain variations in their conclusions and provides recommendations to those designing 
and applying harm/benefit balance sheets. The chapter concludes with a discussion of 
some future challenges, such as the introduction of new screening modalities and person-
alized screening, that are likely to affect the balance of benefits and harms.
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PLAIN LANGUAGE SUMMARY
Breast cancer affects millions of women worldwide. Screening mammography has the 
potential to detect breast cancer early, leading to more effective treatment, reduced 
chance of metastasis, and better survival and quality of life for the patient. Large trials 
performed in the 1970s and 1980s showed that breast cancer mortality was lower in 
women who were invited for mammography screening. This led to widespread implemen-
tation of breast cancer screening, predominantly in Western Europe and North America. 
However, the implementation of screening introduced harms in addition to benefits. The 
major harm of breast cancer screening is overdiagnosis, the detection of a breast cancer 
that would never have become symptomatic during a woman’s lifetime in the absence of 
screening. False-positive test results, a positive screening mammography result in a wom-
an who does not have breast cancer, are the most common harm. Over recent decades, a 
debate has been ongoing as to whether the benefits of breast cancer screening outweigh 
the harms. In an effort to guide decision-making, a number of organizations have summa-
rized the available evidence in reviews, balance sheets and screening recommendations, 
aiming to help women and their physicians make an informed choice about screening. 
Despite the fact that all reviews are based on evidence from similar sets of trials and ob-
servational studies, some have concluded that screening should be stopped, while others 
recommend continuation of screening activities. In this chapter, we show that the differ-
ences between these reviews are at least partly related to choices about which studies to 
include, which screening strategies to consider, and how screening harms and benefits are 
defined. One of the challenges is that estimates of breast cancer mortality reduction due 
to screening are generally based on ‘old trials’ and do not consider more recent observa-
tional studies that have evaluated mortality reductions using data from modern screening 
programs. Harms, on the other hand, are almost exclusively assessed based on today’s 
screening practice. Another factor that complicates the comparability of the reviews is 
that the benefits and harms are not expressed in the same way, using different mea-
sures and populations. Finally, there are differences across countries in the organization of 
health care, cultural factors and medicolegal considerations that shift the relative balance 
of harms and benefits. This is best illustrated in the large difference in the risk of a false 
positive screening result, which is much higher in the USA compared to Europe. Future 
evaluations of the benefits and harms of breast cancer screening should base estimates 
of breast cancer mortality, overdiagnosis and false-positives on the same screening set-
ting, including time period, age, screening test, screening frequency, and organization of 
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screening. If the aim is to compare the balance of harms and benefits between countries, 
it is important to ensure that the balances are indeed comparable. Finally, those creating 
or applying balance sheets should be aware that additional challenges lie ahead with the 
implementation of new screening tests and more personalized screening strategies. All of 
these are likely to affect the current balance of benefits and harms.   
INTRODUCTION
The primary aim of breast cancer screening is to reduce mortality from the disease, but it 
is well-understood that screening does harm as well as good. Mammography is the pre-
ferred screening test for early detection of breast cancer and has been studied in more 
than 600,000 women in 11 randomized trials over the past 50 years. Over the past sev-
eral decades, mammographic breast cancer screening has been the subject of contro-
versy, with some questioning whether the benefit in terms of mortality reduction is large 
enough to justify the recognized harms of screening, in particular overdiagnosis.1 Others 
reviewing essentially the same accumulated evidence have concluded that the pros out-
weigh the cons.2 
In light of this debate, this chapter focuses on reviews that evaluate the balance of 
screening mammography benefits and harms that have been used to guide decision-
making or provide recommendations for breast cancer screening. We have selected the 
reviews to represent evidence from different settings where screening practices vary, but 
acknowledge that many more reviews could potentially have been included. In this sense, 
the selected reviews serve as examples to illustrate how researchers and decision makers 
reach conclusions on the balance of benefits and harms. This provides the background for 
a discussion of the methodologies used to determine this information and present results 
and conclusions. 
The balance of the benefits and harms of a breast screening program can be com-
municated in a number of ways and to a variety of audiences. The format depends on the 
purpose of the balance and the intended audience. In this chapter, the focus is on benefit/
harm balance sheets as presented in the scientific literature rather than communication 
to individual women or decision makers. However, these scientific balance sheets should 
serve as the primary source of information for estimates communicated to women in the 
target population, health professionals and policy makers. Outcome measures may be 
chosen according to the purpose of communication, but by necessity should be based on 
the same evidence. However, recommendations based on the same evidence may still dif-
fer, depending on the relative weight that is placed on different outcomes. 
BENEFITS 
Breast cancer mortality reduction
Screening mammography aims to reduce breast cancer mortality through detection and 
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treatment of tumors at an early stage, leading to better survival than symptomatically de-
tected tumors. As such, there is agreement across all reviews presenting a harm/benefit 
balance sheet on relative or absolute reductions in breast cancer mortality as the main 
benefit of screening. Nevertheless, some authors have suggested adopting all-cancer or 
all-cause mortality as the main outcome measure in order to avoid overestimation of the 
benefit due to bias in cause of death classification.3 Several studies have explicitly assessed 
the quality of cause-of-death determination in relation to mammographic screening and 
have found no significant evidence of bias.4-6 Further, the randomized trials of screening 
mammography were not designed to estimate overall or all-cancer mortality and were 
thus not powered to adequately estimate these outcome measures. Absence of evidence 
for an effect on these outcomes can thus not be taken to indicate evidence for absence of 
an effect. Estimates of screening benefit from randomized trials and observational studies 
are further detailed in Chapters 3 and 5*, respectively. 
Effects of screening on breast cancer mortality can be quantified as lives saved or life-
years saved. Evidence reviews typically translate decreases in breast cancer mortality risk 
into absolute effects in terms of lives saved. However, since absolute risk is higher among 
older women, most of the benefit accrues at older ages in which the total number of 
life-years saved may be relatively small.7 Life-years saved attributable to breast cancer 
screening have been reported by some cost-effectiveness analyses8, but are not generally 
included in evidence reviews.
Other benefits 
Early detection of breast cancer only confers benefit if it is followed by appropriate treat-
ment, resulting in a more favorable outcome than would have been achieved had the 
treatment been given later in the course of disease or not at all. Early detection and treat-
ment are also expected to improve quality of life for the women diagnosed, since less 
invasive procedures are more likely to be an option when the tumor is detected at a more 
favorable stage, e.g. breast conserving surgery as opposed to mastectomy. Thus the ma-
jority of women participating in screening do not experience a benefit, and even those 
with a screen-detected cancer benefit only if earlier treatment leads to reduced morbidity 
and mortality. Although improved quality of life is expected to result from screening for 
some women, this benefit is not typically considered in balance sheets. 
Since the ultimate impact of service screening on breast cancer mortality is inevitably 
long-term, there are several indicators that can assess the performance of a screening 
* Refers to chapters 3 and 5 of the book ‘Breast Cancer Screening’ edited by Houssami N. and Miglioretti D.
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program in its early phases and that can also be used to predict whether an effect on 
breast cancer mortality is likely. These early benefits are mostly related to the stage shift 
that is introduced with screening and is expected to result in a higher rate of small cancers 
and a lower rate of advanced cancers.9 Although these measures are intuitive, there are 
many methodological challenges associated with their definition and interpretation.10,11 
Moreover, assumptions need to be made in order to estimate their consequent effect on 
breast cancer mortality.2 The latter may explain why these outcomes are not usually con-
sidered in the evidence reviews.
HARMS
Overdiagnosis & overtreatment
Overdiagnosis, and resulting overtreatment, is regarded as the major harm of breast can-
cer screening. In cancer screening, overdiagnosis is defined as the detection of cancers 
that would not present symptomatically during one’s lifetime in the absence of screening. 
Although there is ongoing research focusing on identification of overdiagnosed tumors12, 
at present the extent of overdiagnosis can only be estimated on the population level by 
comparing breast cancer incidence in the presence and absence of screening or by using 
simulation models. 
Overdiagnosis is harmful in two major ways. The first harm is simply due to the un-
necessary detection of a breast cancer. This diagnosis transforms women into cancer pa-
tients, a transformation that would not have taken place in the absence of screening. The 
second and major harm of overdiagnosis is overtreatment. Although some tumors will not 
become life-threatening during the lifespan of the woman, it is currently not possible to 
distinguish dangerous from non-life-threatening cancers. As a consequence, women with 
an overdiagnosed cancer receive unnecessary treatment, referred to as overtreatment. To 
prevent unnecessary treatment, a few trials have begun to compare usual care with active 
surveillance, a ‘wait-and-see’-procedure, for cancers that have a high risk of being over-
diagnosed, i.e. low grade ductal carcinoma in situ (DCIS). In a ‘wait-and-see’-procedure 
cancers are only treated if and when they progress.13,14 
The extent of overdiagnosis in breast cancer screening remains highly uncertain, with 
estimates ranging from 0 to 54%.15,16 A major reason for this disagreement is the difficulty 
in estimating overdiagnosis. Overdiagnosis in cancer screening can be estimated with a va-
riety of study designs, including randomized trials, pathological or imaging studies, model-
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ing studies, and observational studies.15,17  In breast cancer screening, the most common 
designs are randomized trials2,3, observational studies16 and modeling studies17,18. However, 
each design has limitations (See chapter 6*). In randomized trials and observational stud-
ies, overdiagnosis is estimated by comparing breast cancer incidence in the presence and 
absence of screening. Breast cancer screening works by identifying cancers at an earlier, 
more treatable stage. As a result, after the initiation of screening there will be a tran-
sient increase in breast cancer incidence. In the absence of overdiagnosis, this increased 
incidence will be compensated for by a subsequent decrease in cancer diagnoses.15 To 
determine if the cancers diagnosed during screening were attributable to early detection 
or overdiagnosis, women should be followed after leaving screening to account for this 
effect. Ideally, this follow-up after leaving screening should be until death.2 In randomized 
trials, there may be incomplete adjustment for early detection, although women were 
followed for 15 years after leaving screening in the Canadian trials19 and in the Malmö tri-
al20. This leads to overestimation of the extent of overdiagnosis. In observational studies, 
longer follow-up periods are possible, but there is no comparable population that is not 
offered screening. As a result, breast cancer incidence in the absence of screening is esti-
mated using extrapolation of prescreening trends21, control regions22, non-attenders23,24, or 
adjustment for the effect of screening25. Because unscreened populations may differ from 
screened populations in characteristics that are also related to breast cancer incidence, all 
observational studies of overdiagnosis have the potential for bias. The primary limitation 
of using modeling studies to estimate overdiagnosis is the heavy dependence of overdiag-
nosis estimates from these studies on modeling assumptions such as lead time.15 
False-positives
False-positive test results are the most common harm of screening mammography. Con-
ceptually, a false-positive is defined as a positive screening mammography result in a 
woman who is cancer free. In the US and other settings where screening mammography 
interpretation is performed according to the American College of Radiology Breast Imag-
ing Reporting And Data Systems (BI-RADS) Atlas26, a positive examination has been opera-
tionalized as a screening mammography initial assessment of 0:Needs Additional Evalua-
tion, 3:Probably Benign, 4:Suspicious, or 5:Highly Suggestive of Malignancy. In organized 
screening programs such as those in Europe and Australia, a positive screening result is 
defined by recall for further evaluation. Typically, recalled women who are determined 
to be cancer free at the end of diagnostic evaluation and for one year after the recall are 
* Refers to chapter 6 of the book ‘Breast Cancer Screening’ edited by Houssami N. and Miglioretti D.
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considered to have experienced a false-positive. False-positive results can be sub-divided 
into those receiving further evaluation with imaging only and those that undergo invasive 
procedures including biopsy or fine needle aspiration.
False-positive test results have a number of negative consequences. The greater the 
false-positive risk, the lower the efficiency of the screening program and the more unnec-
essary imaging is performed. This adds to the overall resource use and cost of screening. 
False-positives also have negative psychological consequences for the affected women. 
Studies have found that women receiving false-positive test results experience increased 
anxiety and psychological distress.27 This anxiety and distress is greater in women who un-
dergo invasive procedures rather than additional imaging only.28 However, a recent study 
found that the associated anxiety resolved quickly once the women were determined to 
be cancer free.29 The experience of receiving false-positive test results can also be a de-
terrent to participation in future screening. This has been found to be the case in several 
of the organized screening programs in Europe and Canada.30 Conversely, in the United 
States women receiving false-positive test results have been found to be more likely to 
return for future screening.31 Finally, false-positive results lead to additional radiation ex-
posure through subsequent mammography and mammography-guided biopsy. Although 
radiation exposure due to mammography is small,32-35 the aggregate burden among wom-
en experiencing repeated false-positives could become large and should be minimized to 
avoid the increased risk of radiation induced cancer.
False-positive screening mammography results are common, occurring in approxi-
mately 10% of exams in the US36 and 1-7% of mammograms in European service screening 
programs.37 False-positives are generally more common in younger women and those with 
dense breasts.36 Because false-positive mammography results are common, the propor-
tion of women participating in regular screening who receive a false-positive result over 
the course of their screening participation is large. Most evaluations of the balance of 
harms and benefits have quantified this harm in terms of the cumulative false-positive risk 
of screening mammography, defined as the probability that a woman will receive at least 
one false-positive mammography result over the course of a fixed number of screening 
mammograms, typically either 10 or the total number recommended by the screening 
program. 
Other harms
There are a variety of screening mammography harms that are not typically explicitly in-
cluded when evaluating the balance of benefits and harms. When considering the harms 
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of screening, it is important to consider not only direct harms but harms that result indi-
rectly from downstream effects of the screening process, such as unnecessary treatment 
resulting from incidental findings.38 However, evidence reviews have not typically included 
indirect harms. 
Additional direct harms not typically considered by evidence reviews, can be divided 
into harms that are serious but very rare and those that are common but have a gener-
ally minor impact. A false-negative screening mammography result is one harm that is 
very serious but relatively rare. A false-negative occurs when a woman is diagnosed with 
cancer following a negative screening mammography assessment (in the BI-RADS lexicon, 
an assessment of 1:Negative or 2:Benign). A negative mammography result could give a 
woman false reassurance that she is cancer free and may lead to delays in seeking care 
for new symptoms.39 Some evaluations of screening mammography include measures of 
the diagnostic accuracy of screening mammography interpretation, which typically pro-
vide an assessment of false-negatives at a single screening round.36,40-42 However, these are 
not commonly included in evaluations of the balance of harms and benefits. Radiation 
induced cancer is another harm that is very serious but considered extremely rare.34,43  
Radiation induced cancer may be more of a concern in women with very large breasts 
or breast augmentation who require extra views at each exam for full coverage of breast 
tissue.35 Additional minor harms of screening mammography include the pain of the ex-
amination itself. A systematic review found that 28-77% of women report experiencing 
pain associated with mammography.32 Pain due to mammography has been found to be 
associated with discontinuation of screening.44  
REVIEWING THE BALANCE OF HARMS AND BENEFITS
We have selected a number of influential reviews from North America and Europe to 
serve as examples for the comparison of reviews of benefits and harms of breast cancer 
screening. In this section, we will describe the context of these reviews, the general ap-
proach adopted by the authors, the sources of data used and the main outcomes of the 
reviews, both in relative and absolute measures. Tables 2.1 to 2.3 summarize the data 
from these reviews for breast cancer mortality, overdiagnosis and the cumulative risk of 
false-positives.
North America
In North America, the landscape of guidelines for screening mammography is charac-
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terized by recommendations from numerous groups. A variety of independent panels, 
professional societies, and advocacy groups issue screening recommendations. Several 
of these conduct an evaluation of the balance of harms and benefits in order to support 
their recommendations, while others rely on existing evaluations. Canadian provinces of-
fer a defined screening mammography program to women age 50-69 but practices for 
younger and older women vary across provinces. No defined screening program exists in 
the USA, where it is left to individual providers and patients to make decisions that are in-
formed by recommendations. Guidelines issued by the US Preventive Services Task Force 
(USPSTF) are particularly influential because they inform Medicare coverage decisions 
and many private insurers follow the same coverage practices as the Center for Medi-
care and Medicaid Services. Below we summarize the evidence review conducted by the 
USPSTF45 as well as that of the Canadian Task Force on Preventive Health Care (Canadian 
Task Force)46,47, a similar independent panel for Canada. Finally, we discuss the American 
Cancer Society (ACS) guideline statement48 as an example of an influential North American 
organization issuing recommendations related to screening mammography.
US Preventive Services Task Force
The USPSTF is an independent panel authorized by the US Congress and supported by 
the Agency for Healthcare Research and Quality (AHRQ) to make evidence-based recom-
mendations about clinical preventive services. The USPSTF commissioned a review of the 
evidence on benefits and harms of screening mammography in preparation for an up-
date to their recommendations on screening mammography issued in 2015. The review 
included evidence on harms and benefits of mammography for all women age 40 years 
and older. Evidence on harms and benefits of other screening modalities including breast 
MRI and digital breast tomosynthesis was also reviewed. The USPSTF in conjunction with 
AHRQ developed the key questions used to structure the review. The review itself was 
then conducted by an independent contractor sponsored by AHRQ, the Pacific Northwest 
Evidence-based Practice Center.
The primary benefit of screening mammography as defined by the draft USPSTF evi-
dence review was reduction in breast cancer mortality.45 Other benefits considered includ-
ed reductions in all-cause mortality, advanced breast cancer cases, and treatment-related 
morbidity. Harms were radiation exposure, pain during procedures, patient anxiety and 
other psychological responses, false-positive and false-negative test results, overdiagno-
sis, and overtreatment. Evidence on breast cancer mortality was obtained from random-
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ized controlled trials of screening mammography in women age 40 and over. The evidence 
review identified eight eligible studies by searching the Cochrane Register of Controlled 
Trials, Cochrane Database of Systematic Reviews, and MEDLINE, as well as by manually 
reviewing references. Observational studies and systematic reviews were also included, 
although quantitative evaluation of breast cancer benefits was based on RCTs. A variety of 
evidence sources were used for evaluating harms. Systematic reviews and meta-analyses 
were included as well as recently published primary studies. Primary analysis of observa-
tional data on screening mammography from the Breast Cancer Surveillance Consortium 
(BCSC) was conducted to provide information on performance characteristics of screening 
mammography. Simulation modeling from the Cancer Intervention Surveillance Network 
(CISNET) as well as a new simulation model for radiation exposure were also incorporated.
A meta-analysis of the 8 trials included in the draft USPSTF evidence review estimated 
a relative risk (RR) of breast cancer mortality of 0.88 (95% CI: 0.73-1.00) for women age 
39-49 years. Similar estimates were obtained for women 50-59 and 60-69. For women 
over age 70 three trials met inclusion criteria, but results of the meta-analysis in this age 
group had broad confidence intervals indicating substantial uncertainty in the benefit (RR 
= 0.80 (95% CI: 0.51-1.28)). The evidence review summarized the absolute benefit cor-
responding to these RRs in terms of breast cancer deaths prevented by screening for 10 
years per 10,000 women screened. The number of breast cancer deaths prevented was 
estimated at 4.1 (95% CI, -0.1-9.3) for women aged 39-49, 7.7 (95% CI, 1.6 -7.2) for women 
aged 50-59, 21.3 (95% CI, 10.7-31.7), and 12.5 (95% CI, -17.2-32.1) for women aged 70-74. 
the number needed to invite (NNI), the number of women who must be invited to partici-
pate in screening mammography for 10 years in order to prevent 1 breast cancer death. 
For women age 40-49 and 50-59 the NNI was estimated at approximately 2,000 women. 
The draft USPSTF evidence review also included a summary of breast cancer mortality 
reduction based on observational studies using the results of the EUROSCREEN review. 
However, estimates based on observational studies were not incorporated into numerical 
summaries of breast cancer mortality reduction due to the risk of bias inherent in obser-
vational studies.
The evidence review for overdiagnosis found that estimates varied substantially across 
studies and methodologies. Included studies consisted of a meta-analysis of five trials, a 
systematic review of observational studies, and 17 individual studies. A meta-analysis of 
3 trials considered to be least biased, estimated overdiagnosis to be 19% (95% CI: 15%-
23%). In observational and modeling studies using varied methodologies, overdiagnosis 
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estimates ranged from <1%-54%. The risk of false-positive mammography at a single 
screening round was estimated using data from the BCSC. Estimates ranged from 65-121 
per 1,000 examinations across age groups. Two observational studies of cumulative false-
positive risk from the US were identified that met inclusion criteria. Overall, cumulative 
false-positive risk after 10 years of annual mammography was estimated at 61%. Risk was 
higher among women 40-49 with heterogeneously dense breasts (69%) or extremely 
dense breasts (66%).
Overall, the evidence review found a significant benefit of screening mammography cou-
pled with relatively frequent harms, with more modest benefits and more common harms 
in women under 50 years of age. On the basis of this review, the USPSTF issued new draft 
guidelines in 2015 supporting biennial mammography for women age 50-74 years. Rou-
tine screening for women younger than 50 was not recommended.
Canadian Task Force on Preventive Health Care
The Canadian Task Force is an independent panel that makes recommendations on 
preventive clinical services, similar to the USPSTF in the US. They commissioned the Evi-
dence Review and Synthesis Centre to undertake a review of screening mammography to 
support updated recommendations in 2011. Because the USPSTF had conducted an evi-
dence review using similar methodology in support of their 2009 breast cancer screening 
guidelines, the Canadian Task Force used the USPSTF evidence review and updated this 
review with studies published in the intervening period. The USPSTF review was used for 
evidence up to 2008 and updated with additional data through October 2011. The Cana-
dian Task Force review identified breast cancer mortality as the benefit of screening mam-
mography and expressed their results in terms of the number needed to screen (NNS) 
defined as the number of women who would need to be screened once every 2 years over 
about 11 years to prevent one breast cancer death. Results from nine trials were included 
in estimates of the benefit of screening mammography. The estimated NNS for women 
40-49 was 2,108, while for women 50-69 it was only 721. On the basis of a review of four 
primary studies and one prior systematic review, the Canadian Task Force estimated the 
overdiagnosis rate at 5 per 1,000 women screened. Unlike the USPSTF review, evidence 
reviewed on false-positive risk did not incorporate primary data and was expressed only 
in terms of the number of false-positives associated with one breast cancer death pre-
vented, not as a cumulative false-positive risk. The false-positive risk was found to be 
highest in the youngest age group at 690 false-positives per breast cancer death averted 
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compared to only 204 in the 50-69 year age group. 
The conclusions of the Canadian Task Force echo those of the USPSTF. The benefit of 
screening mammography was found to be smaller in younger women and harms were 
found to be more common. Screening every 2-3 years for women aged 50-74 was recom-
mended. Routine screening was not recommended for women under 50 years of age.
American Cancer Society
In 2015, the ACS updated their breast cancer screening guidelines based on an indepen-
dent systematic review conducted by the Duke University Evidence Synthesis Group, new 
analyses of observational data conducted by the BCSC, and data on burden of disease 
provided by the ACS Surveillance and Health Services Research Program. The benefit of 
screening mammography for the ACS review was defined as reduction in breast cancer 
mortality and increase in life expectancy and quality-adjusted life expectancy. Evidence on 
breast cancer mortality from RCTs, recent observational studies including at least 1,000 
women, and simulation modeling studies were included. New meta-analyses were not 
conducted, but pooled estimates of the relative risk of breast cancer mortality from meta-
analyses conducted by the Canadian Task Force, UK Independent Panel, and Cochrane 
review were considered. Absolute mortality benefit was expressed as the NNS biennially 
for 15 years to prevent one breast cancer death. Assuming a 20% or 40% mortality reduc-
tion, the NNS was 1,770 or 753 for women 40-49, 1,087 or 462 for women 50-59, and 835 
or 355 for women 60-69. The ACS guideline group concluded that there was evidence that 
screening mammography leads to increases in life expectancy and quality-adjusted life ex-
pectancy but concluded that uncertainty about key parameters related to life expectancy 
precluded quantification of this benefit. 
Harms included in the ACS evidence review were false-positive results, overdiagnosis, 
and overtreatment. Evidence on false-positive results was derived from two observational 
studies using data from the BCSC. Both observational and modeling studies of overdiagno-
sis were reviewed, but the ACS concluded that all existing studies relied upon unverifiable 
assumptions or were subject to potential biases. They therefore concluded that the risk of 
overdiagnosis could not be quantified using the available evidence.  
On the basis of this evidence, the ACS recommended annual mammography for wom-
en aged 45 to 54 years and biennial mammography for women 55 years and older, as long 
as they are healthy and have a life expectancy of at least 10 years. Because the absolute 
risk of breast cancer is similar among women 45-49 and those aged 50-54, the ACS con-
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cluded that benefits outweigh harms beginning at age 45 years.  Among women under 45, 
the harms were judged to likely outweigh the benefits.
Europe
Early evidence on the efficacy of mammography screening became available with the first 
publications of the randomized controlled trials in the early 1980s. Thus, when the Eu-
rope Against Cancer (EAC) program was initiated in 1986 in an effort to control cancer in 
Europe, its Committee of Cancer Experts decided that secondary prevention should be 
included.49 Breast, cervical and colorectal cancers were considered. For breast cancer, a 
European Network was created in 1989, co-funded by the European Community, to imple-
ment mammography screening pilot programs in a number of member states. The target 
population in the pilots was women aged 50-64, but variation was allowed in the starting 
and stopping ages. It was expected that these pilots would provide a practical basis for the 
implementation of nation-wide breast cancer screening programs. At the time of imple-
mentation of the pilots, population-based screening programs were already established 
in a limited number of countries, including the UK, the Netherlands, Finland and Sweden. 
The positive results of the EAC program prompted the European Council to publish a 
recommendation on cancer screening in 2003. In this recommendation, member states 
were invited to take common action to implement national cancer screening programs 
with a population-based approach, according to European quality assurance guidelines 
where they existed. Following this recommendation, numerous additional programs were 
established in Western Europe in the 1990s and, more recently, also in Eastern Europe. 
The first report on cancer screening in the European Union noted that in 2007 breast can-
cer screening programs were running or being established in at least 26 of the 27 member 
states. The majority of the programs have a 2-year screening interval and invite at least 
women in the age group 50-69, as specified in the Council Recommendation. However, 
despite this broad consensus, the way screening programs are implemented still varies 
across the EU. 
The debate on breast cancer screening in Europe, and elsewhere, was not new but 
reignited with the publication of the first Cochrane Review in 2001. Below we summa-
rize the outcomes of the Cochrane Review3, based on its last update in 2013. We further 
summarize the reviews performed by the UK Independent Panel2,50 and the EUROSCREEN 
group51,52 that were initiated in response to the continuing debate and were published in 
2012. 
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Nordic Cochrane review
The Cochrane Collaboration is an international, independent, not-for-profit organization, 
funded by a variety of sources including governments, universities, hospital trusts, chari-
ties and personal donations. The first Cochrane review on screening for breast cancer with 
mammography was performed following a request of the Danish National Board of Health 
in 1999 and published in 2001. Updates were published in 2006, 2009, 2011 and 2013. 
The last review in 2013 was declared stable as no new randomized controlled trials on 
mammography screening had been identified. No further updates are expected.  
The authors of the Cochrane review aimed to study the effect of screening for breast 
cancer with mammography on mortality and morbidity. A broad search strategy was used 
in Pubmed to identify both randomized trials and observational studies, as the latter were 
considered to provide important new knowledge, e.g. in relation to evidence on overdi-
agnosis and other harms of screening. References were manually searched and letters, 
abstracts, grey literature, and unpublished data retrieved where possible. The outcome 
measures of the review included mortality from breast cancer, mortality from cancer, all-
cause mortality, use of surgical interventions, use of adjuvant therapy, and harms of mam-
mography. 
The Cochrane review identified eight eligible randomized clinical trials, but excluded 
one because it was not adequately randomized. Intention to treat analyses were per-
formed for breast cancer mortality, even though the authors judged breast cancer mortal-
ity to be an unreliable outcome, biased in favor of screening, and recommended overall 
mortality as primary outcome measure. Trials using less reliable randomization methods 
were evaluated separately. The pooled relative risk for the three trials with adequate ran-
domization was 0.90 (95% CI: 0.79-1.02) and did not show a significant effect of screening 
on breast cancer mortality. The four trials classified as having suboptimal randomization 
had a pooled relative risk of 0.75 (95% CI: 0.67-0.83) indicating a 25% reduction in breast 
cancer mortality. The overall estimate for all seven trials combined was 0.81 (95% CI: 0.74-
0.87), consistent with a 19% reduction after 13 years. The authors further assessed the 
impact of screening on all-cause mortality as well as deaths ascribed to any cancer and 
found no reductions. To express the results in absolute numbers, the authors assumed a 
15% reduction in breast cancer mortality after 13 years of follow-up which means that 
for every 2,000 women invited for screening throughout 10 years, one will avoid dying 
of breast cancer. Data from the randomized trials were further assessed for surgical in-
terventions and radiotherapy, with significantly more operations performed in the study 
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groups and more women receiving radiotherapy. Little information was found on other 
adjuvant therapy and no comparative data was reported on psychological morbidity. 
In contrast to outcomes relating to benefit, the harms of screening were summarized 
only in the discussion section. The review does not state explicitly how the randomized 
trials and/or observational studies referred to in this section were selected. The outcomes 
discussed include overdiagnosis and overtreatment, in particular the increase in mastec-
tomies, false-positives, psychological distress and pain. Based on the references selected, 
the authors conclude that the level of overdiagnosis and overtreatment was about 30% 
in the trials that did not introduce early screening in the control group and somewhat 
larger in the trials with suboptimal randomization. These findings were supported in a 
number of observational studies with overdiagnosis estimates ranging from 18 to 60%. 
In terms of absolute numbers, the authors estimated that for every 2,000 women invited 
for screening throughout 10 years, 10 women would be overdiagnosed and overtreated, 
under the assumption that the level of overdiagnosis is 30%. For false-positive results, the 
cumulative risk after 10 mammograms was found to range from about 20 to 60%, with the 
highest risk reported for the USA. No mention is made of the estimate used to calculate 
the absolute numbers, but the authors stated that it is likely that more than 200 women 
will experience false-positive findings and psychological distress for every 2,000 women 
invited for screening throughout 10 years.  
The authors of the Cochrane review concluded that the evidence reported in the re-
view cast doubts on the effectiveness of breast cancer screening and that ‘the time has 
come to re-assess whether universal mammography screening should be recommended 
for any age group’. In their view, women should be made more aware of the harms associ-
ated with attending screening, since the benefits are small at best.   
United Kingdom
The Independent UK Panel on Breast Cancer Screening (referred to below as the Inde-
pendent UK independent panel) issued a report in 2012 that was jointly commissioned by 
Cancer Research UK and the Department of Health (England). The group was convened to 
review the evidence for the benefits and harms of breast screening in the UK. Members 
of the independent UK panel had relevant expertise but had not previously published 
on breast screening in order to ensure an objective and independent assessment of the 
evidence. A patient advocate was an integral member of the independent UK panel. The 
evidence considered included randomized controlled trials of breast screening as well as 
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observational studies, including prospective follow up and case-control studies. The inde-
pendent UK panel reviewed the literature, but did not perform a formal systematic review, 
and heard testimony from experts in the field, from both sides of the debate. The key 
outputs of the review were an estimate of the effect of breast screening on breast cancer 
mortality, as the main benefit, and an estimate of the risk of overdiagnosis, as the main 
harm. Besides these, the independent UK panel considered other relevant issues, includ-
ing additional harms through invitation, screening, diagnosis, and treatment, as well as 
women’s perceptions and cost effectiveness. Although the independent UK panel did not 
make a systematic appraisal of evidence in all these areas, it did provide comments on 
each of these issues.
The independent UK panel’s estimate of the quantitative effect of breast screening on 
breast cancer mortality is based on randomized trials of screening, while acknowledging 
that these trials are not perfect. The analysis focused on 10 of the 11 randomized trials 
(excluding Edinburgh) and the meta-analysis conducted in the Cochrane review, using 13 
years of follow-up (published in 2011).  A relative risk reduction in breast cancer mortality 
of 20% (95% CI: 11-27%) was estimated for groups invited to screening. The absolute risk 
reduction was expressed as the number of women needed to be screened for 20 years to 
prevent one death from breast cancer and was estimated at 180 women. The independent 
UK panel estimated that for 10,000 women attending screening from age 50 for 20 years, 
43 deaths would be prevented. The independent UK panel looked at observational stud-
ies as a possible guide to more contemporary estimates of the benefit of breast cancer 
screening. They noted that in general these studies showed beneficial effects in the same 
direction as those seen in the trials, but expressed concern about inadequate control for 
the potential non-comparability of screened and unscreened women (self-selection bias). 
The independent UK panel based its estimate of the risk of overdiagnosis on three 
randomized trials that did not systematically screen the control group at the end of the 
screening period. Estimates were on the order of 11% (95% CI: 9-12%) from a population 
perspective, and about 19% (95% CI: 15-23%) from the perspective of a woman invited to 
screening. In absolute terms, the independent UK panel estimated that for every 10,000 
UK women invited to screening from age 50 for 20 years, about 681 cancers will be found 
of which 129 will represent overdiagnosis. Information from observational studies was 
also considered, but the independent UK panel concluded that these studies could not 
give reliable estimates of the extent of overdiagnosis. For the specific case of diagnosing 
DCIS via a screening program, it was noted that diagnoses of DCIS do not solely represent 
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overdiagnosis, but that these diagnoses undoubtedly contribute to the cases of overdi-
agnosis. The independent UK panel did not mention the cumulative risk of false-positive 
results among the other harms of breast screening, but noted that a false-positive result 
can cause psychological distress. 
The independent UK panel concluded that breast screening reduces breast cancer 
mortality, but that some overdiagnosis occurs. Based on the estimates for the UK, one 
breast cancer death is prevented for every three overdiagnosed cases identified and treat-
ed. Evidence from a focus group further showed that many women feel that accepting the 
offer of breast screening is worthwhile. 
EUROSCREEN
The effort of the EUROSCREEN group to summarize the accumulated evidence on the im-
pact of population-based breast cancer screening in Europe was launched in the context 
of the European Screening Network in 2010. EUROSCREEN is a self-initiated cooperative 
group that includes scientists and professionals experienced in planning and evaluating 
most of the population-based screening programs running in Europe. In contrast to the 
other reviews presented in this chapter, EUROSCREEN focused on observational studies 
to systematically assess the impact of established service screening programs in Europe. 
The aim was to develop the best current estimate of the impact of service screening on 
breast cancer mortality, as well as screening harms, in particular the risk of overdiagnosis 
and false-positive screening results. Outcomes of EUROSCREEN were published in eight 
peer-reviewed papers, including a summary of main findings in the form of a balance 
sheet. The series of literature reviews further addressed the methodological standards of 
evaluation and the importance of using appropriate statistical methodology to design and 
analyze observational studies of mammography. 
EUROSCREEN defined the reduction in breast cancer mortality for women invited vs. 
not invited and/or women screened vs. not screened as the primary benefit, and overdi-
agnosis of breast cancer and false-positive screening tests as the most important harms. A 
systematic search of Pubmed identified observational studies reporting on breast cancer 
mortality in relation to service screening programs in Europe implemented between 1970 
and 2007. In line with European policy recommendations, eligible studies had to include 
at least part of the age group between 50 and 69. Since the aim of the review was to 
report on estimates from ongoing population-based screening programs, the studies had 
to have at least a three years’ overlap with the current regional or national screening pro-
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gram. Based on these criteria, 83 studies were selected and grouped according to study 
design, i.e. trend studies, incidence-based mortality studies and case-control studies. The 
trend studies that aimed to quantify the impact on breast cancer mortality were too dif-
ferent to produce a pooled estimate of the effect of screening. Pooled estimates of breast 
cancer mortality reduction based on incidence-based mortality studies and case-control 
studies were on the order of 25-31% for women invited and 38-48% for women actually 
screened. The search strategy for overdiagnosis identified 13 studies that provided 16 
explicit estimates from European population-based screening programs. Unadjusted esti-
mates varied widely with estimates in the range of 0-54%. Studies were further classified 
according to the adjustment for breast cancer risk and lead time bias. Adequately ad-
justed studies report estimates of overdiagnosis in the range of 1-10%. Literature review 
and manual search of references for studies of the cumulative risk of a false-positive result 
in European service programs identified three unique studies. The pooled estimate from 
these studies indicated a cumulative risk of 20% for women aged 50-69 undergoing 10 bi-
ennial screening tests. The cumulative risk of a false-positive result in women undergoing 
needle biopsy was reported in two studies with a pooled estimate of 3%. 
The evidence from the literature reviews was further summarized in the form of a 
balance sheet. For every 1,000 women screened biennially from ages 50 to 51 years until 
ages 68 to 69 years and followed up until age 79 years, an estimated seven to nine breast 
cancer deaths are avoided, four cases are overdiagnosed, 170 women have at least one 
recall followed by non-invasive assessment with negative results, and 30 women have at 
least one recall followed by invasive procedures yielding a negative result. In conclusion, 
the pooled experience in European countries showed that the chance of saving a wom-
an’s life is greater than that of overdiagnosis. EUROSCREEN recommended continuing the 
population-based screening programs currently ongoing in Europe. 
DIFFERENCES BETWEEN EVIDENCE REVIEWS
In the previous section, we gave an overview of the existing evidence reviews and showed 
that they differed in both methodology and outcomes (Tables 2.1-2.3). In this section, we 
provide a detailed explanation of some of the methodological differences between the 
reviews that partly explain variations in their conclusions. We focus on four methodologi-
cal issues: study design, screening setting, outcome measure and reference population. 
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Study design
There are a number of epidemiological study designs used to quantify breast cancer mor-
tality reduction, overdiagnosis and cumulative risk of a false-positive result attributable to 
screening mammography. The well-known hierarchy of research evidence puts systematic 
reviews and meta-analyses at the top. Single studies are classified as to their strength 
of evidence in the following order: randomized controlled trials, cohort studies (i.e. in-
cidence-based mortality studies), case-control studies, and ecological studies (i.e. trend 
studies). We will discuss the study designs selected by the reviews separately for breast 
cancer mortality reduction, overdiagnosis and false-positives.
Breast cancer mortality reduction
Five reviews estimated breast cancer mortality reduction on the basis of randomized tri-
als, but the number of trials included in each review differed (see Table 2.1). In total, 
there have been 11 randomized trials of mammography: HIP, Malmö I and II, Swedish Two 
County [Kopperberg and Östergötland], Canada I and II, Stockholm, Göteborg, Edinburgh, 
and UK Age trial. All reviews excluded the Edinburgh trial because of methodological limi-
tations. The Nordic Cochrane Review made a distinction between adequately and subop-
timally randomized trials.  Four trials were included as adequately randomized (Malmö 
I, Canada I and II, UK Age trial) and the other trials, except for the Edinburgh trial, were 
included as suboptimally randomized. 
EUROSCREEN based their estimate of breast cancer mortality reduction predomi-
nantly on incidence-based mortality studies and case-control studies from Europe. They 
reported separate pooled estimates for incidence-based mortality studies (25%) and case-
control studies (31%). Because trend studies have major methodological limitations in 
evaluating the effect of screening on breast cancer mortality53, the outcomes were re-
ported but not pooled. 
The USPSTF, ACS and the independent UK panel also considered observational data on 
mortality as a guide for more contemporary estimates of screening because the random-
ized controlled trials, which are older, are limited in their ability to estimate the effect of 
modern mammographic screening. These reviews concluded that the effect of mammo-
graphic screening was larger in incidence-based mortality and case-control studies than 
in randomized trials. Comparison of the reviews reveals a similar picture: meta-analyses 
of randomized trials show a smaller breast cancer mortality reduction than meta-analy-
ses of incidence-based mortality and case-control studies. It remains unknown, however, 
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whether this difference is due to limitations in observational studies, such as selection 
bias, or differences in the details of screening practice, as will be discussed in the secion 
on screening setting.
Overdiagnosis
Of the six reviews, only the Nordic Cochrane Review and the independent UK panel cre-
ated a single overdiagnosis estimate, while EUROSCREEN used the average of the most 
plausible overdiagnosis estimates. The three reviews from North America included over-
diagnosis, but did not report a single estimate.
Two out of the three reviews, i.e. Nordic Cochrane review and the independent UK 
panel, based their estimates of overdiagnosis on RCTs. They both included three trials 
that did not offer screening to women in the control group at the end of the trial; Malmö 
I, Canada I and II. 
EUROSCREEN estimated overdiagnosis in European population-based mammographic 
screening programs using observational studies. They included both cohort studies and 
ecological studies.16 Case control studies estimating overdiagnosis in Europe were not 
published at that time and therefore, could not be included. EUROSCREEN did not classify 
the studies estimating overdiagnosis according to study design, but on the basis of two 
methodological limitations relating to overdiagnosis, adjustment for lead time and under-
lying breast cancer risk.
Both trials and observational studies have limitations when it comes to estimating 
overdiagnosis. The major limitation of trials is the short follow-up period after the end of 
screening. This limitation can be overcome in observational study designs. However, these 
designs lack a comparable non-screened control group. A non-screened control group 
is often created by extrapolating pre-screening trends, using control regions, using non-
attenders or other approaches. All of these approaches require assumptions, which can 
have a large impact on the overdiagnosis estimate, and do not necessarily create a com-
parable non-screened control group.50
False-positives
Five reviews reported the cumulative risk of a false-positive result: the Nordic Cochrane 
review, EUROSCREEN, USPSTF, the Canadian Task Force, and the ACS. The independent UK 
panel did not consider the cumulative risk of false-positives, because they felt there was 
more agreement about the nature and magnitude of false-positives.2 When reported, the 
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cumulative risk of false-positives was always based on observational study designs.
EUROSCREEN was the only review that systematically searched the literature for stud-
ies on the cumulative risk of false-positives. The Nordic Cochrane review provides a range 
of cumulative risks based on several studies which were not obtained using a systematic 
search. The USPSTF showed both the cumulative risk of false-positives in percentages and 
absolute numbers, but based on different studies. In total, two studies were listed for 
the cumulative risks and unpublished results from the BCSC were used for false-positive 
estimates at a single screening round. The same two observational studies were used by 
the ACS to inform estimates of cumulative false-positive risk. The Canadian Task Force also 
reports the absolute number of false-positives per 1,000 women without clearly mention-
ing the basis for this estimate.   
Screening setting
Although the research hierarchy of epidemiological studies is widely accepted in the 
medical literature, it is not absolute or fixed. Well-executed studies of lower order might 
provide more valid evidence than poorly executed studies of higher order. Furthermore, 
other factors relating to external validity may make studies of lower order more relevant 
than studies of higher order. In this section, we will discuss factors relating to the external 
validity of the executed studies. To this end, we will compare current screening practice to 
the intervention delivered in the trials and observational studies in terms of study period, 
age groups, screening test, and screening organization.
Breast cancer mortality reduction
The differences between breast cancer mortality estimates in the reviews can largely be 
explained by the period during which the studies were conducted. One study54 indicated 
that the effectiveness of mammographic screening has increased over time. Screening 
mammography programs have improved over time, and some studies show increased 
breast cancer detection with newer technologies, such as digital mammography55 and dig-
ital breast tomosynthesis.56,57 Randomized trials were executed between 1963 and 1991, 
while most incidence-based mortality and case-control studies were executed more re-
cently.58 This might explain why EUROSCREEN estimated a higher breast cancer mortality 
reduction based on observational studies than the other reviews which based their esti-
mated on the randomized trials. Potential factors that have changed over time and may 
have contributed to this effect are improvements in screening tests and treatments and a 
growing awareness of breast cancer among women.
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Another factor that differs between randomized trials and observational studies is age. 
The randomized trials included women in the age range 38-74. The mean age of the trial 
participants is not reported, but will be relatively low given that three trials focused solely 
on women below age 50. In most European screening programs, as evaluated by EURO-
SCREEN, the starting age is 40 or 50 and stopping age is 69 or 74. Because most studies in 
Europe are executed in countries that start screening at age 50, the age range included in 
trials and studies included in the EUROSCREEN review might differ. This may have affected 
the estimates, because some studies show a larger effect of screening in older women.59
Overdiagnosis
Age and screening test are known to influence overdiagnosis. The risk of overdiagnosis 
increases substantially at older ages,7 because of a higher risk of death due to compet-
ing events. Screening tests with improved sensitivity, such as digital mammography, also 
increase the risk of overdiagnosis60,61, because more life threatening as well as non-life 
threatening breast cancers can be detected. 
Although overdiagnosis is influenced by the details of screening practice, it is difficult 
to determine which factors explain the differences in overdiagnosis estimates between 
the reviews. Currently, there is much discussion about the optimal methodology to esti-
mate overdiagnosis.15,17 Factors, such as the length of follow-up after the end of screening 
and the underlying breast cancer incidence rate may have a larger influence on the over-
diagnosis estimates than screening policy. As a consequence, the differences in overdiag-
nosis estimates are likely primarily explained by methodological differences rather than 
differences in screening practice.
False-positives
Difference in screening organization is the major factor explaining the differences be-
tween the cumulative false-positive risks reported in the reviews. This is best illustrated 
by comparing the cumulative risk reported by the ACS and USPSTF with the risk reported 
by EUROSCREEN. The US evidence reviews reported cumulative risks of false positives 
about double or triple the risks of false-positives estimated in Europe and Australia.30 This 
difference may be partially explained by the fact that in the US typically a single radiologist 
decides whether to recall or not, while in Europe and Australia two or three radiologists 
make this decision. As a consequence, recall rates are generally higher in the US.62,63 Ad-
ditionally, the requirements for screening radiologist accreditation differ between the US 
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and other countries. For example, the US requires 960 mammograms read in the prior 2 
years to maintain accreditation,64 while the European guidelines for quality assurance in 
breast cancer screening and diagnosis recommend that each screening radiologist should 
read a minimum of 5,000 screening cases per year in a centralized program.65
Other details of screening practice also influence the cumulative risk of a false posi-
tive, including screening test60, screening interval7 and age36,47. In general, cultural factors, 
organization of health care and the medicolegal context also affect the threshold used to 
determine whether to recall, and thus the cumulative risk of false-positive recall in differ-
ent screening settings. 
Outcome measure
Here we consider the measures used to quantify breast cancer mortality reduction, over-
diagnosis and cumulative risk of false-positives. For example, overdiagnosis can be ex-
pressed as a percentage of cancers in the presence or absence of screening. Even when 
the absolute number of overdiagnosed cases per 1,000 women is the same, this leads to 
different overdiagnosis estimates. The resultant major drawback is the incomparability 
of estimates across reviews due to differences in choice of outcome measures. We will 
discuss several differences in outcome measures that at least partially explain differences 
between the reviews. 
Breast cancer mortality reduction
Across outcome measures, the percentage breast cancer mortality reduction reported by 
the reviews ranges from 10% to 48%. However, the range is reduced to 10% to 33% when 
expressed as the breast cancer mortality reduction in women invited to screening. Trials 
and incidence-based mortality studies usually estimate the breast cancer mortality reduc-
tion in women invited to screening, e.g. intention to treat. In case-control studies, the 
effect of screening on breast cancer mortality is most often expressed in women actually 
screened. EUROSCREEN calculated the breast cancer mortality reduction in both women 
invited and women screened, thereby increasing comparability with estimates based on 
trials.  
Another factor that affects the estimated breast cancer mortality reduction is length 
of follow-up. The independent UK panel and Nordic Cochrane review both used a 13 year 
follow-up period for the randomized trials. EUROSCREEN defined adequate follow-up as 
‘at least 10 years from the date of full coverage by invitation’.58
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Overdiagnosis
The extent of overdiagnosis depends greatly on the method of estimating overdiagnosis 
and all reviews used a different method. EUROSCREEN pooled overdiagnosis estimates 
with different denominators and concluded that overdiagnosis was on average 6.5% in the 
absence of screening (average of the most plausible overdiagnosis estimates).52 However, 
they did not report the age range for breast cancers included in the absence of screening, 
which has a large influence on the overdiagnosis estimate. Including breast cancers diag-
nosed in women outside the age range of the screened population provides an estimate 
reflective of the overdiagnosis risk among the total population of women. However, this 
estimate will be lower than overdiagnosis estimates including only women of screening 
age since women outside the screened age range are not at risk of having cancers over-
diagnosed. The independent UK panel expressed overdiagnosis as a percentage of breast 
cancers in women invited to screening. They also proposed two age ranges, i.e. breast 
cancers in all ages and breast cancers in the invited age range. Because of the difference 
in methods, the percentages of overdiagnosis from the reviews are incomparable. 
The extent of overdiagnosis is also dependent on the type of breast cancer studied: 
overdiagnosis estimates of invasive breast cancer are lower than overdiagnosis estimates 
of invasive breast cancer plus ductal carcinoma in situ (DCIS). Although the effect of the 
type of breast cancer studied can be large,25 it is not directly visible in the reviews because 
the choice of denominator masks this difference. 
False-positives
All reviews use more or less the same definition to calculate the cumulative risk of false 
positives. If there are any differences between the reviews in the definition of the cumula-
tive risk of false positive, these will be minimal, e.g. inclusion or exclusion of false-positive 
recalls due to insufficient technical quality.30 Therefore, differences in outcome measures 
will have a minor effect on the difference in the cumulative risk of false-positives between 
the reviews.
Reference population
In all reviews, the relative breast cancer mortality reduction was translated to absolute 
numbers. Overdiagnosis and cumulative false-positives risks were also expressed in ab-
solute terms by all reviews except for ACS. For these purposes, each review uses a so-
called ‘reference population’, i.e. the breast cancer incidence and mortality of a certain 
population under a particular screening scenario.52 The absolute risk estimates for each 
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Table 2.4 Reported and recalculated absolute breast cancer mortality reduction per 1,000 
women for each evidence review  
Balance 
Absolute breast cancer mortality reduction per 1,000 women 
Absolute reduction 
as reported 
Percent reduction 
for invited women 
Absolute reduction 
recalculateda 
USPSTF 39-49 years: 0.4 
50-59 years: 0.8 
60-69 years: 2.1 
70-74 years: 1.3 
39-49 years: 12% 
50-59 years: 14% 
60-69 years: 33% 
70-74 years: 20% 
39-49 years: 3 
50-59 years: 4 
60-69 years: 11 
70-74 years: 6 
ACS 40-49: 0.6-1.3 
50-59: 0.9-2.2 
60-69: 1.2-2.8 
Not provided  
EUROSCREEN 50-69 years: 7-9 25% and 31% 7-10 
Independent UK panel  50-69 years: 
4.3 (invited) 
5.6 (screened) 
20% 6 
Nordic Cochrane 
Institute 
0.5b 10% 2 
Canadian Taskforce 40-49 years: 0.5 
50-69 years: 1.4 
70-74 years: 2.2 
40-49 years: 15% 
50-69 years: 21% 
70-74 years: 32% 
All ages: 18% 
40-49 years: 4 
50-69 years: 6 
70-74 years:10 
All ages: 5 
 
a The recalculated absolute mortality reductions are based on UK mortality rates (2008-2010) and 
independent UK panel’s calculations.42 In 2008-2010, 1.70% of the women aged 50 are expected to die 
from breast cancer between age 55 and 79. The absolute risk reduction (r) is the breast cancer mortality 
risk in absence of screening (=1.70/RRinvited) minus the breast cancer mortality risk in presence of screening 
(=1.70). The absolute number of breast cancer mortality cases prevented was calculated as the inverse of 
the risk reduction (1/r) times the coverage rate of the screening program in the UK (0.77).  
b The Nordic Cochrane review did not explicitly mention the age range of the absolute breast cancer 
mortality reduction. They based their absolute reduction on the control group (age range 39-69)  
of the outcome measures depend largely on the underlying breast cancer mortality and 
incidence in the reference population50 as we will show here.
Breast cancer mortality reduction 
All reviews used a reference population to obtain the absolute numbers of breast cancer 
deaths prevented by screening. The Cochrane review used the control groups of the trials, 
which had low breast cancer mortality because of the low mean age.50 The independent 
UK panel and EUROSCREEN calculated absolute numbers with a different approach, but 
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both based their estimates on the screened age range in the United Kingdom. The USPSTF 
and Canadian Taskforce did not clearly describe which reference population was used to 
obtain the absolute breast cancer mortality reduction estimate. The ACS estimate was 
based on incidence-based mortality among US women reported by SEER but does not 
clearly describe the included age range. 
The absolute number of breast cancers prevented by breast cancer screening ranges 
from 0.4 to 9 per 1,000 women across the reviews. The USPSTF reports the lowest number 
of breast cancers prevented in the age group 39-49 (0.4) and EUROSCREEN reports the 
highest number of breast cancers prevented (7-9). The reviews from North America re-
port absolute breast cancer mortality reductions that are on the lower end, 0.8 for wom-
en 50-59 years and 2.1 for 60-69 years reported by the USPSTF and 1.4 by the Canadian 
Taskforce. The independent UK panel reports that 5.6 breast cancer deaths are prevented 
per 1,000 women screened. Since the reported absolute numbers are based on different 
reference populations and screening scenarios, they are not comparable.
When applying the UK reference population to the relative mortality reductions es-
timated by each review, the absolute number of breast cancer deaths prevented ranges 
from 2 to 11 per 1,000 women screened (see Table 2.4). For all reviews, these absolute 
estimates are higher than those provided in the review, with the exception of the inde-
pendent UK panel which provided the reference population. The Nordic Cochrane review 
still reports the lowest number of breast cancers prevented and EUROSCREEN the highest. 
The change in absolute breast cancer deaths prevented was most notable for the Canadi-
an Taskforce, which reported a relative risk reduction equal to the independent UK panel 
and an absolute risk reduction of 4.2 per 1,000 less than the independent UK panel before 
recalculation. After applying the reference population of the independent UK panel, the 
Canadian Taskforce reported absolute risk reductions equal to the independent UK panel.
Overdiagnosis
The underlying breast cancer incidence in the reference population is an important deter-
minant of the absolute number of overdiagnosed cases. Unfortunately, we were not able 
to recalculate the absolute number of overdiagnosed cases, because the absolute number 
of breast cancers in the denominator was unknown in most reviews. However, it can be 
expected that the choice of reference population has a similar or even larger effect on 
overdiagnosis compared to its effect on breast cancer deaths prevented.
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False-positives
The influence of the reference population on the absolute number of false-positives is 
limited, because false-positives are not highly dependent on breast cancer incidence and/
or mortality. The risk of a false-positive is likely to increase with a higher risk of breast 
cancer. For example, some studies indicate that women with a family history of breast 
cancer, and therefore a higher risk of having breast cancer themselves, also have a higher 
risk of false-positives. However, this effect is likely too minor to explain the differences 
between reviews.
CONCLUSION
This chapter provided an overview of reviews of the benefits and harms of mammograph-
ic screening and discussed factors that can explain the differences between  reviews. In 
this concluding section, we provide recommendations to those designing and applying 
harm/benefit balance sheets. We conclude with a discussion of some future challenges, 
including the introduction of new screening modalities and personalized screening, that 
are likely to affect the current balance between benefits and harms.
Recommendations
Most reviews quantified breast cancer mortality reduction using estimates from random-
ized trials. The majority of these randomized trials were executed at least 25 years ago 
and estimated the effect of mammography using older technology and screening pro-
tocols tested in different populations than those for whom recommendations are being 
made. The continued reliance on these older trials reflects the fact that the validity of 
breast cancer mortality reduction estimates is valued more highly than their generalizabil-
ity. As we discussed in this chapter, both study design and screening policy can affect esti-
mates of breast cancer mortality reduction. Given that breast cancer screening continues 
to improve and new randomized controlled trials investigating the effect of breast cancer 
screening including an unscreened arm are unlikely to be executed, we recommend put-
ting more weight on the generalizability of breast cancer mortality estimates and thus on 
estimates from well-executed observational studies. Estimates of cancer incidence and 
mortality from observational studies are potentially affected by healthy screenee bias.66 
Many factors may also differ between screened and unscreened populations or individu-
als screened more or less frequently, leading to possible confounding. Development of 
rigorous methodological criteria for the validity of observational studies of cancer screen-
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ing is therefore needed.
Furthermore, it may be misleading to use breast cancer mortality reduction estimates 
from randomized controlled trials in combination with overdiagnosis and cumulative false-
positive risk estimates based on observational studies of current screening programs, as 
this may distort the balance of benefits and harms. Breast cancer mortality reduction, 
overdiagnosis and cumulative risk of false-positives are strongly related to each other via 
features of the mammography screening program.67 When breast cancer mortality reduc-
tion is greater, overdiagnosis and the cumulative false-positive risk are also likely to be 
greater. Therefore, the harm/benefit balance should be based on estimates of breast can-
cer mortality, overdiagnosis and false-positives from the same screening setting, including 
period, age, test, interval and organization of screening.
There is also geographical variation in the harm/benefit balance, especially with regard 
to the cumulative risk of false-positives. The cumulative risk of false-positives is strongly 
dependent on a country’s screening organization, the organization of health care, cultural 
factors and the medicolegal context. The largest differences are observed between the 
USA compared to Europe and Australia.30 Therefore, balances should only include cumula-
tive risks of false-positives from countries with similar screening settings. 
Those creating and applying balances should further be aware of the effect of the 
choice of reference population. The absolute numbers of breast cancer deaths prevented 
and overdiagnosed cases depend on breast cancer incidence and mortality in the refer-
ence population. Consequently, the absolute numbers of breast cancer deaths prevented 
and cases overdiagnosed cannot be compared directly between reviews. For this reason, 
the relative effects should be preferred above the absolute effects for comparison be-
tween reviews. Furthermore, those creating balance sheets should clearly identify the 
reference population used to calculate absolute estimates, thereby allowing readers to 
evaluate the generalizability of their estimates.
The reviews differed most in their estimates of overdiagnosis. This is likely because 
there is still much uncertainty and disagreement about the optimal methodology for esti-
mating overdiagnosis and the outcome measure of overdiagnosis. The reviews were gen-
erally less systematic in their choice of which studies on overdiagnosis to include and used 
different outcome measures for overdiagnosis. These and other challenges regarding un-
derstanding and quantifying overdiagnosis are further discussed in Chapter 6*.  Balance 
sheets reporting on overdiagnosis should include clear descriptions of the methodology, 
* Refers to chapter 6 of the book ‘Breast Cancer Screening’ edited by Houssami N. and Miglioretti D.
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outcome measures, and reference populations used in order to facilitate comparisons 
across reviews.68
Future challenges
Overdiagnosis, resulting in overtreatment, is undoubtedly the most serious harm of 
breast cancer screening. Currently, all breast cancers, including DCIS, are treated as if they 
are life threatening. However, this may be changing as current research seeks to identify 
characteristics of tumors that are not likely to progress and that can therefore safely be 
left untreated. This research would resolve the ambiguity in distinguishing life threatening 
from non-life threatening cancers, thereby substantially alleviating the uncertainty about 
overdiagnosis which fuels much of the current controversy about the relative harms and 
benefits of screening mammography.
The introduction of new screening modalities is a topic of current research that will 
pose new challenges to estimates of the balance of benefits and harms. The existing ran-
domized trials of screening mammography all used older technology. Currently screen-
ing mammography is conducted almost exclusively using full field digital mammography 
while the randomized trials used film-screen technology. Digital mammography has been 
shown to have increased sensitivity at the cost of somewhat decreased specificity rela-
tive to film-screen mammography.69,70 The balance of benefits and harms is likely to differ 
for digital mammography compared to film-screen with higher sensitivity increasing the 
possible mortality benefit as well as overdiagnosis61 and lower specificity leading to more 
false-positives. 
Other new imaging technologies are rapidly being introduced into clinical practice, 
such as digital breast tomosynthesis, breast magnetic resonance imaging, and whole 
breast ultrasound. These technologies are already being used for screening in the US and 
may increasingly be used in other screening settings in the future. This evolution is further 
detailed in chapter 14*. Of interest, these technological advances take place too rapidly 
for clinical trials with mortality endpoints to be feasible. In order for benefit/harm bal-
ance sheets to remain relevant it will be critical to incorporate clinical trial results using 
alternative endpoints, such as stage shift, interval cancer reduction and results from ob-
servational studies. 
Another challenge is presented by the shift towards personalized screening, as ex-
plained in Chapters 8 to 10* on risk-based breast screening. Decision makers increasingly 
* Refers to chapters of the book ‘Breast Cancer Screening’ edited by Houssami N. and Miglioretti D.
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recognize that the balance of harms and benefits may be optimized for low risk women by 
providing less intensive screening and for high risk women by intensifying screening regi-
mens. The evidence for personalized screening recommendations is derived entirely from 
observational studies and microsimulation models. While personalization has the poten-
tial to shift the overall balance of benefits and harms in a favorable direction, obtaining 
unbiased estimates to support personalized screening decisions is challenging. Given the 
potential for bias, observational studies of harms and benefits of personalized screening 
strategies must adhere to rigorous methodological standards. 
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ABSTRACT
Background: Breast cancer incidence and mortality are higher in women with a high so-
cio-economic status (SES). The potential to prevent death from breast cancer is therefore 
greater in the high SES group. This does, however, require that the effectiveness of screen-
ing in the high SES group is equal to or greater than the effectiveness in the low SES group. 
The aim of this study is to assess the relative effectiveness of mammographic screening 
on breast cancer mortality by SES.
Methods: In Nijmegen, the Netherlands, women are invited to participate in biennial 
mammographic screening since 1975. Postal code is collected at each round and is used 
to calculate the SES of each woman based on the SES indicator of the Netherlands Insti-
tute for Social Research.  The Dutch average was used to classify the SES score of each 
woman as either high or low. We designed a case-control study to investigate the effect 
of mammographic screening in women aged 50-75, 40-75 and 50-69, and calculated the 
odds ratios (ORs) and 95% confidence intervals (CIs).
Results: 10% of the women invited to the mammographic screening program in Nijmegen 
had a high SES. In women aged 50-75, the breast cancer death rate was 38% lower in 
screened women than in unscreened women. The ORs for women with high SES (OR=0.77; 
95% CI=0.29-2.05) and low SES did not differ significantly (OR=0.62, 95% CI=0.48-0.79).
Conclusion: Mammographic screening reduces breast cancer mortality, but we did not 
observe a significant difference in the relative effectiveness of screening by SES. Because 
women with a high SES have a greater risk of breast cancer death, the absolute number of 
breast cancer deaths prevented by mammographic screening is expected to be greater in 
the high SES than low SES group.
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INTRODUCTION
Many European countries have implemented a population-based mammographic screen-
ing program.1 Virtually all programs define the target population invited to screening by 
age alone. Because mammographic screening benefits some women and harms others2,3, 
the question is arising whether mammographic screening can be optimized, i.e. obtaining 
a more favorable benefit-harm balance. A more favorable balance between the benefits 
and harms of screening may be achieved by more targeted screening, i.e. defining a target 
population for screening based on more risk factors in addition to age.
A potential risk factor for breast cancer that can be considered in this respect is socio-
economic status (SES). SES is associated with a range of risk factors for breast cancer, such 
as a mother’s age at first childbirth and alcohol consumption.4-6 In addition, previous re-
search has shown that women with higher SES have a higher breast cancer incidence and 
mortality than women with low SES.4,7,8 The absolute number of breast cancers prevented 
by mammographic screening may, therefore, be higher in women with high SES than in 
women with  low SES. The prerequisite is that the effectiveness of mammographic screen-
ing in women with high SES is equal to or greater than the effectiveness of screening in 
women with low SES.9 Because high SES is associated with a higher breast density10, which 
can mask tumors on mammograms,11 the relative effect of screening might actually be 
smaller in women with high SES than low SES. 
Only one study9 investigated the relative effect of mammographic screening in younger 
women (aged 40-49) with either high or low SES. In women aged 40-49 years, the relative 
effect of mammographic screening on breast cancer mortality did not differ significantly 
between women with high and low SES.9 However, the effect of screening on breast can-
cer mortality in women with either high or low SES remains unknown in the most com-
monly targeted age groups.1 Therefore, the aim of this study is to investigate the relative 
effect of mammographic screening on breast cancer mortality in women with either high 
or low SES (based on income, employment and education) aged 50-75, 40-75 and 50-69. 
METHODS
Setting
The case-control study was conducted within the population invited to the biennial mam-
mographic screening program in Nijmegen, the Netherlands. In 1975, at the initiation of 
the program, women aged 35 years and over were invited for screening. In 1989, at the 
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start of the national screening program, the targeted age range was limited to 50-69 con-
forming to national screening policy. In 1998, the national program also started to invite 
women aged 70-75. Until 2014, the first screening examination consisted of two views 
(mediolateral oblique and craniocaudal view) and the subsequent screening examina-
tions consisted of one view (lateral view in first three rounds and mediolateral view from 
the fourth round onwards). Additional craniocaudal views during subsequent screening 
increased over time. From 2014 onwards, two views became standard in subsequent 
screening examinations (mediolateral oblique and craniocaudal view). Mammograms are 
read independently by two radiologists who must reach consensus on recall. In 2007-
2008, digital mammography was introduced.
The Nijmegen screening registry holds data on screening attendance, age and postal 
code per screening round. It also collects information on vital status (date of death or 
migration) and cause of death of women diagnosed with breast cancer who are living in 
Nijmegen. Vital status is obtained from the Municipal Personal Records Database (GBA) 
and cause of death is assessed by a committee that is unaware of the screening history. All 
women consented to the use of their anonymous data for scientific research.
SES indicator
SES was based on the scores of the Netherlands Institute for Social Research (SCP-score).12 
This SCP-score is available for all 4-digit postal codes with more than 100 households and 
is provided every four years by the Netherlands Institute for Social Research since 1995. 
The score is based on mean household income, percentage of households with a low 
income, percentage of inhabitants without a paid job and percentage of households with 
a low mean education. This information is obtained via phone calls from the organization 
EDM BV (Evers Direct Marketing Besloten Vennootschap) to one person in each 6-digit 
postal code (usually one street) and aggregated to 4-digit postal codes.
We made groups of high and low SES based on the SCP- score using the mean score of 
each four year period (-0.26 for 1995-1998, -0.12 for 1999-2002, 0.21 for 2003-2006 and 
0.17 for 2007-2010). The SES indicator in the period 1995-2002 was used to determine the 
SES in the period 1975-1994, assuming that the SES did not change from high to low or 
vice versa in this time period. Nijmegen had a lower mean SES score than the Netherlands 
and covered about one third of the total range of the SCP-scores.
Study design
We used a case-control study to evaluate the effect of mammographic screening on breast 
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Figure 3.1. The screening attendance over time for women with a high and low SES aged 50-75 (A), 40-75 (B) 
and 50-69 (C).
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cancer mortality in women with a high and  low SES. Cases were defined as women who 
were aged 50-75, 40-75 or 50-69 at diagnosis, were invited to participate in the mammo-
graphic screening program, were living in Nijmegen and died from breast cancer before 
1 January 2013. For each case, five controls were sampled according to the incidence 
density sampling procedure using the syntax of Richardson.13 Controls had to be in the 
same age range as the cases, invited to participate in the screening program at the time of 
diagnosis of the case, living in Nijmegen, and alive at the time of death of the case. 
Breast cancer screening is only effective in the period that breast cancer is detectable 
by the screening test and not yet symptomatic. Because the detectable pre-clinical pe-
riod is unknown at individual level, we set the time frame for invitation at 4-years before 
the diagnosis of the case based on estimated lead times for breast cancer.14,15 In biennial 
screening, a 4-year period covers two consecutive screening invitations: the invitation be-
fore breast cancer diagnosis of the case (index invitation) and the invitation preceding 
the index invitation (pre-index invitation). The age at index invitation and SES at index 
invitation were used to determine the age and SES, respectively, of both the cases and 
referents.
Statistical analyses
We used a chi square test for independence to compare the clinical characteristics of 
the cases with high and low SES. Unconditional logistic regression was used to calculate 
the odds ratio (OR) of the breast cancer mortality rate in women with high and low SES 
accepting or declining the screening invitation. Unconditional logistic regression results 
in an unbiased OR if the proportion of women screened remains stable during the study 
period.16 In the Nijmegen screening program, the percentage of attendance was relatively 
stable (see Figure 3.1).
We calculated ORs and their corresponding 95% confidence intervals (95% CI) for 
women with high and low SES separately and combined. The ORs were calculated for 
three age ranges, thereby covering most of the targeted age ranges in Europe: 50-75 (the 
Netherlands), 40-75 (Sweden) and 50-69 (Norway, Italy).1 All analyses were adjusted for 
age and executed in SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). 
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RESULTS
Study population
In the period 1975-2012, 10% of the women invited for screening had a high SES and 89% 
of the women had a low SES. SES was unknown for 0.24% of the women aged 50-75. The 
percentage of high SES increased over time: from 4% in 1975 to 20% in 2012. The atten-
dance percentages were slightly higher for women with high SES than for women with low 
SES (see Figure 3.1A, B and C). For women aged 50-75, the average attendance was 67.4% 
for low SES and 73.0% for high SES. For women aged 40-75 and 50-69, the average atten-
dance was 69.1% and 70.7% for low SES and 73.1% and 72.3% for high SES, respectively.
Case-control study
In the study period, 368 women aged 50-75, 449 women aged 40-75 and 311 women 
aged 50-69 died from breast cancer (cases). Table 3.1 presents the clinical characteristics 
of the cases stratified by SES, which shows that the cases with high and low SES do not 
differ statistically significant with respect to mode of detection, age at diagnosis, lymph 
node status, tumor size, breast density, estrogen receptor (ER) and progesterone receptor 
(PR) status. We randomly sampled five controls per case leading to 1840, 2245, and 1555 
controls in the age groups 50-75, 40-75, and 50-69 respectively. The median age at index 
invitation was 61 (interquartile range (IQR), 55-67) for the cases aged 50-75 and 60 (IQR, 
54-66) for the controls aged 50-75. For women aged 40-75 and 50-69, the median age at 
index invitation was 58 (IQR, 51-66) and 59 (IQR, 54-63) for cases and 56 (IQR, 50-64) and 
58 (IQR, 53-63) for controls, respectively.
Table 3.2 shows that screened women experience a lower breast cancer mortality rate 
than unscreened women. The overall mortality reduction by screening adjusted for age 
was 38% (OR: 0.62, 95% CI: 0.49-0.80) for women aged 50-75, 32% (OR:0.68, 95% CI: 0.54-
0.85) for women aged 40-75 and 36% (OR:0.64, 95% CI:0.49-0.84) for women aged 50-69. 
The effect of SES on the effectiveness of mammographic screening was not significant 
and differed with age group. The effectiveness was higher for high SES than for low SES in 
women aged 40-75 and 50-69, while the effectiveness was lower for high SES than for low 
SES in women aged 50-75. For women aged 50-75, the age-adjusted mortality reduction 
by screening is 38% (OR:0.62, 95% CI: 0.48-0.79) for low SES and 23% (OR:0.77, 95% CI: 
0.29-2.05) for women with high SES. For women aged 40-75, the age-adjusted mortality 
reduction by screening is 31% (OR:0.69, 95% CI:0.54-0.87) for low SES and 36% (OR:0.64, 
95% CI:0.28-1.44) for high SES.
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Table 3.1 Clinical characteristics of cases aged 40 to 75 years at diagnosis 
  
N (%) P-value1 
  
High SES Low SES 
Mode of detection 
    
.85 
 
Screen-detected 11 (34%) 133 (32%)  
 
Interval 8 (25%) 123 (30%)  
 
Interval >24 months 6 (19%) 90 (22%)  
 
Non-participant 7 (22%) 71 (17%)  
Age at diagnosis 
    
.98 
 
40-49 5 (16%) 75 (18%)  
 
50-59 12 (38%) 157 (38%)  
 
60-69 11 (34%) 133 (32%)  
 
70-75 4 (13%) 52 (12%)  
Lymph node status 
    
.14 
 
Positive 22 (69%) 225 (54%)  
 
Negative 5 (16%) 135 (32%)  
 
unknown 5 (16%) 57 (14%)  
Tumor size 
    
.34 
 
<10 mm 2 (6%) 15 (4%)  
 
10-14 mm 0 (0%) 32 (8%)  
 
15-19 mm 3 (9%) 42 (10%)  
 
20-29 mm 5 (16%) 103 (25%)  
 
>30 mm 14 (44%) 139 (33%)  
 
Diffuse 0 (0%) 6 (1%)  
 
Unknown 8 (25%) 80 (19%)  
Breast density 
    
.09 
 
Non-dense 11 (34%) 224 (54%)  
 
Dense 14 (44%) 141 (34%)  
 
Unknown 7 (22%) 52 (12%)  
ER status 
    
.38 
 
Positive 17 (53%) 234 (56%)  
 
Weakly positive 0 (0%) 13 (3%)  
 
Negative 11 (34%) 105 (25%)  
 
unknown 4 (13%) 65 (16%)  
PR status 
    
.28 
 
Positive 11 (34%) 178 (43%)  
 
Weakly positive 1 (3%) 21 (5%)  
 
Negative 16 (50%) 143 (34%)  
 
Unknown 4 (13%) 75 (18%)  
1 Cases with missing data on the variable lymph node status, tumor size, breast density, ER status 
and/or PR status (i.e. unknown group) were excluded for the calculation of the p-value. 
Abbreviations: SES=socio-economic status, ER=estrogen receptor, PR=progesteron receptor 
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Two to four women, selected either as case or referent, had a missing SES at the index 
round. The ORs changed maximal 0.01 point when women with missing SES at the index 
round were included in the analyses using the SES of another round with known SES and 
closest to the index round. 
DISCUSSION
To our knowledge, this is the first study investigating the relative effect of screening on 
breast cancer mortality in women with high and low SES in the target age range of most 
European screening programs. We showed that mammographic screening reduces breast 
cancer mortality in women with high and low SES, but that the relative effectiveness of 
screening does not differ significantly between women with high SES and low SES in this 
study.
Effectiveness
So far, only one study investigated the effectiveness of mammographic screening for 
women with high and low SES  aged 40-49.9 This study showed, like the study reported 
here, no statistically significant difference in the relative effectiveness of mammographic 
screening by SES. The absence of a difference in the relative effect of mammographic 
Table 3.2. The relative effect of mammographic screening on breast cancer mortality for women 
with a high and low socio-economic status unadjusted and adjusted for age 
 
Age SES status Cases Controls OR (95% CI) 
  
screened 
(unscreened) 
screened 
(unscreened) Unadjusted Adjusted for age 
50-75 
      
 
low 223 (117) 1294 (412) 0.61 (0.47-0.78) 0.62 (0.48-0.79) 
 
high 20 (7) 105 (26) 0.71 (0.27-1.85) 0.77 (0.29-2.05) 
 
total 243 (125) 1402 (438) 0.61 (0.48-0.77) 0.62 (0.49-0.80) 
40-75 
      
 
low 286 (129) 1594 (472) 0.65 (0.52-0.83) 0.69 (0.54-0.87) 
 
high 22 (11) 137 (41) 0.60 (0.27-1.34) 0.64 (0.28-1.44) 
 
total 308 (141) 1732 (513) 0.65 (0.52-0.81) 0.68 (0.54-0.85) 
50-69 
      
 
low 197 (91) 1134 (332) 0.63 (0.48-0.84) 0.64 (0.49-0.85) 
 
high 17 (6) 72 (15) 0.59 (0.20-1.75) 0.57 (0.19-1.70) 
  total 214 (97) 1207 (348) 0.64 (0.49-0.83) 0.64 (0.49-0.84) 
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screening by SES may be real or not found because of limitations of the current study.
A difference in the relative effect of mammographic screening by SES may be expected 
because women with high and low SES may differ in treatment17, mammography test char-
acteristics18, and/or breast cancer awareness.19 Adequate treatment after the detection 
of breast cancers by screening is essential for screening to be effective.20 Previous studies 
indicated that treatment inequalities between women with low SES and high SES may 
explain the lower survival from screen-detected breast cancer for women with low SES.17,21 
The main source of the treatment inequalities is probably not SES itself, but rather the 
higher presence of comorbid conditions in women with low SES.22,23 If women with low SES 
had less and/or less favorable treatment than women with high SES in the current study, 
it would be expected that the relative effect of mammographic screening is smaller for 
women with low SES than for women with high SES.
However, there are more factors that can potentially influence the effectiveness of 
mammographic screening by SES and that have an opposite effect, i.e. mammographic 
test characteristics and breast cancer awareness. Mammographic screening test charac-
teristics, such as sensitivity, may be lower for women with high SES. This is mainly because 
SES is positively associated with breast density10 and high breast density can mask tumors 
on mammograms.11 SES itself is not likely to affect the screening test characteristics in the 
Netherlands, because quality of screening does not depend on SES and evaluating radi-
ologists are unaware of SES. Furthermore, the relative effect of mammographic screening 
may be smaller for women with high SES than for women with low SES because women 
with high SES have higher breast cancer awareness.19 A high breast cancer awareness is 
associated with cancer-related behavior such as healthcare seeking.19 As a consequence, 
women with high SES that did not participate in the index or the pre-index round may 
still have been detected early, leading to a smaller effect of screening in women with high 
than low SES. Because the effect of treatment and breast cancer awareness are in an op-
posite direction, if existing in our study population, they may cancel out and result in an 
unobservable effect in this study. 
Limitations and strengths
The absence of a difference in the relative effect of mammographic screening may also 
be the result of limitations of the current study. In this study, SES was based on an area-
based measure, which does not capture individual SES as well as an individual level SES 
measure.24 Furthermore, we extrapolated the SES of the period 1995-1998 to the period 
1975-1994. These two limitations of the SES indicator used in this study may have caused 
87The relative effect of mammographic screening on breast cancer mortality by socio-economic status 
misclassification of SES and attenuated the effect of SES towards the null. Besides this, 
Nijmegen had in general a low SES, especially in the early years, leading to a small number 
of cases with high SES. As a consequence, the OR for women with high SES had wide con-
fidence intervals. This problem can be overcome by using a larger number of cases, i.e. by 
linking national cancer and screening registries. We would, however, like to point out that 
Hellquist et al9 also found no significant difference in the effectiveness of mammographic 
screening by SES, even though this study had an individual measure and a high number of 
women who died from breast cancer.
Our study also had strengths and limitations related to study design, study population 
and external validity. Major strengths of our study were the use of a population-based ap-
proach, histological ascertainment of breast cancer and accurate ascertainment of cause 
of death by a panel. A limitation of our study is the risk of self-selection bias, because 
we compared attenders with non-attenders that may have a different background risk of 
breast cancer. Self-selection bias in the Netherlands is, however, small25 and we did not 
adjust for self-selection because it is related to SES. Furthermore, our study population 
covered only about one third of the SES range in the Netherlands, thereby excluding the 
most extreme SES groups. We cannot exclude the possibility that the highest and lowest 
SES groups have a different impact on the effectiveness of mammographic screening, al-
though this seems unlikely. Caution should also be taken in generalizing the results of this 
study to other countries, because SES is not an uniform concept26 and depends on cultural 
factors.8 We did, however, use a combination of factors that are often used to conceptu-
alize SES, i.e. education, income and e mployment, and this combination of factors may 
have the same effect on the effectiveness of mammographic screening in countries that 
are comparable to the Netherlands.
Usefulness of SES in personalized screening
Finally, we would like to discuss the potential usefulness of SES in personalized screen-
ing. Factors relevant for personalized screening should be able to differentiate women 
with a more favorable benefit-harms balance from women with a less favorable, or even 
unfavorable, benefit-harm balance. Socio-economic status seems to have this potential: 
assuming that the effectiveness of screening does not vary by SES, it can be expected that 
the absolute number of breast cancer deaths prevented by screening, i.e. the benefit, is 
higher for women with a high SES. However, the harms of screening (false-positives, false-
negatives and overdiagnosis) should not be disproportionally higher for women with high 
SES than for women with low SES. We would further like to point out that discussion is 
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needed to decide whether it is ethical to use SES as a factor for personalized screening. 
It is well-known that women with high SES generally have lower all-cause mortality and 
higher life-expectancy. Thus, if a personalized screening program would result in a more 
favorable benefit-harm balance for women with high SES than low SES, this would lead to 
further health inequality. 
Conclusion
To conclude, mammographic screening reduces breast cancer mortality in women tar-
geted in most European mammographic screening programs, i.e. women aged 50-75, 40-
75 and 50-69. We did not observe a difference in the relative effect of mammographic 
screening on the breast cancer mortality between women with high and low SES. As a 
consequence, the absolute number of breast cancers prevented is likely to be higher for 
women with high SES than for women with low SES. To complete the benefit-harm bal-
ance for women with high and low SES, the harms of screening in terms of false-positives, 
interval cancers and overdiagnosis, should also be estimated for SES subgroups.
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The effect of co-morbidities on the benefit of 
mammographic screening: a case control study
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ABSTRACT
Objective: Women with co-morbidities have a higher risk of all-cause mortality and breast 
cancer specific mortality, even when breast cancers are diagnosed early. Consequently, 
women with co-morbidities may benefit less from population based breast cancer screen-
ing.  The objective of this study is to evaluate the effect of mammography screening on 
breast cancer mortality for women with and without co-morbidities.
Methods:  In Nijmegen, the Netherlands, a population-based screening programme was 
initiated in 1975, inviting women aged 50-75 years for biennial breast cancer screening. 
We designed a case-control study to investigate the effect of mammographic screening on 
breast cancer mortality stratified for co-morbidity. Data on co-morbidities was obtained 
from general practices in Nijmegen and selected based on the Charlson Co-morbidity In-
dex. We conducted ten complete case analyses and ten sensitivity analyses with multiply 
imputed co-morbidity data. 
Results: Of the women with registered co-morbidity data and invited to mammograph-
ic screening, 15.5% had at least one medical condition, i.e. potential co-morbid condi-
tion. Women with co-morbidities attended screening less frequently than women with 
co-morbidities. Overall, mammographic screening had a positive effect on breast cancer 
mortality reduction, which was stronger in the sensitivity analyses (odds ratio (OR) rang-
ing between 0.67 and 0.75) than in the complete case analyses (OR ranging between 0.78 
and 0.93). The effectiveness was not significantly different for women with and without 
co-morbidities: there were wide confidence intervals and the direction of the effect de-
pended on the control selection.
Conclusion: Breast cancer screening reduces breast cancer mortality in women aged 50-
75 years. The breast cancer mortality reduction was not significantly different for women 
with and without co-morbidity due to lack of power. However, it remains likely that wom-
en with co-morbidities benefit less from breast cancer screening, because co-morbidity 
decreases breast cancer survival.
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INTRODUCTION
The proportion of women diagnosed with multiple medical conditions increases with age. 
In addition, the co-existence of a medical condition next to breast cancer, i.e. co-morbid-
ity, increases. Around 7-9% of women aged under 50 have at least one or more serious 
coexistent diseases next to breast cancer, whereas 21% of women aged 50-79 has one 
or more serious co-morbidities.1,2 The incidence of co-morbid diseases will only further 
increase over time due to demographic ageing. This could have implications for the ef-
fectiveness of healthcare interventions targeting individuals of 50 years and older, such as 
the population based mammographic screening programme for breast cancer. 
Women aged 50-75 years represent the target group for population based mammog-
raphy breast cancer screening in the Netherlands. Overall, population based mammogra-
phy screening programmes have been shown to facilitate early detection of breast cancer, 
thereby reducing breast cancer mortality and improving treatment outcomes.3,4 However, 
little is known about the effectiveness of breast cancer screening for women with co-
morbidities, even though they form a substantial portion of the screening population. 
Previous research has shown that early breast cancer diagnosis (stage 1) versus later 
stage breast cancer diagnosis (stage 2) has no apparent advantageous effect on survival for 
women over 66 years with co-morbidities.5-7 Co-morbidity has been shown to negatively 
affect prognosis, independent of a woman’s age or stage of disease at time of diagnosis.1 
In addition, the presence of co-morbid conditions has consistently been shown to affect 
breast cancer mortality.5,8,9  Women with severe co-morbidities have higher breast cancer 
mortality rates than women with no or mild co-morbidities. It has been argued that the 
presence of co-morbid conditions and breast cancer stage at diagnosis are equally impor-
tant in predicting breast cancer mortality.10 This detrimental effect of co-morbidities on 
breast cancer survival could be due to suboptimal treatment2,5,8,11, accelerated co-morbid 
disease progression due to breast cancer treatment7, or a prior increased risk of mortality 
due to the co-morbid condition12. 
Consequently, it is conceivable that women with co-morbidities experience the posi-
tive effects of screening differently, calling for a more personalised approach which takes 
co-morbidity status into account when determining, for example, the frequency of breast 
cancer screening.13 However, the effect of mammography screening on breast cancer 
mortality in women with co-morbidities compared with women without co-morbidities 
remains unknown. Therefore, the present study aims to assess the relative effect of mam-
mography screening on breast cancer mortality for women with and without chronic co-
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morbidities applying a case-control design.    
METHODS  
Setting
In 1975 the Nijmegen breast cancer screening programme was established inviting women 
aged 35 years and older to participate in mammography screening. After the programme 
became nationwide in 1989, only women aged 50-69 years were eligible for screening 
biennially. In Nijmegen, women aged over 70 years who had participated in the previ-
ous screening round were also eligible for screening if they scheduled an appointment. 
In 1997 the age-criteria were expanded to include women aged 70-75 years. Attendance 
rates stabilised from 1979 onwards to around 62% of women aged 50-69 years and 22% 
for women aged 70 years and over.14
Participant data
To evaluate the effect of the mammographic screening programme for women with and 
without co-morbidities, data were obtained for women who lived in Nijmegen, the Neth-
erlands. We linked two databases, the breast cancer screening database and the General 
Practitioner (GP) database, using probabilistic linkage based on date of birth, four-digit 
postal code and general practice (See Figure 4.1). The breast screening database holds 
information on screening invitation, screening attendance and vital status (date of death 
or migration) of all women invited to organized mammographic screening since 1975. 
Furthermore, the registry contains medical information on all breast cancer patients in 
Nijmegen diagnosed within and outside the screening programme, including incomplete 
data on co-morbidity from hospitals. Cause of death was assessed by a committee of phy-
sicians comprising a pathologist, a medical oncologist and a radiologist who were blind 
to the woman’s screening history.15 All women included in the breast cancer screening 
database consented to the use of their anonymous data for scientific research.
The GP database of the department of Primary and Community Care at the Radboud 
university medical center contains demographic and diagnostic data. In 2013, this data-
base contained data from electronic health records of 197 general practices in the Eastern 
part of the Netherlands, covering a population of approximately 750,000 patients. Dis-
eases (co-morbidities for the cases) were coded according to the International Classifica-
tion of Primary Care (ICPC), expanded with Dutch ICPC sub-codes.16,17 The GP Database 
complies with the Code of Conduct for Health Research, which has been approved by the 
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Data Protection Authorities for conformity with the applicable Dutch privacy legislation.
After probabilistic linkage of the breast cancer screening database and GP database, 
we obtained the ‘linked’ database (see Figure 4.1). The linked database included nearly 
all women of the breast cancer screening database with a changed working number. Only 
women with a disease that affected less than ten women were removed from the data-
base (n=8 for HIV/AIDS) to prevent the possibility of linking data to a unique woman. In 
the linked database, we only included diseases from the GP database that were listed in 
the Charlson Co-morbidity Index (CCI).18 Diseases listed in the CCI are chronic diseases that 
have been shown to affect the breast cancer mortality (See Supplement). In the current 
study, we only included the co-morbidity data of women who had a unique combina-
tion of date of birth, four-digit postal code and general practice and thus perfect linkage. 
After linking, a rate of 68.7% missing data on co-morbidity status was identified for the 
total population of women invited for screening. The linkage proposal was submitted to a 
Dutch organisation protecting the data rights of individuals, i.e. College Bescherming Per-
Breast cancer screening database 
N = 63,154 
 
- Screening invitation and attendance 
- Breast cancer diagnosis  
- Vital status 
- Cause of death 
General practitioner database 
N = About 750,000 patients 
 
- Medical conditions (Coded using the 
International Classification of Primary 
Care, ICPC) 
 
Linked dataset 
N = 63,146   
 
- All women from the breast cancer screening 
database who had no HIV/aids (n=8) 
- All diseases from the general practitioner 
database listed in the Charlson’s Comorbidity 
Index 
Complete case analysis 
N = 19,741 
Sensitivity analysis 
N =  63,146 
Cases 
N = 241 
 
Women who were 
invited for 
mammographic 
screening and died from 
breast cancer between 
1975 and 2013 
 
 
 
Controls (5 per case) 
N = variable 
 
Women who matched 
the case on year of birth, 
were invited for 
screening and free of 
breast cancer at the 
index round of the case, 
were alive at time of 
death of the case, and 
were living in Nijmegen 
Cases 
N = 370 
 
Women who were 
invited for 
mammographic 
screening and died from 
breast cancer between 
1975 and 2013 
 
 
 
Controls (5 per case) 
N = 1,850 
 
Women who matched 
the case on year of birth, 
were invited for 
screening and free of 
breast cancer at the 
index round of the case, 
were alive at time of 
death of the case, and 
were living in Nijmegen 
Figure 4.1 - Participant data
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soonsgegevens. For this study, approval of an external ethics committee was not required. 
Study design and participant selection
A case-control study was performed studying the effect of exposure to mammographic 
screening on breast cancer mortality, for women with and without co-morbidities. For 
each case, five controls were selected. Cases were identified as women who died from 
breast cancer before January 2013, lived in Nijmegen, and were invited for mammograph-
ic screening at least once between 1975-2012. To measure exposure, the index round was 
determined for each case, i.e. the year of the mammographic screening round in which 
the case was diagnosed or the round preceding the breast cancer diagnosis in case of an 
interval cancer. Cases had to be invited for screening in the index round, but they did not 
have to attend screening (i.e. exposure versus no exposure to mammography screening). 
Time of exposure to mammographic screening was set at 4 years before the breast cancer 
diagnosis of the case, based on estimated lead-times of breast cancer19,20, covering two 
consecutive screening rounds (i.e. biennial screening). Therefore, the pre-index round 
was also determined; i.e. the round preceding the index round. Exposure to mammo-
graphic screening was determined based on screening attendance in the pre-index and/
or the index round (yes/no). For every case, five controls were randomly selected using 
incidence density sampling.21 The controls had to meet the following criteria: 1) match the 
case on year of birth, 2) invited for screening and free of breast cancer at the index round 
of the case, 3) alive at time of death of the case, and 4) living in Nijmegen. Controls had 
to be invited for screening at the index round of the case, to ensure equal opportunity to 
the exposure variable (i.e. mammographic screening). For this same reason controls had 
to be free of breast cancer at the index round of the case. If the control had been diag-
nosed with breast cancer around that time period, she would have been unlikely to attend 
screening, hampering the equal opportunity principle. A control can develop breast can-
cer and/or become a case in a later screening round. Exposure to mammographic screen-
ing for the controls was measured as screening attendance in the pre-index and/or index 
round of the case (yes/no). 
Analyses 
The outcome variable ‘breast cancer mortality’ was analysed as a dichotomous variable 
(cause of death breast cancer yes/no). Exposure to mammography screening was defined 
as: the case or control attended screening in the pre-index and/or index round of the case 
(yes/no). Co-morbidity was defined as ‘the case or control had a diagnosed condition 
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listed in the CCI at the time of the index round of the case’ (yes/no). Descriptive statis-
tics were calculated for age at index round, index round, year of breast cancer diagnosis, 
(co-)morbidity, and screening attendance for the cases and controls. Conditional logistic 
regression analyses were performed for the matched case-control sets, stratified for co-
morbidity, to evaluate the effect of mammography screening for women with and without 
chronic co-morbidities. Ten complete case analyses were performed on a dataset without 
missing values on co-morbidity. In addition, ten sensitivity analyses were performed with 
multiply imputed co-morbidity data. Imputation of missing data is only valid if the data 
is missing at random. In our dataset, missings were related to calendar period with more 
missing data in earlier years. Therefore, we imputed the missing data using index round 
(as approximation of calendar period), age at index round, socio economic status (SES), 
screening attendance, breast cancer mortality, and the interaction between screening at-
tendance and breast cancer mortality. SES was determined based on the four-digit postal 
code used as the SES indicator of the Netherlands Institute for Social Research.22 SES was 
added to the imputation model, because of the known association of SES with co-morbid-
ity status.23,24 Since the rate of missing co-morbidity data in the original ‘linked’ database 
was 68.7%, a total of 75 imputed databases were generated with 100 iterations.25,26 Analy-
ses were performed using SAS 9.2 software (SAS Institute Inc, Cary, NC), and IBM SPSS 
version 22 (Armonk, NY: IBM Corp).
RESULTS 
Study population
The number of women with a known co-morbidity status increased substantially over 
time, from 1.3% in 1975 to 73.8% in 2013 (See Figure 4.2). The percentage of women with 
at least one co-morbidity (of the total number of women with registered co-morbidities) 
also increased over time: from 6-9% in 1975-1993, rapidly increasing to 42.0% in 2013. 
On average, 15.5% had at least one medical condition, whereas 84.5% had no medical 
condition.
Figure 4.3 presents the screening attendance rates for women with and without co-
morbidities from 1991 to 2013. We chose to only display attendance rates for this period, 
because the co-morbidity data for this period was more precise and extensive, facilitating 
meaningful interpretation of the results. Figure 4.3 shows that women with co-morbidi-
ties have consistently lower screening attendance rates than women without co-morbidi-
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Figure 4.2 - Percentage of women with known co-morbidity status
ties. The same pattern was observed in 5-years age groups.     
Effectiveness of mammography screening 
During the study period, 370 women died from breast cancer (cases), however co-morbid-
ity data was only available for 241 of these women. Therefore, the complete case analysis 
included 241 cases, whereas the sensitivity analysis included 370 cases. Of the 129 extra 
cases included in the sensitivity analyses, 106 cases (87%) were detected during the first 
five screening rounds. For each case, five controls who matched the eligibility criteria 
were randomly sampled. The number of controls was lower in the complete analyses, 
because a small number of cases were matched to fewer than five controls (see Table 4.1). 
Table 4.1 and 4.2 present the effect of mammographic screening on breast cancer 
mortality for women with and without co-morbidities for the complete case analyses and 
sensitivity analyses, respectively. The tables show that mammographic screening has a 
positive effect on breast cancer mortality for the total population. This effect was smaller 
in the complete case analyse (OR ranging between 0.78 and 0.93) than in the sensitivity 
analyses (OR ranging between 0.67 and 0.75). Furthermore, Table 4.1 and 4.2 show that 
the effect of co-morbidity on the effectiveness of mammographic screening to reduce 
breast cancer mortality was non-significant. The direction of the effect is dependent on 
the control selection and the confidence intervals are wide.
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Figure 4.3 - Mammography screening attendance rates (% attendance) for women with and without co-morbid-
ities from 1991 onwards (biennial screening)
In both the complete case analyses and sensitivity analyses, the cases with co-morbid-
ities generally were older and diagnosed in later screening rounds than the cases without 
co-morbidities. In order to validate the sensitivity analyses, we compared the percentage 
of controls with co-morbidities in the complete case analyses and sensitivity analyses. In 
the complete case analyses, the percentage of controls ranged between 12.3% and 15.1%, 
whereas it ranged between 23.7% and 26.4% in the sensitivity analyses.
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Table 4.1 The effect of mammographic screening on breast cancer mortality for women with and 
without co-morbidities for the complete case analyses 
    Cases Controls   
    Screened  (not screened) Screened  (not screened) OR (95% CI)a 
Complete case analysis 1 
    
 
Total 156 (85) 797 (384) 0.86 (0.63, 1.16) 
 
Co-morbidity 20 (13) 131 (47) 0.78 (0.20, 3.06) 
 
No co-morbidity 136 (72) 666 (337) 0.97 (0.70, 1.36) 
Complete case analysis 2 
    
 
Total 156 (85) 778 (403) 0.93 (0.69, 1.25) 
 
Co-morbidity 20 (13) 125 (41) 0.65 (0.20, 2.08) 
 
No co-morbidity 136 (72) 653 (362) 1.00 (0.72,1.39) 
Complete case analysis 3 
    
 
Total 156 (85) 819 (362) 0.78 (0.58, 1,06) 
 
Co-morbidity 20 (13) 112 (33) 0.80 (0.24, 2.68) 
 
No co-morbidity 136 (72) 707 (329) 0.88 (063, 1.23) 
Complete case analysis 4 
    
 
Total 156 (85) 806 (375) 0.82 (0.60, 1.12) 
 
Co-morbidity 20 (13) 117 (39) 0.27 (0.07, 1.03) 
 
No co-morbidity 136 (72) 689 (336) 0.84 (0.60, 1.18) 
Complete case analysis 5 
    
 
Total 156 (85) 801 (380) 0.84 (0.62, 1.14) 
 
Co-morbidity 20 (13) 120 (42) 0.88 (0.26, 2.94) 
 
No co-morbidity 136 (72) 681 (338) 0.90 (0.65, 1.26) 
Complete case analysis 6 
    
 
Total 156 (85) 795 (386) 0.86 (0.63, 1.17) 
 
Co-morbidity 20 (13) 116 (46) 3.10 (0.59, 16.3) 
 
No co-morbidity 136 (72) 679 (340) 0.92 (0.66, 1.29) 
Complete case analysis 7 
    
 
Total 156 (85) 780 (401) 0.92 (0.68, 1.25) 
 
Co-morbidity 20 (13) 116 (43) no optimization 
 
No co-morbidity 136 (72) 664 (358) 0.98 (0.70, 1.38) 
Complete case analysis 8 
    
 
Total 156 (85) 807 (374) 0.82 (0.61, 1.11) 
 
Co-morbidity 20 (13) 122 (43) 1.64 (0.48, 5.63) 
 
No co-morbidity 136 (72) 685 (331) 0.90 (0.65, 1.26) 
Complete case analysis 9 
    
 
Total 156 (85) 795 (386) 0.86 (0.64, 1.17) 
 
Co-morbidity 20 (13) 130 (20) 0.80 (0.23, 2.87) 
 
No co-morbidity 136 (72) 665 (349) 1.01 (0.72, 1.41) 
Complete case analysis 10 
    
 
Total 156 (85) 817 (364) 0.79 (0.58, 1.07) 
 
Co-morbidity 20 (13) 117 (45) 0.18 (0.02, 1.55) 
  No co-morbidity 136 (72) 700 (319) 0.85 (0.60, 1.19) 
a The ORs presented in the table do not correspond to the ORs calculated based on the presented cell-entries due to 
   the conditional nature of the regression analyses  
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Table 4.2 The effect of mammographic screening on breast cancer mortality for women with and 
without co-morbidities for the sensitivity analysesa 
    Cases Controls   
    Screened  (not screened) Screened  (not screened) OR (95% CI)b 
Sensitivity 1 
     
 
Total 245 (125) 1348 (502) 0.72 (0.56, 0.92) 
 
Co-morbidity 49  (23) 319 (117) 1.16 (0.44, 3.10) 
 
No co-morbidity 196  (102) 1029 (385) 0.65 (0.47, 0.89) 
Sensitivity 2 
     
 
Total 245 (125) 1355 (495) 0.70 (0.55, 0.90) 
 
Co-morbidity 49 (24) 370 (90) 0.65 (0.22, 1.92) 
 
No co-morbidity 195 (102) 985 (405) 0.76 (0.55, 1.04) 
Sensitivity 3 
     
 
Total 245 (125) 1336 (514) 0.74 (0.58, 0.95) 
 
Co-morbidity 48 (24) 333 (109) 0.69 (0.26, 1.84) 
 
No co-morbidity 197 (101) 1003 (405) 0.77 (0.55, 1.06) 
Sensitivity 4 
     
 
Total 245 (125) 1363 (487) 0.68 (0.53, 0.88) 
 
Co-morbidity 50 (26) 381 (103) 0.50 (0.19, 1.34) 
 
No co-morbidity 195 (99) 982 (384) 0.76 (0.55, 1.04) 
Sensitivity 5 
     
 
Total 245 (125) 1342 (508) 0.72 (0.57, 0.93) 
 
Co-morbidity 47 (22) 352 (92) 0.66 (0.21, 2.12) 
 
No co-morbidity 198 (103) 990 (416) 0.79 (0.57, 1.09) 
Sensitivity 6 
     
 
Total 245 (125) 1329 (521) 0.75 (0.59, 0.96) 
 
Co-morbidity 48 (23) 338 (113) 0.75 (0.27, 2.12) 
 
No co-morbidity 197 (102) 991 (408) 0.73 (0.53, 1.02) 
Sensitivity 7 
     
 
Total 245 (125) 1342 (245) 0.73 (0.57, 0.93) 
 
Co-morbidity 44 (23) 323 (94) 0.66 (0.21, 2.15) 
 
No co-morbidity 201 (102) 1019 (414) 0.80 (0.58, 1.09) 
Sensitivity 8 
     
 
Total 245 (125) 1365 (485) 0.67 (0.52, 0.86) 
 
Co-morbidity 42 (20) 255 (94) 0.78 (0.24, 2.57) 
 
No co-morbidity 213 (105) 1110 (391) 0.68 (0.49, 0.93) 
Sensitivity 9 
     
 
Total 245 (125) 1340 (510) 0.73 (0.57, 0.94) 
 
Co-morbidity 48 (25) 307 (106) 0.63 (0.21, 1.83) 
 
No co-morbidity 197 (100) 1033 (404) 0.74 (0.54, 1.03) 
Sensitivity 10 
     
 
Total 245 (125) 1349 (501) 0.71 (0.56, 0.91) 
 
Co-morbidity 43 (21) 378 (112) 0.82 (0.29, 2.35) 
  No co-morbidity 202 (104) 971 (389) 0.75 (0.55, 1.02) 
a Co-morbidity imputed using index round, age at index round, social economic status, screening attendance, breast cancer 
mortality, and the interaction between screening attendance and breast cancer mortality 
b The ORs presented in the table do not correspond to the ORs calculated based on the presented cell-entries due to 
   the conditional nature of the regression analyses  
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DISCUSSION  
To our knowledge, this is the first study evaluating the effectiveness of mammographic 
screening on breast cancer mortality for women with and without serious co-morbidities. 
The results confirm an overall significant positive effect of screening on breast cancer 
mortality. However, the effectiveness of mammographic screening on breast cancer mor-
tality differs not statistically significant for women with and without co-morbidity. 
Previous research showed that women with co-morbid diseases have a higher breast 
cancer mortality12, even when breast cancers are diagnosed early.8,9 Mammographic 
screening may be effective for women with mild to moderate co-morbidity6, but older 
women with severe or multiple co-morbidities seem to have no survival advantage at 
all from early detection.6,7 Therefore, we expected to find a decreased effect of mammo-
graphic screening on breast cancer mortality for women with co-morbidities. Our results 
could not confirm this hypothesis due to lack of power: the number of women with one 
or more co-morbidities who died from breast cancer (cases) was small which resulted in 
unstable odds ratios with wide confidence intervals.
 Another limitation of our dataset was the large number of missing data for co-
morbidity. Therefore, we estimated the effect of mammographic screening on breast 
cancer mortality in two datasets: one including only women with complete data on co-
morbidity (about 30% of the data) and one including all women using multiple imputation 
to impute missing co-morbidity data. Both datasets have some limitations. The analyses 
on the dataset including only women with complete data on co-morbidity, i.e. complete 
case analyses, may be subjected to selection bias. This selection has likely resulted in a 
small bias, because we observed a smaller effect of mammographic screening for the total 
population in the complete case analyses than in the sensitivity analyses. The co-morbid-
ity status of women attending other general practices in Nijmegen that were not included 
in the GP database could also have related differently to screening attendance and this 
exclusion may have resulted in additional selection bias. However, the lower mammogra-
phy screening attendance rates for women with co-morbidities in our study corresponds 
to previous findings.27 
On the other hand, the analyses based on the dataset were missing co-morbidity data 
was imputed, i.e. sensitivity analyses, may also be subjected to errors. Co-morbidity was 
missing for 68.7% of the total population and for less than 35% of the cases. The number 
of missing data was however not the main issue, the (lack of) randomness of the missing 
data was. The missing data was related to the period in time (as shown in Figure 4.2), 
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and therefore we used, among other variables the index round to impute missing data. 
This may have been suboptimal, because the percentage of controls with co-morbidities 
was lower in the complete case analyses (12.3%-15.1%) than in the sensitivity analyses 
(23.7%-26.4%). An opposite effect was expected based on the fact that 87% of the cases 
with missing co-morbidity data were diagnosed with breast cancer in the first five screen-
ing rounds. Furthermore, imputation was based on the selected cases and controls rather 
than the complete dataset. This may have influenced the ‘randomness’ of the missing 
data and resulted in unreliable effects. Because both analyses may be subjected to differ-
ent types of bias, we chose to provide a comprehensive overview of the potential sources 
of bias to aid interpretation of the results.
We would also like to point out that we used co-morbidity data from hospitals for the 
cases and co-morbidity data from general practitioners for the total population. Previous 
research has shown that the registration of medical information is dependent on the set-
ting.28 This was also observed in our study: six women had co-morbidity according to the 
hospital data, but not according to the data of the general practices. However, these co-
morbidities were registered in the earlier years of the screening program. Since then, the 
(co-)morbidity registration of the general practices has improved substantially.29 Future 
studies should try to obtain co-morbidity from databases that are most likely used in prac-
tice if co-morbidity will be used to define the target population of breast cancer screening.
We did not adjust our analyses for potential confounding factors. Confounding bias 
is inherent to case-control studies, because women who chose to attend screening are 
compared with women who chose not to attend (self-selection bias). It is conceivable that 
attendees have a different set of predisposing risk factors for breast cancer (e.g. family his-
tory of breast cancer) than non-attendees. However, self-selection bias has been shown 
to be small in the Netherlands and a correction factor for self-selection is not available for 
co-morbidity subgroups; therefore it was chosen not to apply a correction.30
This study has some major limitations that withhold us from drawing a reliable con-
clusion on the effectiveness of mammographic screening on breast cancer mortality for 
women with co-morbidities. Still, we would like to make some recommendations for prac-
tice and research. Firstly, we believe that co-morbidity is useful factor to define the target 
population of mammographic screening. Regardless of the relative effect of screening, 
which we aimed to assess in this study, the absolute benefit of mammographic screen-
ing is likely to be smaller for women with co-morbidities. Co-morbidity has consistently 
been shown to have a significant negative effect on survival even when adjusted for age 
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and stage of diagnosis.1,12 Furthermore, it is conceivable that women with co-morbidities 
have a higher risk of overdiagnosis (one of the major harms of screening), because these 
women have generally a lower life-expectancy.31,32 Consequently, the presence of co-mor-
bidities is a potentially important and unique factor in the development of a risk-based 
personalised screening programme. In the United States, this is already recognized by 
multiple organisations which recommend including a woman’s life-expectancy and co-
morbidity status in the screening consideration.32 
Secondly, we recommend researchers to further explore the influence of co-mor-
bidities, preferably individual co-morbidities, on the effectiveness of mammographic 
screening on breast cancer mortality. Even though a woman’s life-expectancy is useful for 
personalised screening, the effectiveness of mammographic screening on breast cancer 
mortality for women with co-morbidities will provide additional insight. It investigates 
the interaction between screening and co-morbidity. If screening effectiveness is affected 
by co-morbidity status, this can be used to further improve individualised breast cancer 
screening, i.e. provide each women with the optimal screening regimen.
 To conclude, mammographic screening reduces breast cancer mortality in the current 
target population. The breast cancer mortality reduction was not significantly different for 
women with and without co-morbidity due to lack of power of this study. Co-morbidity 
is however a potentially relevant and important factor for personalised mammograph-
ic screening, because co-morbidity decreases breast cancer survival. Consequently, the 
harm-benefit ratio of mammographic screening for women with co-morbidities should 
be re-examined.
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SUPPLEMENT
Table S4.1 Overview of the co-morbidities included in the present study with 
complementing ICPC codes 
 
Weight Conditions ICPC-codes 
1 Myocardial infarction K75; K76 
1 Congestive heart failure K77 
1 Peripheral vascular disease K91; K92; K99.1; K99.5; K99.6 
1 Dementia P70 
1 Cerebrovascular disease K89; K90 
1 Chronic pulmonary disease R91; R95; R96 
1 Connective tissue disease L88; L99.12 
1 Ulcer disease D85; D86 
1 Mild liver disease D96; D97 
1 Diabetes T90 
2 Hemiplegia N18 
2 Moderate or severe renal disease K87; U85; U88; U99.1 
2 Any tumor B74; D74; D75; D76; D77; 
F74.1; H75.1; K72.1; L71.1; 
N74; R84; R85; S77; T71; U75; 
U76; U77; X75; X77;  
2 Leukemia B73 
2 Lymphoma B72 
3 Moderate or severe liver disease D72 
6 Metastatic solid tumor A79 
 
 

CHAPTER 5
Breast cancer screening effect across breast density 
strata: a case-control study
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ABSTRACT
Background: Breast cancer screening is known to reduce breast cancer mortality. A high 
breast density may affect the mortality reduction. Breast density is a breast cancer risk fac-
tor, and dense tissue masks tumours on mammograms. We assessed the effect of screen-
ing on breast cancer mortality in women with high and low breast density separately. 
Methods: Analyses were performed within the Nijmegen (Dutch) screening programme 
(1975-2008), which invites women (50-74 years) biennially. Screening performance mea-
sures were determined across breast density strata. Furthermore, a case-control study 
was performed for women having a dense and women having a non-dense breast pattern. 
Breast density was assessed visually, based on a dichotomized version of the Wolfe scale: 
non-dense (<25%) and dense (>25%). Breast density data were available for case subjects. 
The prevalence of dense breasts in the control group was estimated based on age-specific 
prevalence rates from the general population. Sensitivity analyses were performed on 
these prevalence estimates. 
Results: Screening performance was better in the non-dense than in the dense group 
(e.g., sensitivity 75.7% vs. 57.8%). The mortality reduction appeared to be smaller for 
women with dense breasts, with an estimated effect of 15% in the dense (OR 0.85, 95%CI 
0.51-1.43) and 41% in the non-dense group (OR 0.59, 95%CI 0.44-0.80).
Conclusion: High breast density results in lower screening performance and appears to 
be associated with a smaller mortality reduction. Breast density is thus a likely candidate 
to include in risk-stratified screening. However, more research is needed to establish the 
association between density and screening harms to gain insight into the overall screen-
ing balance.
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INTRODUCTION
Breast cancer is the number one cancer death in women worldwide, even though mor-
tality has been decreasing over time.1-3 Screening programmes, aimed to detect breast 
cancer at an early stage, have contributed to this mortality reduction. According to the 
independent UK panel, who used published trial data, invitation to screening will reduce 
breast cancer mortality by 20%.4 Developments in the field of screening techniques, how-
ever, have not stopped after completion of these screening trials.4 For example, screen-
film mammography has been replaced by full-field digital mammography, which produces 
higher quality images. In addition, the survival improvements due to the introduction and 
increasing uptake of new adjuvant therapies since the 1970s may have changed the syn-
ergistic dynamic between treatment and screening.5,6 As a result, the trial data cannot be 
used to draw conclusions on the current screening programme or to explore opportuni-
ties for improvement, such as the inclusion of breast cancer risk factors in determining 
screening regimens. Observational study designs are thus needed in the evaluation of 
continuing programmes.
Several case-control studies have estimated the effect of participating in breast cancer 
screening on breast cancer mortality.7-15 None of these studies have, however, addressed 
potential differences in screening effect (effect modification) by risk factors other than 
age. The assessment of effect modification is important for the identification of relevant 
risk groups in the context of risk-stratified or personalised screening. Alternative screening 
regimens could potentially be applied in these groups for an optimal benefit-harm ratio. 
The effect of screening may, for example, vary across breast density strata. Dense tissue 
can mask tumours on a mammogram, and a high breast density is associated with greater 
tumour size and possibly lymph node involvement at the time of diagnosis.16 Furthermore, 
mammographic density is an independent breast cancer risk factor.17 If the screening ef-
fect is indeed heterogeneous and the differences are clinically relevant, adapting screen-
ing based on breast density level may improve the benefit-harm ratio of screening for 
individual participants. Possibilities include the use of additional imaging techniques, for 
example ultrasound or MRI. With these techniques, breast density would give little to no 
hindrance in tumour detection.
The problem with breast density, and many other risk factors, is that often very limited 
information is available from the general screening population, particularly at the indi-
vidual level. This is an important limitation, most profoundly in studies based on existing 
data. Obtaining complete risk factor information can be difficult, especially in women who 
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choose not to participate in breast cancer screening. Adequate methodology therefore 
has to be developed to study subgroup effects while dealing with missing risk factor in-
formation. 
Here, we address screening performance and the effect of screening on breast cancer 
mortality in different breast density strata, while dealing with incomplete risk factor in-
formation in the control group. Data from the long-running Nijmegen (Dutch) screening 
programme were used in this study. The screening effect in women with dense breasts 
and in women with non-dense breasts was assessed with case-control analyses. 
METHODS
Setting
Breast cancer screening was introduced in Nijmegen (the Netherlands) in 1975. In the 
current programme, all women aged 50 to 75 years biennially receive an invitation to 
participate.18-20 They can be screened at fixed or mobile screening units. Mammograms are 
evaluated by certified screening radiologists in an independent double reading setting. 
When suspect findings are observed, the woman will be recalled for additional imaging 
and, if necessary, a biopsy. In 2007, the screening programme switched from screen-film 
to digital mammography. Digital mammography was introduced in the hospitals several 
years before. In the current study, only screen-film mammograms were included. Data 
on vital status of invited women were obtained via linkage with the Municipal Personal 
Records Data Base (GBA). All women consented to the use of their anonymous data for 
scientific research.
Mammographic density assessments
Since 2014, both a mediolateral oblique (MLO) and craniocaudal (CC) view are obtained 
in the Dutch screening programme. MLO was the standard view before 2014, whereas 
a CC was only obligatory at first screening and performed on indication at subsequent 
screening examinations. Mammographic density assessments were based on all available 
views. Density patterns were classified visually according to a four-category scale, based 
on the quantification of the Wolfe breast density pattern (N1, P1, P2, DY): <5%, 5-25%, 25-
75%, >75%.21, 22 A strong correlation between the Wolfe classification and the qualitative 
BI-RADS scale has previously been observed.23 Density estimates were available for clinical 
mammograms, when additional imaging had been performed, and for screening mam-
mograms (determined by a trained research assistant) for women who had ever been 
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recalled. Breast density was dichotomized into a ‘non-dense’ (≤25%) and a ‘dense’ (>25%) 
group for the statistical analyses.
Breast density and screening test performance
Several screening performance measures were determined for the descriptive analyses 
(see Table 5.1). This includes the programme sensitivity ((Screen-detected)/(Screen-
detected+Interval)×100%) and positive predictive value of recall ((Screen-detected)/Re-
call×100%). Data were used from the time period before the introduction of digital mam-
mography, up until 2006. The age is based on age at invitation to the screening round. 
Interval tumours were defined as breast cancer diagnoses within 24 months after a nega-
tive screening exam. Log-binomial regression was used to estimate risk ratios (RR).
Breast density and the effect of screening on breast cancer mortality:                                                                        
case-control analyses
Cases and controls
Case subjects were women who died of breast cancer in Nijmegen between 1975 and 
2008. Each case subject was matched to 5 control subjects via incidence density sam-
pling.24, 25 Control subjects had to be alive at the time of death of the matched case. In ad-
dition, controls had to be free of breast cancer up until the diagnosis date of the matched 
case to ensure an equal screening opportunity. This is referred to as the pseudo-diagnosis 
date of the control subjects. The index round is the screening round at which breast can-
cer is diagnosed for screen-detected cases, or the round preceding the (pseudo-)diagno-
sis date (within 2 years) for interval or non-participating cases and controls. All women 
included in our study, both case subjects and control subjects, had been invited to the 
index round. 
For the cases, the breast density pattern was based on the screening mammogram of 
the index round (n=196). If this was not available (for example, for non-participants), the 
estimate was based on the clinical mammogram (n=111) or the screening mammogram 
from the round preceding the index round (n=3), respectively. Case subjects who still had 
a missing breast pattern (n=23), only non-participants, were randomly allocated to the 
dense group (n=5) or the non-dense group (n=18) based on the density distribution in 
the other non-participating case subjects (22.2% high density). There were no noticeable 
differences between the non-participating case subjects with and without a registered 
breast density pattern. The age distribution of the non-participant cases without an es-
timate of the density pattern (median 62y, IQR 56-69) was similar to the age distribution 
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Table 5.1 Screening performance in different time periods for women with dense 
and non-dense mammographic breast patterns 
 
  
Breast density pattern: N (%)a 
 
Total Non-dense Dense 
Density 
unknown 
Period 1975-1982 
    Recalled 432 269 (62.7) 160 (37.3) 3 
Screen-detected cancer 183 131 (71.6) 52 (28.4) 0 
False-positive 249 138 (56.1) 108 (43.9) 3 
Interval cancer 83 45 (54.9) 37 (45.1) 1 
Programme sensitivity 68.8% 74.4% 58.4% 
 PPV Recall 42.4% 48.7% 32.5% 
 Period 1983-1990 
    Recalled 268 189 (70.8) 78 (29.2) 1 
Screen-detected cancer 177 123 (69.5) 54 (30.5) 0 
False-positive 91 66 (73.3) 24 (26.7) 1 
Interval cancer 88 40 (45.5) 48 (54.5) 0 
Programme sensitivity 66.8% 75.5% 52.9% 
 PPV Recall 66.0% 65.1% 69.2% 
 Period 1991-1998 
    Recalled 345 263 (76.2) 82 (23.8) 0 
Screen-detected cancer 188 149 (79.3) 39 (20.7) 0 
False-positive 157 114 (72.6) 43 (27.4) 0 
Interval cancer 75 46 (61.3) 29 (38.7) 0 
Programme sensitivity 71.5% 76.4% 57.4% 
 PPV Recall 54.5% 56.7% 47.6% 
 Period 1999-2006 
    Recalled 739 513 (69.6) 224 (30.4) 2 
Screen-detected cancer 293 212 (72.6) 80 (27.4) 1 
False-positive 446 301 (67.6) 144 (32.4) 1 
Interval cancer 126 66 (55.9) 52 (44.1) 8 
Programme sensitivity 69.9% 76.3% 60.6% 
 PPV Recall 39.6% 41.3% 35.7% 
 a Unless indicated otherwise. The percentages in brackets are row percentages.  
PPV = positive predictive value 
 
of the non-participant cases with a density estimate (median 60y, IQR 56-69). The case 
subjects with missing density patterns were diagnosed between 1981 and 2007.
Breast density estimates in the control group were only available for a very selective 
group, namely women who had been recalled. We therefore estimated the overall preva-
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lence of dense breasts in the control subjects, in order to make a contingency table for 
women with dense and non-dense breasts. Based on a sample (n=1430) from the first 
two screening rounds in Nijmegen in the same age group, the prevalence of a high breast 
density was 20% in the population participating in screening. A log-binomial model was 
fitted with breast density (high/low density) as the outcome and age as the predictor.26, 27 
This resulted in the following formula:
Log(High density) = 1.5351 - 0.0517 × Age
The model was applied to the participants and non-participants in the control group sepa-
rately to estimate the prevalence in these groups. This resulted in estimates of 23% high 
breast density among participants and 19% among non-participants. 
In addition, we performed sensitivity analyses with different prevalence estimates (10% 
to 65%) of ‘dense breasts’ in the participating and non-participating controls. This reflects 
varying degrees of potential self-selection related to breast density in this population. 
Statistical analyses
Logistic regression was used to estimate odds ratios (OR) with corresponding 95% con-
fidence intervals (CI) for the association between screening exposure and breast cancer 
mortality. Screening exposure was defined as attending the index screening round and/or 
the screening examination preceding the index round. This reflects the screening partici-
pation within the 4 years before (pseudo-)diagnosis. All analyses were stratified by breast 
density pattern. 
RESULTS
Breast density and screening performance
Table 5.1 shows various performance parameters for different time periods since the 
start of the screening programme in 1975. The proportion of women with dense breasts 
among the interval cases ranged from 38.7% to 54.5%, and these proportions were al-
ways greater than for the screen-detected cases (ranged from 20.7% to 30.5%). For the 
false-positive recalls, the proportion of women with dense breasts varied from 26.7% to 
43.9%, with the highest proportion observed in the first time period. In most screening 
programmes, recall patterns tend to be different during the first screening round com-
pared with later rounds. 
The programme sensitivity remained relatively stable over time in both the dense 
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Table 5.2 Effect of screening on breast cancer mortality overall and for women 
having dense or non-dense mammographic patterns, using estimates based on the 
age distribution.a 
 
 Screened Non-screened 
Overall   
Case subjects  220 113 
Control subjects 1240 425 
OR (95% CI) 0.67 (0.52-0.86) 
Dense   
Case subjects 75 25 
Control subjects 285 81 
OR (95% CI) 0.85 (0.51-1.43) 
Non-dense   
Case subjects 145 88 
Control subjects 955 344 
OR (95% CI) 0.59 (0.44-0.80) 
a The estimated prevalence was 23% in the screened group and 19% in the non-screened 
group.    
(overall estimate 57.8%) and the non-dense group (overall estimate 75.7%), and the sensi-
tivity was higher in the non-dense group in all time periods. There was no consistent trend 
in PPV recall, which probably reflects the changes in recall over time.19, 29 The highest PPV 
in both groups was observed between 1983 and 1990, with the dense group then even 
having a slightly higher PPV than the non-dense group (69.2% vs. 65.1%). In all other time 
periods, the PPV in the dense group (overall 41.4%) was notably lower than the PPV in the 
non-dense group (overall 49.8%). The risk of false-positive recall is thus increased in dense 
breasts (RR 1.17, 95% CI 1.07-1.28). The risk of being diagnosed with an interval cancer 
rather than a screen-detected cancer is higher in dense breasts (RR 1.75, 95% CI 1.48-2.07) 
as well.
The sensitivity and the PPV were also higher in the non-dense women in all age groups, 
apart from the 65- to 69-year-olds (See supplement). The PPV in that age group was higher 
for women with a high breast density, with 54.3% compared to 48.1%. Both the sensitivity 
and the PPV increased with age, with a similar trend in sensitivity in the non-dense women 
only. 
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Breast density and screening effect: case-control analyses
Screening effect on breast cancer mortality
Table 5.2 shows the ORs associated with the effect of breast cancer screening on breast 
cancer mortality. The analyses were based on 333 breast cancer deaths that occurred be-
tween 1978 and 2008. Of these case subjects, 220 (66.1%) had attended screening during 
the index round and/or the pre-index round. This includes 123 (36.9%) screen-detected 
tumours. Screening attendance in the last two rounds preceding pseudo-diagnosis was 
74.5% (n=1240) among the 1665 control subjects. Overall, screening attendance during 
the index round and/or pre-index round reduced breast cancer mortality with 33% (OR 
0.67, 95% CI 0.52-0.86). Adjustments for age at the index screening round had little effect 
on the observed mortality reduction (OR 0.69, 95% CI 0.53-0.89). 
Study population by breast density
As shown in Table 5.3, most women (n=39, 41.1%) in the dense group were aged 50-54 
years at index screening. In the non-dense group, on the other hand, most women were 
in the age category 60 to 64 years (n=52, 24.2%). The first breast cancer death among 
the women who had been invited to the programme occurred in 1978. Breast cancer 
deaths were evenly distributed over time. It appeared that a somewhat larger proportion 
of women had a tumour size <20 mm in the non-dense group than in the dense group 
(27.4% vs. 20.0%), with average-sized tumours (20-40 mm) being more common in the 
dense group (48.4% vs. 58.9%). 
Screening effect by breast density
A breast density pattern was available for all case subjects who had attended screening 
recently (n=220). In this group, 75 (34.1%) women had a dense breast pattern. With the 
prevalence estimates based on the age distribution in participants and non-participants, a 
greater effect of screening is observed in the non-dense group (OR 0.59, 95% CI 0.44-0.80) 
than in the dense group (OR 0.85, 95% CI 0.51-1.43) (Table 5.2). 
Sensitivity analysis
A sensitivity analysis was performed to assess the robustness of our analysis, given the 
uncertainty in our breast density prevalence estimates for the control group. The effect 
of screening in different breast density strata (i.e., non-dense/dense) was explored us-
ing different assumptions on the prevalence of dense breasts in participants and non-
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Table 5.3 Age at death, year of diagnosis and year of screening invitation, and tumour characteristics of all 
breast cancer deaths according to breast density pattern at diagnosis 
 
 
N (%)a 
 
Total 
(N=333) 
Dense 
(N=95) 
Non-dense 
(N=215) 
Density 
unknown 
(N=23) 
Age at death (years)   
  50-54 16 (4.8) 7 (7.4) 6 (2.8) 3 (13.0) 
55-59 50 (15.0) 19 (20.0) 27 (12.6) 4 (17.4) 
60-64 58 (17.4) 19 (20.0) 34 (15.8) 5 (21.7) 
65-69 64 (13.0) 13 (13.7) 48 (22.3) 3 (19.2) 
70-74 68 (20.4) 21 (22.1) 43 (20.0) 4 (17.4) 
75-79 47 (14.1) 11 (11.6) 32 (14.9) 4 (17.4) 
80-84 19 (5.7) 4 (4.2) 15 (7.0) 0 (0.0) 
85+ 11 (3.3) 1 (1.1) 10 (4.7) 0 (0.0) 
Age at invitation (years)   
  50-54 81 (24.3) 39 (41.1) 38 (17.7) 4 (17.4) 
55-59 73 (21.9) 19 (20.0) 48 (22.3) 6 (26.1) 
60-64 70 (21.0) 13 (13.7) 52 (24.2) 5 (21.7) 
65-69 58 (17.4) 13 (13.7) 42 (19.5) 3 (13.0) 
70+ 51 (15.3) 11 (11.6) 35 (16.3) 5 (21.7) 
Year of death   
  1975-79b 7 (2.1) 0 (0.0) 7 (3.3) 0 (0.0) 
1980-84 55 (16.5) 17 (17.9) 34 (15.8) 4 (17.4) 
1985-89 50 (15.0) 13 (13.7) 36 (16.7) 1 (4.3) 
1990-94 61 (18.3) 19 (20.0) 39 (18.1) 3 (13.0) 
1995-99 60 (18.0) 19 (20.0) 37 (17.2) 4 (17.4) 
2000-04 56 (16.8) 18 (18.9) 35 (16.3) 3 (13.0) 
2005-08 44 (13.2) 9 (9.5) 27 (12.6) 8 (34.8) 
Year of diagnosis   
  1975-79 71 (21.3) 23 (24.2) 46 (21.4) 2 (8.7) 
1980-84 69 (20.7) 19 (20.0) 48 (22.3) 2 (8.7) 
1985-89 56 (16.8) 17 (17.9) 37 (17.2) 2 (8.7) 
1990-94 62 (18.6) 18 (18.9) 41 (19.1) 3 (13.0) 
1995-99 35 (10.5) 9 (9.5) 22 (10.2) 4 (17.4) 
2000-04 33 (9.9) 9 (9.5) 18 (8.4) 6 (26.1) 
2005-08 7 (2.1) 0 (0.0) 3 (1.4) 4 (17.4) 
Tumour size (in mm)   
  <20 79 (23.7) 19 (20.0) 59 (27.4) 1 (4.3) 
20-40 164 (49.2) 56 (58.9) 104 (48.4) 4 (17.4) 
>40 58 (17.4) 16 (16.8) 36 (16.7) 6 (26.1) 
Diffuse 10 (3.0) 1 (1.1) 7 (3.3) 2 (8.7) 
Unknown 22 (6.6) 3 (3.2) 9 (4.2) 10 (43.5) 
 
a The percentages in brackets are column percentages. 
b First death occurred in 1978. 
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participants in the control group. In Table 5.4, the grey area highlights estimates where 
there was a stronger screening effect in the non-dense group than in the dense group. In 
most of our scenarios, the mortality reduction is smaller in the dense group than in the 
non-dense group. Take for example the scenario based on a prevalence of 30% in control 
women who participated in screening and a prevalence of 25% in women who did not 
Table 5.4 ORs for the effect of screening on breast cancer mortality in the dense (D) and the non-dense (ND) 
group, assuming different breast density prevalence estimates in the participating and non-participating 
controls. 
 
 
  
Prevalence density in participating controls 
   
10% 15% 20% 25% 30% 35% 40% 45% 50% 55% 60% 65% 
Prevalence density in non-
participating controls 
            
 
10% D 1.02 0.68 0.51 0.41 0.34 0.29 0.26 0.23 0.20 0.19 0.17 0.16 
  
ND 0.57 0.60 0.64 0.68 0.73 0.78 0.85 0.93 0.85 1.13 1.27 1.45 
 
15% D 1.54 1.02 0.77 0.61 0.51 0.44 0.38 0.34 0.31 0.28 0.26 0.24 
  
ND 0.53 0.57 0.60 0.64 0.69 0.74 0.80 0.87 0.80 1.07 1.20 1.37 
 
20% D 2.05 1.36 1.02 0.82 0.68 0.58 0.51 0.45 0.41 0.37 0.34 0.31 
  
ND 0.50 0.53 0.57 0.60 0.65 0.70 0.75 0.82 0.75 1.01 1.13 1.29 
 
25% D 2.56 1.71 1.28 1.02 0.85 0.73 0.64 0.57 0.51 0.47 0.43 0.39 
  
ND 0.47 0.50 0.53 0.57 0.61 0.65 0.71 0.77 0.71 0.94 1.06 1.21 
 30% D 3.07 2.05 1.54 1.23 1.02 0.88 0.77 0.68 0.61 0.56 0.51 0.47 
  
ND 0.44 0.47 0.49 0.53 0.57 0.61 0.66 0.72 0.66 0.88 0.99 1.13 
 
35% D 3.58 2.39 1.79 1.43 1.19 1.02 0.90 0.80 0.72 0.65 0.60 0.55 
  
ND 0.41 0.43 0.46 0.49 0.53 0.57 0.61 0.67 0.61 0.82 0.92 1.05 
 
40% D 4.09 2.73 2.05 1.64 1.36 1.17 1.02 0.91 0.82 0.74 0.68 0.63 
  
ND 0.38 0.40 0.42 0.45 0.48 0.52 0.57 0.62 0.57 0.75 0.85 0.97 
 
45% D 4.61 3.00 2.30 1.84 1.54 1.32 1.15 1.02 0.92 0.84 0.77 0.71 
  
ND 0.35 0.37 0.39 0.41 0.44 0.48 0.52 0.57 0.52 0.69 0.78 0.89 
 
50% D 5.12 3.41 2.56 2.05 1.71 1.46 1.28 1.14 1.02 0.93 0.85 0.79 
  
ND 0.31 0.33 0.35 0.38 0.40 0.43 0.47 0.51 0.47 0.63 0.71 0.81 
 
55% D 5.63 3.75 2.82 2.25 1.88 1.61 1.41 1.25 1.13 1.02 0.94 0.87 
  
ND 0.28 0.30 0.32 0.34 0.36 0.39 0.42 0.46 0.42 0.57 0.64 0.73 
 
60% D 6.14 4.09 3.07 2.46 2.05 1.75 1.54 1.36 1.23 1.12 1.02 0.94 
  
ND 0.25 0.27 0.28 0.30 0.32 0.35 0.38 0.41 0.38 0.50 0.57 0.65 
 
65% D 6.65 4.44 3.33 2.66 2.22 1.90 1.66 1.48 1.33 1.21 1.11 1.02 
  
ND 0.22 0.23 0.25 0.26 0.28 0.30 0.33 0.36 0.33 0.44 0.49 0.57 
 
P = participating control, NP = non-participating control 
The presence of a ‘high breast density’ was estimated in the control subjects. The control subjects were divided into 
screening participants and non-participants. The percentages indicate the different prevalence estimates. The numbers in 
the table represent the ORs in the different density strata (dense/non-dense).  
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participate in screening. The ORs would then be 0.85 and 0.61 in the dense group and in 
the non-dense group, respectively. Under the assumption that the prevalence of dense 
breasts is similar in participants and non-participants, there would be no mortality reduc-
tion (OR 1.02) in the dense group and a 43% (OR 0.57) reduction in the non-dense group. 
The 95% CI slightly depends on the prevalence estimates. At 10% prevalence of dense 
breasts in the control group (both participants and non-participants), the 95% CI would be 
(0.58-1.81) and (0.42-0.76) in the dense group and non-dense group, respectively. At 65% 
prevalence, the interval in the dense group is smaller (0.64-1.64), while the effect on the 
CI in the non-dense group is limited (0.41-0.78). 
DISCUSSION
Women who participated in screening in the four year period before (pseudo-)diagno-
sis had a 33% lower risk of breast cancer death than women who did not participate. 
High breast density is associated with a lower programme sensitivity (57.8% vs. 75.7%) 
of mammographic screening and mostly a lower PPV (41.4% vs. 49.8%) throughout the 
study period, which is expected to decrease the effect of screening on breast cancer mor-
tality. The analyses on screening effectiveness across breast density strata support the 
hypothesis of a differential effect (estimated mortality reduction: 41% non-dense and 15% 
dense breasts), although prevalence estimates have been shown to affect the absolute 
difference. 
The effect of breast density on screening sensitivity has been studied previously 
with film-screen mammography.30-35 Digital mammography is expected to perform better 
in women with dense breasts than screen-film mammography. The preliminary results 
from a study by Wanders et al. showed that sensitivity indeed improved, but there was 
still a difference in sensitivity estimates between the dense and the non-dense group.36 
Kerlikowske et al. reported a similar gradient in sensitivity across breast density levels.37 
Literature estimates of PPV, negative predictive value, and specificity are generally lower 
in women with increased breast density.30 We found that the positive predictive value 
tended to be lower in the dense group (41.4%) than in the non-dense group (49.8%), 
although this varied over time. Breast density is also likely to explain at least part of the 
changes in screening test performance with age, based on the knowledge that there is an 
inverse association between age and breast density. 
As a result of the decreased screening performance in women with dense breasts, 
more breast tumours would be missed during screening. These may be detected at a later 
123Breast cancer screening effect across breast density strata: a case-control study
screening round or turn up as symptomatic interval tumours. A high breast density indeed 
appears to be associated with an increased risk of interval cancer.37-40 Among the interval 
cases in our population, a relatively large proportion of the women had a dense breast 
pattern. Due to the late detection, tumours that occur in dense breasts are expected to 
have reached a more advanced stage at diagnosis. Studies have shown that a high breast 
density is associated with larger tumour size and potentially lymph node involvement.16 
Our results also suggested a greater tumour size at detection. No strong associations 
have been observed between breast density and other prognostic tumour characteristics, 
which implies that a high breast density is not associated with the occurrence of more 
aggressive tumours. For example, most previous studies did not observe an association 
between breast density and receptor (ER/PR) status.41,42 Ambiguous results have been 
published on the association between breast density and breast cancer survival, which 
suggest that an effect on survival could be explained by the time of diagnosis.43-48 
The overall (i.e., not stratified on breast density) screening effect has been studied 
in case-control studies, with the average mortality reduction being estimated at 31% for 
women invited to screening.49 The effect in women actually participating in screening is 
larger (48% after correction for self-selection bias). The effect in different breast density 
strata has not been presented before. It is challenging to assess this effect, because we 
need an estimate of breast density for the entire invited population. This includes women 
who are free of breast cancer and did not participate in breast cancer screening. These 
women may have never had a mammogram, hence making it difficult to determine mam-
mographic density. In this study, the analyses were based on assumptions regarding prev-
alence of breast density on a sample of the control group. A population measure was thus 
used to predict breast density at the individual level. 
Because most women do not know their breast density, breast density is not assumed 
to directly influence screening participation. However, other risk factors that are associ-
ated with breast density may affect the decision to participate. We found that the partici-
pants were somewhat younger (median age participating controls: 59 years, median age 
non-participating controls: 63 years), which could lead to a higher prevalence of dense 
breasts. Based on the age distribution, 23% of the participants would have dense breasts, 
compared with 19% of the non-participants.
Having a family history of breast cancer is also known to increase breast density50 and 
has been suggested to increase screening participation.51 Screening participation is also 
higher in women with a high socio-economic status,52-54 which appears to be associated 
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with dense breasts as well.55, 56 On the other hand, women with more dense tissue may 
also experience more discomfort or pain during mammography, which could decrease 
participation rates for subsequent screening exams. In our dataset, however, the partici-
pation rate for women with dense breasts was actually slightly higher than in the low 
density group when we looked at the subsequent screens for a sample of women who 
participated in the first screening round (81% vs. 75%, respectively). Body mass index 
(BMI) is strongly associated with breast density as well. A recent study in Denmark by 
Hellmann et al. showed that non-attendance in the Danish programme was higher in 
both underweight (<18.5 kg/m2; 23.0%) and overweight (25.0-29.9 kg/m2; 19.1%) women 
compared to women with a normal weight (18.5-24.9 kg/m2; 12.0%).57 This indicates that 
both extremely dense breasts (underweight women) and very fatty breasts (overweight 
women) would occur more frequently among non-participants. 
A previous study by Paap et al. showed that, overall, little self-selection bias is present 
in the Dutch screening population.58 Assuming that the prevalence of a high breast den-
sity is similar or only slightly (+5%) higher in participants in the control group compared 
to non-participants, the screening effect would be smaller for women with a high density 
compared to women with a low breast density. Only under quite extreme conditions, with 
high density patterns occurring much more frequently in screening participants (>+10%), 
would the benefit of screening be greater in the dense group. It is realistic to expect that 
the prevalence is lower in the controls than in the cases (overall prevalence estimate of 
30%), given that breast density is a risk factor for breast cancer.
Our study has shown that the lack of information on non-participants constitutes a 
challenge in determining the screening effect in different risk factor strata, such as for 
breast density. An additional limitation of our study was that density was only measured 
once via visual assessment, and clinical mammograms were included in these measure-
ments. This may have led to some misclassification. Furthermore, we only had data from 
analogous mammograms. In future studies, automated density measurements can be 
used for digital mammograms, which limits problems with interobserver variability. The 
limited information on non-participants, however, will remain an issue in estimating the 
screening effect in these studies. 
Nevertheless, both our results and recent literature seem to indicate that breast 
density is an important factor to consider when individualizing screening. Women with 
high breast density still appear to benefit from participating in screening, but this benefit 
would be smaller than in women with non-dense breasts. Furthermore, the disadvan-
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tages or harms of screening (e.g., false-positive recall) may be greater in women with 
dense breasts. The balance between harms and benefits could potentially be increased 
by offering additional imaging to women with high breast density. Recent research has, 
however, shown that choices on additional screening should be based on a combination 
of risk factors, rather than breast density alone.37
In conclusion, screening performance differs across breast density levels, which ap-
pears to be true for the screening effect as well. A high breast density decreases screen-
ing performance and appears to be associated with a smaller mortality reduction. Breast 
density is thus a likely candidate to include in risk-stratified screening. More research is, 
however, needed to learn about the association between breast density and screening 
harms to gain insight into the screening balance.
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SUPPLEMENT
S5.1 Table Programme sensitivity of screening mammography and PPV per age group for 
women with dense breasts and women with non-dense breasts. 
 
 Sensitivity  PPV 
 
Total Dense Non-dense  Total Dense Non-dense 
Age group 
 
 
 
    
50-54y 57.5% 50.0% 65.1%  34.3% 34.8% 34.0% 
55-59y 63.1% 53.6% 69.2%  43.8% 38.5% 46.8% 
60-64y 74.7% 68.3% 77.5%  54.5% 47.3% 56.8% 
65-69y 77.3% 67.9% 80.8%  52.7% 54.3% 48.1% 
70-74y 79.5% 65.7% 84.8%  57.4% 56.1% 57.6% 
Total 69.5% 57.8% 75.7%  47.1% 41.4% 49.8% 
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ABSTRACT
Several reviews have estimated the balance of benefits and harms of mammographic 
screening in the general population. The balance may, however, differ between individu-
als with and without family history. Therefore, our aim is to assess the cumulative risk of 
screening outcomes; screen-detected breast cancer, interval cancer, and false-positive re-
sults, in women screenees aged 50-75 and 40-75, with and without a first-degree relative 
with a history of breast cancer at the start of screening. Data on screening attendance, 
recall and breast cancer detection were collected for each woman living in Nijmegen (the 
Netherlands) since 1975. We used a discrete time survival model to calculate the cumula-
tive probability of each major screening outcome over 19 screening rounds. Women with 
a family history of breast cancer had a higher risk of all screening outcomes. For women 
screened from age 50-75, the cumulative risk of screen-detected breast cancer, interval 
cancer and false-positive results were 9.0%, 4.4% and 11.1% for women with a family 
history and 6.3%, 2.7% and 7.3% for women without a family history, respectively. The 
results for women 40-75 followed the same pattern for women screened 50-75 for cancer 
outcomes, but were almost doubled for false-positive results. To conclude, women with a 
first-degree relative with a history of breast cancer are more likely to experience benefits 
and harms of screening than women without a family history. To complete the balance 
and provide risk-based screening recommendations, the breast cancer mortality reduc-
tion and overdiagnosis should be estimated for family history subgroups.
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INTRODUCTION
Early detection of breast cancer by mammographic screening reduces breast cancer mor-
tality.1, 2 However, mammographic screening has a number of harms including overdiagno-
sis, false-positive recall and false-negative results. Therefore, population-based mammo-
graphic screening programmes are only justified when the benefits outweigh the harms. 
Currently, all population-based mammographic screening programmes have a one-
size-fits-all regimen; age is the only risk factor used to select the target population and 
all women within the targeted age range are screened with the same modality and fre-
quency. There is continuing debate about whether the benefits outweigh the harms in 
the current one-size-fits-all screening programmes for breast cancer.2-5 Meanwhile, the 
focus is shifting from this one-size-fits-all approach towards personalized breast cancer 
screening.6 The aim of personalized breast cancer screening is to improve the balance of 
benefits and harms for each woman by tailoring her screening regimen based on breast 
cancer risk. Key to the potential effectiveness of personalized screening is that the bal-
ance between the benefits and harms differs between subgroups of women with differing 
breast cancer risk.
Until now, the effect of risk-based screening on the balance between the benefits and 
harms of breast cancer screening has only been estimated using modeling studies which 
showed favourable outcomes for risk-based screening.7-9 Modeling studies rely on data 
and assumptions that may be incorrect9, and therefore, these findings should be support-
ed by observational studies. Although several large cohort studies have been initiated to 
predict the benefits and harms of screening in individual women, results of these studies 
are still limited and are mainly focused on breast cancer risk prediction.
The aim of this study is to assess the cumulative risk of both favourable (screen-detect-
ed breast cancer) and unfavourable (interval cancer and false-positive results) screening 
outcomes in women screened from aged 50-75 and 50-69, with and without a first-degree 
relative with a history of breast cancer at the start of screening. Because women aged 40 
to 49 years with a two-fold increased risk of breast cancer, i.e. those with a first-degree 
relative with breast cancer7,10, have a similar benefit-harm ratio as average-risk women 
aged 50 to 75 years8, we also assessed the cumulative risk of screening outcomes in wom-
en invitees aged 40-75 and 40-69 with and without a first-degree relative with a history of 
breast cancer at the start of screening.
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METHODS
Setting
In 1975, a biennial mammographic screening programme was implemented in Nijmegen, 
the Netherlands, inviting women aged 35 years and older (born before 1939). In 1989, a 
national biennial screening programme for women aged 50-69 years was implemented 
throughout the Netherlands. Subsequently, the Nijmegen screening programme invited 
the same target group as the national programme, and women aged 70 and older could 
undergo screening only if they made an appointment for the examination themselves.11 
In 1997, the upper age limit of both the national and Nijmegen mammographic screening 
programme was raised to 74 years. 
Until 2013, the screening examination consisted of two views, a mediolateral oblique 
and craniocaudal view, in initial screens and a single view in subsequent screens. Initially, 
the subsequent screens consisted of a lateral view, which was replaced by a mediolateral 
oblique from the fourth round onwards. An additional craniocaudal view was taken dur-
ing the screening examination if abnormalities were suspected or if the quality was not 
good enough for evaluation.11 From 2013 onwards, subsequent screening examinations 
standardly consisted of a mediolateral oblique and a craniocaudal view.  Mammograms 
are read by two independent radiologists, who must reach consensus on recall.12
Ethics, consent and permission
All women consented to the use of their anonymous data for scientific research from 
1990 onwards. Because there was no law on the registration of personal data before 
1989, women participating in the screening programme during the first eight rounds 
(1975-1990) were not asked to give informed consent. After the introduction of the law, 
women were asked to give explicit permission for the use of their personal data to evalu-
ate the mammographic screening programme (1990-2004). From 2004 onwards, women 
received a leaflet with their invitation stating that their personal data is used to improve 
the screening programme. In case women do not agree, they can object by signing a form, 
i.e. an opt-out procedure.
Definition of family history and outcome measures
During the first round, women invited to participate in the breast cancer screening pro-
gramme were asked to fill in a questionnaire before undergoing the screening examina-
tion. In the questionnaire, participants were asked about, among other things, the history 
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of breast cancer in their family (grandmothers, mother, aunt(s), sister(s), and daughter(s)). 
We defined a family history of breast cancer as having at least one first-degree relative 
with a history of breast cancer, i.e. a history of breast cancer in mother, sister(s) and/
or daughter(s). Recall was defined as the recall of a woman by screening radiologists for 
further diagnostic work-up to assess whether the suspicious finding on the screening 
mammogram was malignant. If histological and/or cytological diagnostic work-up con-
firmed the presence of breast cancer within 6 months following recall, the woman had 
a so-called ‘screen-detected breast cancer’, i.e. true-positive. The nature of the screen-
detected breast cancer could be invasive or non-invasive, i.e. ductal carcinoma in situ 
(DCIS). Invasive screen-detected breast cancers were further subdivided in tumours <15 
mm and ≥ 15 mm based on tumour diameter at pathological examination. In a few cases 
we used tumour diameter at the diagnostic mammogram because it was not reported 
at pathological examination (e.g. because chemotherapy preceded surgery). A recall was 
considered to be false-positive when diagnostic work-up did not confirm the presence of 
breast cancer during the first year after screening, even if breast cancer was subsequently 
detected before the next screening examination. Invasive diagnostic work-up included the 
procedures fine needle aspiration cytology, core needle biopsy and surgical biopsy. We 
defined interval cancer (false-negative results) as a breast cancer that was not detected at 
screening but was diagnosed before the next screening examination. 
Data analysis
The cumulative risks of screen-detected breast cancer, invasive screen-detected breast 
cancer stratified by size, interval cancer, false-positives and false-positives with invasive 
work-up were estimated by discrete-time survival models. Separate models were used to 
estimate the risks for each screening outcome. Women were censored after the event of 
interest, a competing event (see Table 6.1), loss to follow-up or death – whichever came 
first.
The discrete-time survival model was fitted using the LOGISTIC procedure in SAS statis-
tical software, version 9.2 (SAS Institute Inc, Cary, NC).13, 14 All logistic regression models in-
cluded number of prior screening rounds attended, family history and age. Prior number 
of screening rounds attended served as the discrete time-scale and ranged from 1 to 19, 
i.e. covering 36 years of follow-up. Family history was classified into three groups; a first-
degree family history, no family history and an unknown family history. Age was grouped 
in two-year age groups between 40 and 75, i.e. 40-41, 42-43 up till 74-75. Women below 
40 were grouped together and above 75 were also grouped together, because of small 
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numbers.
Hubbard et al15 found that women participating in more screening rounds had a dif-
ferent risk of false-positives than women participating in fewer screening rounds, i.e. 
dependent censoring. Because the number of screening rounds appeared to depend on 
the result of previous screening rounds for both cancer and false-positives, we could not 
test formally whether dependent censoring occurred in our population. Because previ-
ous studies have shown dependent censoring in the risk of false-positives, we calculated 
the risk of false-positives and false-positives with invasive work-up under the assumption 
of independent censoring (standard model) and adjusted for dependent censoring. The 
models adjusted for dependent censoring included five categories for the proportion of 
screening rounds attended (≤0.25, >0.25-≤0.5, >0.5-≤0.75, >0.75-<1.0, 1.0) in addition to 
the standard model. Because there is no evidence yet that cumulative risks of cancer are 
affected by dependent censoring, we did not adjust the cumulative risk of screen-detect-
ed breast cancer and interval cancer.      
Additionally, we adjusted the risk of each screening outcome for competing events 
(see Table 6.1). Without adjustment for competing events, the models estimate the latent 
risk of an event in the absence of competing events, i.e. risk of an event had a woman 
continued screening. This is not relevant for women who stop screening because of breast 
cancer diagnosis or death. Therefore, we adjusted the risk of an event in each round for 
 
Table 6.1 Competing events for each screening outcome 
 
Screening outcome Competing events 
False positive recall breast cancer diagnosis (interval cancer ≤ 24 and > 24 
months, screen-detected breast cancer), death 
False positive recall with 
invasive work-up 
breast cancer diagnosis (interval cancer ≤ 24 and > 24 
months, screen-detected breast cancer), death 
Screen-detected breast 
cancer 
Interval cancer ≤ 24 and >24 months, death 
Invasive screen-detected 
breast cancer 
Interval cancer ≤ 24 and >24 months, non-invasive 
screen-detected breast cancer, death 
Invasive screen-detected 
breast cancer <15 mm 
Interval cancer ≤ 24 and >24 months, non-invasive 
screen-detected breast cancer, invasive screen-
detected breast cancer ≥15mm, death 
Interval cancer Screen-detected breast cancer, breast cancers with an 
interval longer than 24 months, death 
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competing events by multiplying the risk by the proportion of women who had no com-
peting event.16
Elveback’s formula17 was used to calculate the cumulative risk of each screening out-
come. In this formula, the risk of the event of interest for each screening round is mul-
tiplied by the proportion of women without the event of interest until that screening 
round. The 95% confidence intervals (CI) were obtained by taking the 2.5 and 97.5 percen-
tiles of 10,000 samples from the multivariate sampling distribution of all model parameter 
estimates.
RESULTS
During the first screening round, 19,703 of the 23,210 women invited to participate un-
derwent a screening examination (84.9%) and filled in a questionnaire including questions 
 
Table 6.2 Absolute number of women per screening round attended for each screening 
outcome 
 
Rounds 
attended 
Screen-detected 
breast cancer Interval cancer False-positive 
False-positive with 
invasive work-up 
1 19703 19601 19703 19703 
2 17476 17408 17338 17863 
3 15732 15674 15549 15616 
4 14318 14273 14099 14174 
5 12950 12905 12703 12785 
6 11743 11703 11502 11586 
7 10577 10530 10342 10426 
8 9240 9203 9022 9098 
9 7768 7731 7571 7638 
10 6715 6672 6526 6594 
11 5689 5667 5516 5579 
12 4913 4888 4758 4816 
13 4169 4139 4014 4082 
14 3485 3470 3347 3410 
15 2890 2876 2759 2820 
16 2214 2202 2115 2159 
17 1551 1545 1471 1515 
18 963 960 911 938  
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about family history of breast cancer. Of the women who filled in the questionnaire, 90.8% 
(n=17,882) had no family history of breast cancer, 5.6% (n=1,101) had one or more first-
degree relatives with a history of breast cancer and 3.7% (n=720) did not know whether 
her mother, sister(s) and daughter(s) had a history of breast cancer. Because women can 
quit screening after one or more rounds, the number of women in follow-up decreased 
with an increasing number of screening rounds (Table 6.2).
Tables 6.3 and 6.4 show the cumulative risk of screen-detected breast cancer, interval can-
cer and false-positives for women with and without a family history in women screened 
from age 50 to 75 and age 40 to 75, respectively. Estimates for screening from age 50-69 
and 40-69 are provided in the Supplement. The tables 6.3 and 6.4 show that women with 
a family history had a higher cumulative risk of a screen-detected breast cancer, interval 
cancer and a false-positive than women without or with unknown family history. Women 
screened from 50 to 75 with a family history of breast cancer had a 9.0% (95% CI, 6.7-
12.1) risk of screen-detected breast cancer, 4.4% (95% CI, 3.1-6.9) risk of interval cancer, 
and 7.6% (95% CI 6.2-10.7) risk of a false-positive. Women screened from age 40 to 75 
with a family history had a 9.1% (95% CI, 7.0-12.7), 5.0% (95% CI, 3.6-8.5) and 13.1% (95% 
CI, 10.2-17.5) risk of screen-detected breast cancer, interval cancer and false-positives, 
respectively. For women without a family history screened from age 50-75 and 40-75, the 
 
Table 6.3 Cumulative risks (95% CI) of screening outcomes for women screened from age 50 
to 75 
 
    50-75 years 
  
No family 
history 
1st degree family 
history 
Family history 
unknown 
% 
 
90.8 5.6 3.7 
Screen-detected breast cancer 6.3 (5.8-7.3) 9.0 (6.7-12.1) 7.3 (6.3-9.0) 
 
Invasive 5.4 (4.9-6.3) 8.4 (6.5-11.5) 6.5 (5.5-8.1) 
 
Invasive <15 mm 2.5 (2.2-3.3) 4.0 (2.7-6.6) 3.3 (2.6-4.7) 
Interval cancer 2.7 (2.4-3.4) 4.4 (3.1-6.9) 2.7 (2.1-3.9) 
False positive recall 5.0 (4.8-6.2) 7.6 (6.2-10.7) 6.0 (5.3-7.7) 
8.4 (7.4-10.2)a 12.8 (9.8-17.3)a 9.7 (8.2-12.3)a 
 
Invasive work-up 2.9 (2.6-3.7) 4.6 (3.4-6.9) 3.5 (2.9-4.6) 
  4.6 (4.0-6.1)a 7.4 (5.4-11.3)a 5.4 (4.4-7.4)a 
a+ Cumulative risks adjusted for dependent censoring 
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Table 6.4 Cumulative risks (95% CI) of screening outcomes for women screened from age 40 
to 75 
 
    40-75 years 
  
No family 
history 
1st degree family 
history 
Family history 
unknown 
% 
 
90.8 5.6 3.7 
Screen-detected breast cancer 6.4 (5.8-7.7) 9.1 (7.0-12.7) 7.4 (6.3-9.4) 
 
Invasive 5.5 (4.9-6.7) 8.5 (6.6-12.1) 6.5 (5.5-8.5) 
 
Invasive <15 mm 2.7 (2.3-3.8) 4.1 (2.8-7.4) 3.4 (2.8-5.4) 
Interval cancer 3.1 (2.8-4.3) 5.0 (3.6-8.5) 3.0 (2.4-4.8) 
False positive recall 8.8 (8.1-10.3) 13.1 (10.2-17.5) 10.4 (8.9-12.6) 
16.5 (14.4-19.9)a 24.4 (19.0-32.4)a 19.0 (16.0-23.7)a 
 
Invasive work-up 5.8 (4.2-6.0) 7.5 (5.5-11.2) 5.8 (4.8-7.7) 
  10.0 (7.7-12.0)a 14.4 (10.4-21.6)a 10.8 (8.7-15.0)a 
a Cumulative risks adjusted for dependent censoring 
 
 
cumulative risks were 6.3% (95% CI, 5.8-7.3) and 6.4 (95% CI, 5.8-7.7) for screen-detected 
breast cancer, 2.7% (95% CI, 2.4-3.4) and 3.1% (95% CI, 2.8-4.3) for interval cancer, 5.0% 
(95% CI, 4.8-6.2) and 8.8% (95% CI, 8.1-10.3) for false-positives, respectively.
Overall, women with a family history had an increased risk of 1.4 (95% CI, 1.1-1.9), 
1.7 (95% CI, 1.1-2.4) and 1.5 (95% CI, 1.1-1.9) times the risk of women without a family 
history for screen-detected breast cancer, interval cancer and false-positives, respectively. 
Women with a family history of breast cancer also had higher cumulative risks of an in-
vasive breast cancer, invasive breast cancer smaller than 15 mm, and false-positives with 
invasive work-up than women without a family history of breast cancer. 
Comparison of the cumulative risk in women screened from 50-75 and 40-75 shows 
that inclusion of five more biennial screening examinations in the age range 40-49 espe-
cially increases the cumulative risk of interval cancers and false-positives. The cumulative 
risk of screen-detected breast cancers increases by only 0.1% in both family history groups 
when adding five extra screens while false-positives increase by 3.8-5.5% in the model 
assuming no dependent censoring and 8.1-11.6% in the model adjusted for dependent 
censoring.
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DISCUSSION
This is the first study estimating the cumulative risk of screen-detected breast cancer, 
false-positives and interval cancers over the course of a screening programme for women 
with and without a first-degree relative with a history of breast cancer. We found that risks 
of both favourable and unfavourable screening outcomes were larger for women with 
than for women without a first-degree relative with a history of breast cancer. This gives 
some first insights into the relative balance of benefits and harms of screening for women 
with and without a family history.
It is well-known that women with a first-degree family history of breast cancer have a 
higher risk of breast cancer than women without a family history.18, 19 However, the relative 
and absolute effect of mammographic screening on breast cancer mortality for women 
his study also indicates that women with a family history have a greater risk of a false-
positive and a false-positive with invasive work-up compared to women with no family 
history. Most other studies have also found higher risks of false-positive recalls16,21-23 or 
false-positives with invasive work-up22,24 for women with a family history. However, the ef-
fect of family history on a false-positive result is larger in this study than in other studies 
from the US. A possible explanation might be that radiologists had access to the family 
history of screened women from 1991 until 2003 and recalled women with a family his-
tory more readily than women without a family history. However, in the US, radiologists 
also have often access to family history. Therefore, a more likely explanation is that the 
high absolute risk of false-positives in the US minimizes the differences between family 
history groups leading to the observed difference between the US and the Netherlands.
False positive results, in particular those requiring invasive follow-up procedures25,26, 
have a negative impact on psychological state25-27 and screening re-attendance27,28. Accord-
ing to a review29, the psychological impact of false-positives for women with a family his-
tory is similar to that in the general population, although some studies show a greater 
negative impact in women with a family history.30 In the Netherlands28 and other European 
countries27, false-positive results negatively affect re-attendance. It is, however, unknown 
whether this effect differs between women with and without a family history of breast 
cancer.
We used different models to estimate the cumulative risk of false-positives and false-
positives with invasive work-up: unadjusted and adjusted for dependent censoring. De-
pendent censoring occurs when women who quit screening have a different risk of a 
screening outcome than women who continue screening.16 Previous research indicated 
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that this is likely for false-positives and provided some solutions for statistical analyses.31 
However, these solutions are not appropriate when women quit because of their false-
positive, which is the case in the Netherlands.28 Therefore, we adjusted for dependent 
censoring by marginalizing the cumulative risk over the attendance probability. Because 
half of the cumulative risk of false-positives was adjusted for dependent censoring and 
the cumulative risk of screen-detected breast cancer was not, we did not estimate the 
cumulative risk of recall. However, the results indicate that recall is likely to be higher in 
women with than without a family history, because the risk of screen-detected breast 
cancer and false-positives were both higher in women with a family history. 
The results of our study cannot be generalized directly to the current era of digital 
mammography, to different screening intervals and/or to other countries such as the US. 
Our results are based on women who started screening in 1975. Over time, recall rates 
changed32, and it is expected that the cumulative risk of screen-detected breast cancer 
and false-positives, with and without invasive work-up, are higher and the cumulative 
risk of interval cancers is lower for women who recently started screening.31 However, we 
expect that the relative risk difference between women with and without family history 
will remain more or less the same. The cumulative risk of screening outcomes should also 
not directly be translated to other screening intervals. For example, the small number 
of extra screen-detected breast cancers found when starting at age 40 instead of 50 are 
likely the result of a 2-year screening interval. A 1-year screening interval in the age group 
40-50 would probably yield a higher number of extra screen-detected breast cancers.33 
Furthermore, our results should only be generalized to countries with similar recall rates, 
including Europe and Australia.14
Furthermore, our analysis has focused on women with and without a first-degree fam-
ily history at the start of screening, which has several implications for the study results. 
Firstly, family history of breast cancer was self-reported, which may cause misclassifica-
tion. Previous research has shown that self-reported family history of breast cancer is 
accurate34 and therefore it is unlikely that this affected our results. Secondly, we did not 
exclude women with a strong family history who are screened outside the mammographic 
screening programme nowadays, i.e. women with BRCA mutations and women below 
60 with a relative risk of breast cancer of 3 or more.35 The effect of this inclusion on the 
cumulative risk of both screen-detected and interval cancer is expected to be small, be-
cause BRCA mutations are rare, even among women with a first-degree family history36, 
and women with a relative risk of 3 or more are invited to participate in the national 
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mammographic screening programme after the age of 60. Thirdly, the presented cumu-
lative risks are based on assessment of first-degree family history at screening initiation 
and therefore  the cumulative risk are only valid for women who are making a decision 
about starting screening. Fourthly, the subgroups of women with a first-degree and with 
unknown family history were small, which may have resulted in wide confidence intervals 
and some unexpected values (i.e. small risk of interval cancer in women with unknown 
family history and small difference in screen-detected cancer between women screened 
from age 40-75 and age 50-75 in all family history subgroups). However, in general, we 
believe that the point estimates are informative despite the broad confidence intervals. 
Finally, we did not investigate the effect of possible confounders, such as breast density, 
on the cumulative risks, which might be able to explain some part of the differences found 
between women with and without family history.
Our study has two major strengths: the use of a population-based approach and many 
years of follow-up. All women who were invited to participate in the mammographic 
screening programme and attended the first screening exam were included in this study, 
thereby minimizing selection bias. Furthermore, the Nijmegen screening database fol-
lowed women for more than 35 years and has an accurate registration of attendance and 
screening outcomes. As a result, we could calculate the cumulative risk of screen-detect-
ed breast cancer, interval cancer and false-positives over the entire period of screening 
eligibility without extrapolation.
To conclude, our study shows that women with at least one first-degree relative with 
a history of breast cancer have a higher risk of favourable (small screen-detected breast 
cancers) and unfavourable (interval cancers and false-positives) screening outcomes than 
women without such family history. Before giving risk-based screening recommendations 
to women with and without family history, further research should complete the benefit-
harm balance, i.e. by estimating the breast cancer mortality reduction and overdiagnosis 
in family history subgroups, and weight the benefits and harms. 
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SUPPLEMENT
In this supplement, we report the cumulative risk of favourable (screen-detected breast 
cancer) and unfavourable (interval cancer and false-positive results) screening outcomes 
in women screened from 50-69 (S6.1-Table) and 40-69 (S6.2-Table) with and without a 
first-degree relative with a history of breast cancer at the start of screening. All cumulative 
risk are calculated according to the methods described in the article.
Table S6.1 Cumulative risks (95% CI) of screening outcomes for women screened from age 50 to 69 
 
    50-69 years 
  
No family 
history 
1st degree family 
history 
Family history 
unknown 
% 
 
90.8 5.6 3.7 
Screen-detected breast cancer 4.2 (3.8-4.8) 5.9 (4.6-8.0) 4.8 (4.1-5.9) 
 
Invasive 3.6 (3.2-4.2) 5.6 (4.3-7.7) 4.3 (3.6-5.4) 
 
Invasive <15 mm 1.6 (1.4-2.1) 2.5 (1.7-4.1) 2.1 (1.7-2.9) 
Interval cancer 2.0 (1.8-2.4) 3.3 (2.3-5.1) 2.0 (1.5-2.8) 
False positive recall 3.6 (3.2-4.2) 5.4 (4.2-7.3) 4.3 (3.6-4.1) 
5.3 (4.8-6.3)a 8.2 (6.3-11.1)a 6.2 (5.2-7.7)a 
 Invasive work-up 2.2 (1.9-2.7) 3.5 (2.5-5.1) 2.7 (2.2-3.5) 
3.3 (2.9-4.1)a 5.3 (3.9-7.8)a 3.9 (3.2-5.2)a 
a Cumulative risks adjusted for dependent censoring 
 
 
 
Table S6.2 Cumulative risks (95% CI) of screening outcomes for women screened from age 40 to 69 
 
    40-69 years 
  
No family 
history 
1st degree family 
history 
Family history 
unknown 
% 
 
90.8 5.6 3.7 
Screen-detected breast cancer 5.0 (4.5-5.9) 7.2 (5.3-9.8) 5.8 (4.9-7.3) 
 
Invasive 4.3 (3.8-5.1) 6.7 (5.1-9.4) 5.1 (4.2-6.5) 
 
Invasive <15 mm 1.9 (1.7-2.7) 3.0 (2.0-5.3) 2.5 (2.0-3.8) 
Interval cancer 2.8 (2.5-3.5) 4.5 (3.2-7.2) 2.7 (2.1-4.0) 
False positive recall 7.0 (6.4-8.2) 10.5 (8.1-14.1) 8.3 (7.1-10.1) 
12.9 (11.2-15.5)a 19.2 (14.9-25.7)a 14.9 (12.5-18.6)a 
 
Invasive work-up 4.8 (3.5-4.8) 6.1 (4.5-9.1) 4.8 (3.9-6.3) 
  7.9 (6.1-9.5)a 11.5 (8.3-17.3)a 8.7 (7.0-11.9)a 
a cumulative risks adjusted for dependent censoring 
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ABSTRACT
Background: Breast cancer screening is shifting from a one-size-fits-all approach, where 
the target population is defined by age alone, towards a personalized approach. Key to 
personalized screening is that the benefits and harms differ according to women’s charac-
teristics. The aim of this study is to assess the cumulative risk of favorable (small screen-
detected breast cancer) and unfavorable (interval cancer and false-positive results) 
screening outcomes for women of differing socio-economic status (SES), a factor associ-
ated with a collection of risk factors for breast cancer.
Patients and methods: Since 1975, women living in Nijmegen (the Netherlands) have 
been invited to participate in biennial mammographic screening. Screening attendance, 
postal code, recall and breast cancer detection are recorded for each woman at each 
screening round. We used a discrete-time survival model to calculate the cumulative risk 
of each major screening outcome for women aged 50-69 and 50-75 stratified by high and 
low SES. SES was dichotomized at the average of the SES indicator of the Netherlands 
Institute for Social Research.
Results: Biennial screening from age 50 to 75 resulted in risks of 8.6%, 2.6%, and 17.6% 
for screen-detected breast cancer, interval cancer and false-positive results, respectively 
for women with high SES (14.6%) and 7.5%, 2.3% and 14.5% for women with low SES 
(85.4%). The cumulative risk of small invasive screen-detected breast cancers was lower 
for women with high SES (2.7% versus 3.0%). 
Conclusion: Women with high SES have a higher risk of unfavorable screening outcomes 
and an equal risk of favorable screening outcomes. This suggests that underlying risk fac-
tors associated with SES, e.g. reproductive factors and health behavior, may affect the 
benefit-harm balance and may be relevant for personalized screening. 
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INTRODUCTION
We are entering a new era in medicine featuring shifts from a ‘one-size-fits-all’ approach 
to care towards a more personalized approach. Preventive medicine in particular, such 
as breast cancer screening, is moving from a ‘one-size-fits-all’ approach, where age is the 
only risk factor used to define the target population, towards a personalized approach, 
where screening is tailored to a woman’s individual breast cancer risk.1-4 A key assump-
tion of personalized breast cancer screening is that the screening benefits (breast cancer 
mortality reduction) and harms (overdiagnosis, false-positives and false-negatives) differ 
according to individual characteristics. Therefore, current research focuses on identifying 
risk factors that are suitable for distinguishing individuals with a favorable benefit-harm 
balance from individuals with a less favorable, or even unfavorable, benefit-harm bal-
ance.1-5 
A potential risk factor that might be able to distinguish relevant subgroups of women 
with a favorable and a less favorable benefit-harm balance is socio-economic status (SES). 
SES reflects a group of risk factors including reproductive factors (age at first menarche, 
mother’s age at birth of first child) and health behaviors (use of hormone replacement 
therapy, alcohol consumption).6,7 Women with a high SES have on average a higher age at 
first birth, consume more alcohol and are more likely to use hormone replacement thera-
py than women with a low SES.6,8 As a consequence, breast cancer incidence and mortality 
in women above 50 is higher for those with high compared to low SES.7,9 Nevertheless, it 
is unknown whether women with a high SES also have a higher risk of favorable screening 
outcomes, like the detection of small screen-detected breast cancers10, and unfavorable 
screening outcomes, i.e. false-positive and false-negative screening test results. 
So far, only one study from the US investigated the effect of median household income 
on the cumulative risk of false-positives, without finding any association.11 However, this 
may be different for Europe, where the overall recall rates in breast cancer screening are 
much lower than in the US.12 Therefore, the aim of this study was to assess the cumula-
tive risk of both favorable (small screen-detected breast cancer) and unfavorable (interval 
cancer and false-positive recall) screening outcomes in women with high and low SES who 
were screened biennially from age 50-69 and 50-75 in Nijmegen, the Netherlands.
152 Chapter 7
Part 3
Ch
ap
te
r 
7
METHODS
Setting
In 1975, a biennial mammographic screening program was implemented in Nijmegen, 
inviting women born before 1940 (aged 35 years and older). In 1989, a national mam-
mographic screening program was implemented throughout the Netherlands, inviting 
women aged 50-69. Subsequently, the Nijmegen screening program adopted the national 
age range and women over 70 could only undergo screening if they made an appointment 
themselves for an examination. In 1998, the upper age limit of the national and Nijmegen 
mammographic screening programs were extended from 69 to 74 years. In 2007-2008, 
digital mammography was introduced in Nijmegen. Mammograms are read independent-
ly by two screening radiologists who decide on whether or not to recall for additional diag-
nostic evaluation.13 In this study, we included all women who were invited to the screening 
program and participated at least once since 1995.
SES indicator
From 1990 onwards, postal codes were recorded at each screening round for all women 
invited to participate in the mammographic screening program. We used 4-digit postal 
codes to calculate the SES at each screening round using the scores of the Netherlands 
Institute for Social Research (SCP-score).14 The SCP-score is based on mean household in-
come, percentage of households with a low income, percentage of inhabitants without 
a paid job and percentage of households with a low mean education. This information is 
obtained via phone calls to a single person in each 6-digit postal code area and aggregated 
to 4-digit postal codes. The SCP-score is provided every four years since 1995.
We used the national average of the scores to classify women into high and low SES 
groups. Nijmegen covered about one third of the national range in SES scores and its aver-
age score was always lower than the national Dutch average, indicating that Nijmegen had 
on average a lower SES.
Definition of screening outcomes
After a screening mammogram, women could be recalled for further diagnostic work-up 
to assess the presence of breast cancer. Women were diagnosed with so-called ‘screen-
detected breast cancer’ (true-positive) when histological and/or cytological diagnostic 
work-up confirmed the presence of breast cancer within 6 months after recall. The screen-
detected breast cancer could be invasive or non-invasive (ductal carcinoma in situ (DCIS)). 
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Screen-detected breast cancers that were invasive were further subdivided according to 
their tumor diameter at pathological examination, which could be <15mm or ≥15mm. 
In case tumor diameter at pathological examination was missing, tumor diameter at the 
mammogram was used. Women had a false-positive result when diagnostic work-up did 
not confirm the presence of breast cancer. Women could also be detected with breast 
cancer between two subsequent screening examinations, a so-called interval cancer.
Statistical analyses
We used single imputation (IBM SPSS, version 20.0) to impute missing data on cancer 
type for screen-detected breast cancer, i.e. invasive or DCIS, and the tumor diameter of 
invasive breast cancers based on SES, age and attendance. Information about cancer type 
was missing in 1.9% (25 out 1345) of screen-detected breast cancers and tumor diameter 
was missing in 4.0% (45 out 1121) of invasive breast cancers. Compared to complete case 
analysis, the width of the confidence intervals (CI) were underestimated by ≤0.1% with 
single imputation. Multiple imputation was not feasible because this would allow us to 
calculate the confidence intervals for the cumulative risks.
The cumulative risk of screen-detected breast cancer, invasive screen-detected breast 
cancer (<15 mm and ≥15 mm), interval cancer and false-positives were estimated using 
discrete survival models. For each screening outcome, we used a separate model where 
women were censored after the event of interest, a competing event (Supplement, Table 
S7.1) or loss to follow-up – whichever came first. In addition to the standard discrete 
survival models, we also used adjusted discrete survival approach model to estimate the 
cumulative risk of false-positives adjusted for dependent censoring.15
Each model was fitted with the logistic regression procedure in SAS statistical software, 
version 9.2 (SAS Institute Inc, Cary, NC). The standard discrete survival models included 
the same set of variables: screening round, SES (low vs high), age (in 2-year age groups) 
and screening result (e.g. false-positive result). Attended screening rounds, rather than 
women, were the unit of analysis. We counted the number of attended screening rounds 
starting from the first round in which a woman participated, but only used the rounds 
after 1995 to estimate model parameters because SES data were not available prior to 
this point. For example, if a woman attended five screening rounds in 1991, 1993, 1995, 
1997 and 1999, we included only rounds three to five in the model and assigned round 
numbers three, four and five to these three rounds. Using this approach, we calculated 
the risk in each SES-group at each screening round and then used these to estimate the 
cumulative risks of each screening outcome. In addition to the variables in the standard 
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model, the discrete survival model adjusted for screening attendance included five cat-
egories for the proportion of screening rounds attended (≤0.25, >0.25-≤0.5, >0.5-≤0.75, 
>0.75-<1.0, 1.0) to account for differential risk among women who screened more or less 
regularly. The risk of a false-positive result was calculated per SES-group and screening 
round by standardizing estimates over the distribution of observed frequencies of atten-
dance probability. 
The risks of all screening outcomes were adjusted for competing events within each 
SES category, age group and attended screening round by multiplying the modeled risk 
by the proportion of women not experiencing a competing event. The risks adjusted for 
competing events were used to calculate the cumulative risk of screening outcomes using 
Elveback’s formula.16 The 95% CIs were obtained by taking the 2.5 and 97.5 percentiles 
of 1,000 samples from the joint multivariate sampling distribution of the parameter esti-
mates.
RESULTS
Of the women participating in the mammographic screening program between 1995 and 
2013, 85.4% had a low SES and 14.6% had a high SES. As shown in Table 7.1, 18,314 
women attended their first screening round after 1995 and were at risk of being detected 
with breast cancer. Until the ninth round, the number of women attending screening de-
creased with increasing number of rounds attended. After the ninth round, the numbers 
increased again, which was possible as a result of the inclusion criteria (i.e. we only count-
ed the attended rounds after 1995).
Tables 7.2 presents the cumulative risks of screening outcomes for women screened 
from age 50-75 (estimates for screening from age 50-69 are provided in the Supplement, 
Table S7.2). Table 7.2 shows that women with high SES had a higher cumulative risk of 
screen-detected breast cancer, interval cancer and false-positive results than women with 
low SES. The cumulative risks of screen-detected breast cancer and interval cancer are 
8.6% and 2.6%  for high SES and 7.5% and 2.3%  for low SES, respectively.  The unadjusted 
and adjusted cumulative risks of false-positives are 17.6% and 20.2% for high SES and 
14.5% and 16.8% for low SES, respectively. Overall, the cumulative risks adjusted for de-
pendent censoring are higher than the unadjusted cumulative risks. 
For women with high compared to low SES, the cumulative risk of invasive screen-
detected breast cancer is higher (6.0% vs 5.6%, p=0.22), but the risk of invasive screen-
detected breast cancer smaller than 15mm is lower (2.7% vs 3.0%, p=0.25). 
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Table 7.1 Absolute number of women at risk for each screening outcome per screening 
round attended 
 
Rounda Breast cancerb False-positives 
1 18314 18299 
2 14903 14438 
3 12425 11957 
4 10533 10154 
5 9445 9090 
6 8635 8332 
7 8395 8116 
8 6944 6722 
9b 6045 5846 
10b 6209 5999 
11b 9222 8928 
12b 8047 7754 
13b 5700 5482 
a We started counting the number of attended rounds when a women first participated in the 
screening program, but only used the attended rounds after 1995 in the model because SES was 
not available prior to this point. As a consequence, it is possible that higher number of rounds 
have a greater number of women at risk than lower number of rounds. 
b Breast cancer includes screen-detected breast cancer and interval cancer 
 
 
Table 7.2 Cumulative risk (95% CI) of screening outcomes for women screened from age 50 
to 75 
 
    50-75 years 
  
Low SES High SES Total 
% 85% 15% 100% 
Screen-detected breast cancer 7.5 (6.9-8.4) 8.6 (7.4-10.2) 7.8 (7.1-8.7) 
 
Invasive 5.6 (5.0-6.5) 6.0 (5.0-7.6) 5.7 (5.1-6.7) 
 
Invasive <15 mm 3.0 (2.6-3.9) 2.7 (2.0-3.9) 3.0 (2.6-3.8) 
Interval cancer 2.3 (2.0-3.1) 2.6 (2.0-3.8) 2.4 (2.1-3.1) 
False positive recall 14.5 (13.8-15.5) 17.6 (16.2-19.5) 15.2 (14.6-16.2) 
    16.8 (15.4-18.2)a 20.2 (18.1-22.6)a 17.4 (16.1-18.9)a 
a Adjusted for dependent censoring 
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DISCUSSION
To our knowledge, this is the first study investigating the cumulative risk of favorable and 
unfavorable screening outcomes by SES in Europe. We showed that women with a high 
SES have a higher risk of unfavorable screening outcomes (interval cancer, false-positives) 
and a lower risk of favorable screening outcomes (small invasive screen-detected breast 
cancer). 
Comparison with literature
It is well known that women with high SES have higher breast cancer incidence than 
women with low SES.7,17,18 This is also reflected in our study where the cumulative risks of 
screen-detected breast cancer and interval cancer are, separately and combined, higher 
for women with high SES compared to low SES. In contrast, we found that the cumulative 
risk of small invasive screen-detected breast cancers was less common in women with 
high SES.
Our study also shows that women with high SES have a higher risk of being harmed 
by screening than women with low SES, i.e. the cumulative risks of interval cancer and 
false-positives were higher for women with high SES. These risks were, however, not dis-
proportionately higher relative to the overall higher frequency of cancers and recalls in 
the high SES group. In both SES groups, interval cancers were 23-24% of all cancers and 
false-positives were 66-72% of all recalls (71-72% for age 50-69 and 66-67% for age 50-
75). To our knowledge, no other studies have compared the cumulative risk of interval 
cancers by SES and only one study from the US examined the effect of race and median 
household income on the cumulative risk of false-positives.11 In contrast to our study, the 
US study indicated that women’s demographic variables did not affect the cumulative risk 
of false-positives.11 These contrasting results may be explained by the use of a different 
SES indicator, i.e. race and household income versus education, income and employment, 
and/or by the setting, i.e. different relationship between SES and breast cancer risk in the 
US than in the Netherlands. 
Furthermore, our study showed that women with high SES have more invasive and 
non-invasive screen-detected breast cancers, but fewer invasive screen-detected breast 
cancers smaller than 15 mm (non-significant difference).  A study from the southern part 
of the Netherlands19 showed similar results: women with high SES had more in situ tumors 
and fewer stage I tumors (tumor size <20 mm20) than women with low SES. However, the 
total percentage of small tumors in women with high SES compared to women with low 
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SES was higher in this study (69% vs 68%) and lower in the current study (63% vs 65%). In 
addition, a study from England observed no relationship between the proportion of small 
invasive cancers (<20 mm) and deprivation.21 This supports the idea that the non-signif-
icant difference between women with high and low SES in the cumulative risks of non-
invasive plus small invasive screen-detected breast cancers is most likely due to chance.
Overall, our study shows slightly higher cumulative risks of all screening outcomes 
than have been reported previously for the Netherlands.22 For women screened from 50 
to 75, the cumulative risk of screen-detected cancer, interval cancer and false-positives 
were 7.8%, 2.4%, and 15.2% (unadjusted) in our study including screening examinations 
since 1995, respectively. Otten et al22 showed cumulative risks of 6.9% for screen-detected 
cancer, 2.9% for interval cancers and 7.3% for false-positives for a cohort starting screen-
ing in 1997 and screened with film-screen mammography. These expected risks were 
higher for digital screening, i.e. 7.1% for screen-detected breast cancer and 16.1% for 
false-positives, which is more similar to our results. Although both studies were based on 
the same dataset, the estimates of the current study are likely more reliable, because our 
estimates are based on a longer period of follow-up, did not depend on extrapolation of 
risks to later screening rounds, and used methods to account for dependent censoring in 
estimates of the cumulative risk of false-positives. 
Our study also has limitations that should be taken into account when interpreting the 
results. First, we used an area-based SES indicator to categorize women into high and low 
SES groups. Because an area-based SES measure does not capture individual SES23, there 
may be some misclassification of SES which may cause a dilution of the effect of SES on 
the cumulative risks.24 Second, we estimated the cumulative risks of screening outcomes 
in the region of Nijmegen, which covers about a third of the Dutch range in SES. As a con-
sequence, women with an extremely high and low SES were not included in this study, 
which may potentially have affected our results. 
Major strengths of the current study were the use of a population-based approach 
and long-term follow-up (more than 26 years). We included all women who were invited 
to participate in the national mammographic screening program in Nijmegen and had at 
least one screening examination since 1995. As a result, the effect of selection bias on the 
reported cumulative risks is minimized. Furthermore, we used the total follow-up period 
of participating women to calculate the number of attended screening rounds, but only 
used data on rounds after 1995 to estimate model parameters. In this way, we were able 
to calculate the risk of each screening outcome without extrapolation of the risks to high-
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er round numbers. We also calculated the cumulative risk of false-positives unadjusted 
and adjusted for dependent censoring, which most likely represent to possible estimates 
for false-positives. 
The results of this study cannot directly be used for personalized screening, because 
a screening regimen guided by SES may well be ethically unacceptable to policy-makers 
and women invited to screening. The results do, however, indicate that the benefit-harm 
balance of mammographic screening for breast cancer is likely to differ by SES. And this 
in turn indicates that underlying risk factors associated with SES, e.g. reproductive factors 
and health behavior, may be useful targets for personalized screening, although more 
research will be needed to confirm this.
In conclusion, women with high SES have a higher cumulative risk of being harmed by 
screening, i.e. experiencing interval cancers or false-positives, and an equal cumulative 
risk of having a favorable screening outcome, i.e. small screen-detected breast cancer, 
than women with low SES. This suggests that screening regimens tailored according to 
reproductive risk factors and/or health behaviors may lead to a more favorable benefit-
harm balance.
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SUPPLEMENT 
Table S7.1 Competing events per screening outcome 
 
Screening outcome Competing events 
False positive result Screen-detected breast cancer, interval cancer, 
cancer detected ≥24 months after last screen, 
death 
Screen-detected breast cancer Interval cancer, cancer detected ≥24 months 
after last screen, death 
Invasive screen-detected breast cancer Non-invasive screen-detected breast cancer, 
interval cancer, cancer detected ≥24 months 
after last screen, death 
Invasive screen-detected breast cancer 
<15 mm 
Non-invasive screen-detected breast cancer, 
invasive screen-detected breast cancer ≥15mm, 
interval cancer, cancer detected ≥24 months 
after last screen, death 
Interval cancer Screen-detected breast cancer, cancer detected 
≥24 months after last screen, death 
 
 
 
Table S7.2 Cumulative risk (95% CI) of screening outcomes for women screened from age 50 
to 69 
 
    50-69 years 
  
low SES high SES Total 
% 85% 15% 100% 
Screen-detected breast cancer 5.1 (4.7-5.8) 5.9 (5.1-7.0) 5.4 (4.9-6.0) 
 
Invasive 3.6 (3.2-4.3) 3.9 (3.2-5.0) 3.7 (3.4-4.3) 
 
Invasive <15 mm 2.0 (1.7-2.5) 1.7 (1.3-2.5) 1.9 (1.7-2.4) 
Interval cancer 1.6 (1.4-2.1) 1.8 (1.4-2.6) 1.7 (1.4-2.1) 
False positive recall 12.5 (11.9-13.4) 15.2 (13.9-16.8) 13.1 (12.5-13.9) 
    14.1 (13.1-15.4)a 17.1 (15.4-19.2)a 14.8 (13.7-16.0)a 
a Adjusted for dependent censoring 
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ABSTRACT
Background: This study illustrates alternative statistical methods for estimating cumula-
tive risk of screening mammography outcomes in longitudinal studies.
Methods: Data from the U.S. Breast Cancer Surveillance Consortium (BCSC) and the 
Nijmegen Breast Cancer Screening Program in the Netherlands were used to compare 
four statistical approaches to estimating cumulative risk. We estimated cumulative risk 
of false-positive recall and screen-detected cancer after 10 screening rounds using data 
from 242,835 women aged 40-74 years screened at BCSC facilities in 1993-2012 and from 
17,297 women aged 50-74 years screened in Nijmegen in 1990-2012.
Results: In the BCSC cohort a censoring bias model estimated bounds of 53.8-59.3% for 
false-positive recall and 2.4-7.6% for screen-detected cancer, assuming 10% increased or 
decreased risk among women screened for one additional round. In the Nijmegen cohort, 
false-positive recall appeared to be associated with subsequent discontinuation of screen-
ing leading to over estimation of risk of a false-positive recall based on adjusted discrete-
time survival models. Bounds estimated by the censoring bias model were 11.0-19.9% for 
false-positive recall and 4.2-9.7% for screen-detected cancer.
Conclusion: Choice of statistical methodology can substantially affect cumulative risk esti-
mates. The censoring bias model is appropriate under a variety of censoring mechanisms 
and provides bounds for cumulative risk estimates under varying degrees of dependent 
censoring.
Impact: This paper illustrates statistical methods for estimating cumulative risks of cancer 
screening outcomes, which will be increasingly important as screening test recommenda-
tions proliferate.
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INTRODUCTION
Although the benefits of screening mammography have been established in clinical tri-
als,1-3 uncertainty remains regarding the absolute magnitude of this benefit as well as its 
relative magnitude in relation to harms. Ongoing evaluation of the harms and benefits 
of screening mammography is needed as mammography performance and subsequent 
diagnostic evaluation and treatment evolve. Many of the harms and benefits of screening 
mammography can be estimated using observational data from routine screening. In the 
US where population-based national screening programs do not exist, investigators have 
evaluated the performance of repeat mammography according to screening guidelines 
using data from registries or healthcare systems.4-6 In Australia and European countries 
with defined cancer screening programs, outcomes of these programs have been evalu-
ated using data from screening centers.7-13 Although most of these investigations have fo-
cused on the cumulative risks of a false-positive mammography result, cumulative risks 
of other screening outcomes including screen-detected cancers and interval cancers can 
also be estimated. 
Prior research on statistical methods for estimating cumulative risk of screening mam-
mography outcomes has focused on data from the US.14-17 Appropriate approaches for use 
in other settings may vary. For instance, in the US the choice of screening interval is largely 
an individual decision made by patients in consultation with their medical providers, while 
in many European nations with organized screening programs, screening interval is deter-
mined at the level of the program. These differences in the organization and delivery of 
screening mammography may give rise to differences in patterns of screening frequency 
and discontinuation of screening that affect the choice of statistical methodology.
The objective of this study is to provide guidance on appropriate statistical methodol-
ogy for estimating the spectrum of cancer screening outcomes over the course of a se-
ries of repeat mammograms with a specific focus on considerations that may vary across 
screening settings. We review alternative censoring mechanisms and appropriate meth-
ods in the presence of each mechanism, noting where considerations may differ across 
outcomes or settings. Using data collected by the Breast Cancer Surveillance Consortium 
(BCSC) in the US and the Nijmegen Breast Cancer Screening Program in the Netherlands 
we compare and contrast results using alternative statistical approaches to estimating the 
cumulative risks of a false-positive result or a screen-detected cancer after 10 rounds of 
screening.
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MATERIALS AND METHODS
Estimating cumulative risk of screening outcomes
A common approach to assessing mammography outcomes after a specified number of 
screening rounds is to estimate the cumulative risk, i.e., the probability that a woman ex-
periences the outcome of interest at least once during the course of a specified number of 
screens. Outcomes of interest include false-positive results, screen-detected cancers, and 
interval cancers. False-positive results can be further sub-divided into false-positive re-
calls, in which the woman is recalled for diagnostic evaluation involving imaging only, and 
complex or invasive false-positives in which the woman undergoes diagnostic evaluation 
requiring pathological evaluation of a tissue sample. The discrete-time survival model18 
provides a fundamental tool for estimating cumulative risks. This approach assumes that 
the risk of experiencing the outcome at a given screening round is independent of the 
“censoring time” defined as the number of screening rounds an individual is observed to 
attend. 
Because this assumption was found to be violated in the case of cumulative risk of 
false-positive results in the US,14,16 adjusted discrete-time survival approaches accounting 
for dependence between outcome risk at a given round and censoring time have been 
proposed. The discrete-time survival model adjusted for censoring round estimates cu-
mulative risk assuming that, had they continued to be observed, the probability of the 
outcome following censoring would have remained the same as that observed prior to 
censoring.14 For false-positive results, this approach fails to account for differences in risk 
of a false-positive result across screening rounds, especially between the first and subse-
quent screening rounds. To overcome this limitation, the discrete-time survival model ad-
justed for censoring round and screening round was proposed.16 This approach estimates 
risk at each round using a regression model dependent on censoring time and screening 
round. The increase in odds associated with a given censoring time is assumed constant 
across screening rounds. Both of these adjusted discrete-time survival approaches rely on 
the assumption that risk following censoring resembles risk prior to censoring. 
An alternative, the censoring bias model, assumes that risk following censoring re-
sembles risk among uncensored individuals with some inflation or deflation factor (the 
censoring bias parameter) to account for systematic differences between censored and 
uncensored individuals.17 For outcomes such as false-positive results where it is possible 
to continue observing screening for an individual after an event has occurred, the censor-
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ing bias parameter can be estimated. When an event always ends the observation period, 
as is the case for cancer diagnosis outcomes, it is not possible to estimate the censoring 
bias parameter; however, the sensitivity of the results to dependent censoring can be ex-
plored by estimating cumulative risk across a range of plausible censoring bias parameter 
values.
Additional methods details and formulas for each of the four methods are provided in 
the Supplementary Methods (See online).
Causes of censoring
There are a number of reasons that an individual may not be observed across all screen-
ing rounds of interest, giving rise to censored data. Under independent censoring, these 
causes are unrelated to the outcome of interest. For example, the study period may end 
before all participants have completed all screening rounds. Contrastingly, in the case of 
dependent censoring, the reason for incomplete observation is associated with the out-
come. For example, women with a family history of breast cancer might be more adherent 
to screening and at higher risk of a false-positive result and screen-detected cancer, induc-
ing dependence between the number of screening rounds a woman participates in and 
her outcome risk at each round. Statistical methods must be selected that appropriately 
account for the relationship between the outcome and the censoring time. Table 8.1 sum-
marizes the considerations discussed in this section for choice of statistical methodology.
Dependent censoring due to covariate dependence
The standard discrete-time survival model relies on the assumption of independent cen-
soring.15 When this assumption does not hold but censoring time is only associated with 
outcome risk through common dependence on a set of observed covariates, conditioning 
on covariates through stratification or regression adjustment achieves conditional inde-
pendence of censoring times and outcome risk, satisfying the independent censoring as-
sumption. For false-positive results, where censoring time is always observed regardless 
of prior occurrence of a false-positive result, it is possible to test the assumption of inde-
pendence of event and censoring times after adjusting for covariates using a regression 
approach16 For instance, this was the case in a study of screen-detected breast cancer risk 
in the Spanish screening program where conditioning on age was sufficient to address 
dependent censoring.19 Conversely, conditioning on observed covariates was not found 
to sufficiently account for dependent censoring in a study of false-positive results in the 
US.16 Regression adjustment can be incorporated into all of the methods described in this 
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Dependent censoring due to competing events
We next consider the case where censoring arises due to occurrence of competing events. 
For instance, when the outcome of interest is interval cancer, observation will be termi-
nated if a screen-detected cancer is diagnosed. If screen-detected cancer and interval 
cancer share common risk factors this will induce dependence between interval cancer 
risk and censoring round. Similarly, false-positive results and breast cancer diagnosis 
share many of the same risk factors including breast density and age.5-9 This induces de-
pendent censoring of false-positive results by cancer outcomes. In this case, risk at each 
round should ideally be estimated adjusting for both censoring time and cause of censor-
ing. In practice, this may be impractical since the number of individuals censored by some 
Table 8.1 Summary of recommended statistical methods by cause of censoring 
and screening outcome 
 
Cause of censoring   Outcome   Method 
Observed covariate  False-positive, Recall, 
Screen-detected cancer, 
Interval cancer  
Discrete-time survival model 
stratification or regression adjustment 
for covariates associated with 
censoring 
Unobserved covariate  False-positive, Recall, 
Screen-detected cancer, 
Interval cancer  
Censoring bias models allow 
exploration of sensitivity to dependent 
censoring attributable to unobserved 
covariates. Likely to be more 
problematic in ad hoc screening where 
patient characteristics play a greater 
role in screening frequency and 
duration than organized screening 
programs. 
Competing event  False-positive, Recall, 
Screen-detected cancer, 
Interval cancer  
Discrete-time survival adjusted for 
censoring time and cause of censoring.  
Event of interest  False-positive, Recall  Censoring bias model. Adjustment for 
censoring time or estimation of 
censoring bias parameter will induce 
bias and should not be used. 
  Screen-detected cancer, 
Interval cancer  
Discrete-time survival model. 
Censoring bias model if dependent 
censoring is suspected. 
 
 
paper. 
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causes, for instance due to interval cancer diagnosis, is likely to be very small. From a 
practical perspective, if certain causes of censoring are very rare it may be unnecessary to 
construct separate estimates simply because the number of individuals experiencing the 
competing event is small enough that they have no meaningful impact on risk estimates. 
In addition to considering the effect of competing events on censoring time, it is also 
necessary to determine whether cumulative risk should be estimated in the presence or 
absence of competing events. Typical survival models that censor at the time of a compet-
ing event estimate the latent risk of the outcome of interest had the competing event not 
occurred. The alternative analysis accounting for competing events estimates the prob-
ability of experiencing the outcome of interest without positing the absence of the com-
peting event. In effect, censoring at the time of a competing event removes individuals 
that experience a competing event from the denominator, computing risk only among the 
population that does not experience a competing event. Accounting for the presence of 
competing risks retains this population in the denominator, providing an estimate of the 
probability of the outcome of interest in the total screened population. All four of the 
statistical methods considered here can be used to estimate cumulative risks accounting 
for competing events. Methods details for estimating cumulative risk under competing 
events are provided in the Supplementary Methods Section (provided online). 
Censoring due to event of interest
Finally, we consider the case where the event of interest causes discontinuation of screen-
ing. This will always be the case when the event of interest is a cancer diagnosis because 
subsequent screening in individuals with a prior cancer diagnosis is considered to be sur-
veillance, at least for some time period after treatment. Discontinuation of screening due 
to the event of interest could also arise in the case of false-positive results if individuals 
lose confidence in the screening program and decide not to return for future screening. 
When the outcome itself leads to censoring, risk will be elevated in the last round attend-
ed. Graphical examination of risk as a function of screening round, stratified by censoring 
time, will reveal a distinctive pattern in which risk is much higher in the last observed 
round if the event of interest tends to lead to discontinuation of screening.
In settings where the event of interest leads to an increase in the probability of dis-
continuation but no dependent censoring mechanisms exist, the standard discrete-time 
survival model can be used. This is the standard survival analysis scenario where individu-
als are followed only until the first of censoring or the outcome of interest. However, if 
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dependent censoring is believed to exist in addition to the event of interest increasing the 
probability of discontinuing screening then alternative methods are needed. Both of the 
discrete-time survival methods adjusted for censoring round overestimate the cumula-
tive risk. Conceptually this occurs because these methods impute risk following censoring 
with risk prior to censoring, stratified by censoring round. When the event itself causes 
censoring, after stratifying by censoring round, risk will always be inflated in the last round 
attended making this an unsuitable estimate of what risk would have been had the wom-
an continued to screen. 
The censoring bias approach accounts for dependent censoring but does not require 
using estimates of risk prior to censoring to impute risk after censoring. By rescaling risk 
among uncensored individuals to impute risk among the censored, this approach facili-
tates investigation of the sensitivity of estimates to departures from independent censor-
ing. Although it is possible to estimate the censoring bias parameter for some outcomes, 
doing so relies on an estimate of the association between censoring and event times, 
which will be inflated when occurrence of the event of interest increases the probability 
of censoring. Thus in this setting a range of values should be investigated, rather than 
estimating the censoring bias parameter based on the data. 
Censoring mechanisms in different screening settings
A variety of statistical approaches have been used to investigate the cumulative risk of 
screening outcomes for screening mammography in the US, Europe, and Australia, most 
often focusing on false-positive test results. The screening context in different geographic 
locations varies substantially and may modify the relationships between risk of the out-
comes of interest, screening round, censoring round, and covariates. The statistical ap-
proach that is most appropriate in one setting may not apply in another.
European countries offer organized population-based screening, whereas in the US, 
decisions about when to begin screening, how frequently to screen, and when or if to 
discontinue screening are more strongly influenced by decision making at the woman 
and provider level. Prior research investigating dependent censoring has found different 
results in the US compared to Europe. In the US, two studies using different data sources 
identified dependent censoring with respect to false-positive results14,16 and found that 
this dependence persisted after adjusting for age, screening interval, calendar year, and 
mammography registry.16 By contrast, two studies from Denmark found no evidence of de-
pendent censoring.9,20 A Spanish study found that adjusting for age was sufficient to elimi-
nate dependent censoring.19 These results suggest that accounting for dependent censor-
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ing may be more relevant in settings without population-based screening programs.
Breast Cancer Surveillance Consortium
The Breast Cancer Surveillance Consortium (BCSC) consists of a geographically diverse 
collection of mammography registries from across the US that collect information from 
community mammography facilities. This study included data from seven BCSC registries 
obtained from the BCSC Research Resource.21 Radiologists’ assessments and recommen-
dations were based on the American College of Radiology’s Breast Imaging Reporting and 
Data System (BI-RADS).22 Breast cancer diagnoses were obtained through linkages with pa-
thology databases, regional Surveillance, Epidemiology, and End Results (SEER) programs, 
and state tumor registries. All BCSC registries and the BCSC Statistical Coordinating Center 
received Institutional Review Board approval for active or passive consenting processes or 
a waiver of consent to enroll participants, link data, and perform analysis. All procedures 
were Health Insurance Portability and Accountability Act compliant, and registries and 
the Coordinating Center received a Federal Certificate of Confidentiality and other protec-
tions for the identities of women, physicians, and facilities.
We included women receiving their first screening examination at a BCSC facility at 
ages 40-74 years from 1993 to 2012. A woman’s first and all subsequent examinations 
were included until the earliest of death, disenrollment from the healthcare system, or 
a discrepancy of 6 months or more between a woman’s self-reported time since last 
mammography and that captured by the BCSC (to ensure that women had not received 
mammography outside of BCSC catchment). We defined a positive mammogram as an 
examination with an initial BI-RADS assessment of 0, 4, or 5 or 3 when accompanied by 
a recommendation for immediate evaluation. A screen-detected cancer was defined as 
a positive mammogram followed by a diagnosis of invasive cancer or ductal carcinoma 
in situ (DCIS) within 12 months and prior to the next screening mammogram. A false-
positive recall was defined as a positive mammogram with no cancer diagnosis within 12 
months and prior to the next screening mammogram.
Nijmegen Breast Cancer Screening Program
In Nijmegen, a city in the Eastern part of the Netherlands, a breast cancer screening pro-
gram was introduced in 1975. Women in the target age range of the national screening 
program, 50-74 years, were invited from 1989 on.23 Data on screening invitation and atten-
dance for each woman living in Nijmegen is collected in one registry. A separate registry 
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collects data on women diagnosed with breast cancer and living in Nijmegen. All women 
consented to the use of their anonymous data for scientific research.
We included all examinations for women aged 50-74 years who received a first screening 
examination between 1990 and 2014. Censoring occurred due to moving out of the catch-
ment region or death. A mammogram was classified as positive if the woman was recalled 
for diagnostic work-up of a suspicious finding on the screening mammogram. In the Nij-
megen cohort, a screen-detected cancer was defined as a positive mammogram resulting 
in a diagnosis of invasive cancer or DCIS at the end of all imaging or biopsy work-up. A 
false-positive recall was defined as a positive mammogram where diagnostic follow-up 
did not confirm the presence of breast cancer during the first year after screening.
Statistical analysis
For each cohort we computed empirical estimates of risk and cumulative risk at each 
of the first ten screening rounds, stratified by censoring round for two outcomes: false-
positive recall and screen-detected cancer. Because the same analytic considerations ap-
ply to screen-detected cancers and interval cancers, we have illustrated the alternative 
methods only using screen-detected cancers. We estimated cumulative risk in the ab-
sence of competing events using the four statistical methods described above. For screen-
detected cancers, risk conditional on censoring time is always zero in all rounds prior to 
the last round attended (because the event causes censoring) which precludes estimating 
the discrete-time survival model adjusted for censoring round and screening round. We 
therefore omit this estimate for screen-detected cancer. For the censoring bias model, we 
obtained estimates assuming that risk increased or decreased by 10% for each additional 
screening round attended. The choice of 10% was motivated by prior work in the BCSC 
which estimated the censoring bias parameter to be 4%.17 We report point estimates of 
cumulative risk after 10 rounds of screening and 95% confidence intervals (CI) based on 
1000 bootstrap replicates. 
RESULTS
We included 242,835 women receiving 539,330 screening mammograms in the BCSC and 
17,297 women receiving 58,951 screening mammograms within the Nijmegen screening 
program (Table 8.2). Women in the BCSC cohort began screening at earlier ages and were 
observed over fewer rounds of screening compared to those in the Nijmegen cohort.
Empirical estimates of the risk of false-positive recall at each screening round in the BCSC 
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cohort provide some suggestion of dependent censoring (Figure 8.1). In general, women 
censored earlier had higher risk of a false-positive recall while those censored later had 
lower risks, although this effect was minor. The BCSC cohort did not demonstrate a pattern 
indicative of censoring due to the event of interest for false-positive recall, with no notable 
increase in risk in the last round prior to censoring. At the tenth screening round, the cu-
mulative risk of false-positive recall from the discrete-time survival model was 56.4% (95% 
CI [55.8, 57.2]). Estimates from both discrete time-survival models adjusted for censoring 
round returned higher estimates, indicative of the higher false-positive recall risk among 
women censored earlier. The estimate from the discrete-time survival model adjusted for 
censoring round and screening round was similar to the censoring bias model estimate 
Table 8.2 Characteristics of women in screening mammography cohorts from the BCSC and 
Nijmegen.  
 
  BCSC Nijmegen 
  N (%) N (%) 
Age at first screening round attended 
  
40-49  172,422 71.0 0 0 
50-59  40,513 16.7 16,088 93.0 
60-69  22,261 9.2 984 5.7 
70-74  7,639 3.1 225 1.3 
Year of first screening round attended 
  
1990-1994  9,733 4.0 159 0.9 
1995-1999  86,075 35.4 2,556 14.8 
2000-2004 81,931 33.7 4,317 25.0 
2005-2009  53,781 22.1 6,000 34.7 
≥2010  11,315 4.7 4,265 24.7 
Number of screening rounds attended 
  
1 108,015 44.5 3,915 22.6 
2 45,594 18.8 2,771 16.0 
3 27,718 11.4 2,183 12.6 
4 18,743 7.7 2,068 12.0 
5 13,328 5.5 1,641 9.5 
6 9,411 3.9 1,577 9.1 
7 6,774 2.8 1,314 7.6 
8 4,885 2.0 1,079 6.2 
9 3,210 1.3 582 3.4 
≥10 5,157 2.1 167 1.0 
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when assuming a 10% decreased risk among individuals attending one additional round. 
Bounds on cumulative risk of a false-positive recall provided by the censoring bias model 
were 53.8-59.3%. For screen-detected cancers, the discrete-time survival model estimate 
after ten screening rounds was 3.7% (95% CI [3.4, 3.9]). The discrete-time survival model 
adjusted for censoring round returned a much higher estimate. However, this estimate is 
expected to overestimate risk by using the inflated risk observed in the last round prior 
to censoring to impute risk after censoring. The censoring bias model provides bounds of 
2.4-7.6% for our risk estimate when risk is increased or decreased, respectively, by 10% 
for each additional round attended.
For the Nijmegen cohort, risk of a false-positive recall appears somewhat higher in 
the last round a woman attended (Figure 8.2), possibly indicative of censoring due to the 
event of interest. In this case, using either of the discrete-time survival models adjusted 
for censoring round results in over-estimating the cumulative risk. In the Nijmegen co-
Figure 8.1 Empirical risk estimates (left), empirical cumulative risk estimates (middle) and model-based risk 
estimates (right) for false-positive results (top) and screen-detected cancer (bottom) for the BCSC cohort. 
Lines in the left-hand and middle plots provide empirical risk estimates stratified by censoring time. Points on 
each line are labeled with the censoring time for the corresponding stratum. In the right-hand panel, the solid 
line gives the discrete-time survival estimate, the dashed line gives the discrete-time survival model adjusted for 
censoring round, the dashed and dotted line gives the discrete-time survival model adjusted for censoring round 
and screening round, and the dotted grey lines give the censoring bias estimates assuming 10% increased and 
decreased risk associated with each additional round attended.
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hort, for both outcomes the discrete-time survival estimates adjusted for censoring round 
are notably higher than the unadjusted estimate (after 10 rounds 13.6%, 95% CI [12.2, 
15.4] for false-positive recall; 5.7%, 95% CI [4.4, 7.2] for screen-detected cancer). Cumula-
tive risk at the tenth screening round varied from 11.0-19.9% for false-positive recall and 
4.2-9.7% for screen-detected cancers when we used the censoring bias model to explore 
10% increased risk or decreased risk, respectively, for individuals attending one additional 
round of screening.
DISCUSSION
Several methods for estimating cumulative risk of screening mammography outcomes 
have been proposed. The foundation for these approaches is the discrete-time surviv-
Figure 8.2 Empirical risk estimates (left), empirical cumulative risk estimates (middle) and model-based risk 
estimates (right) for false-positive results (top) and screen-detected cancer (bottom) for the Nijmegen cohort. 
Lines in the left-hand and middle plots provide empirical risk estimates stratified by censoring time. Points on 
each line are labeled with the censoring time for the corresponding stratum.  In the right-hand panel, the solid 
line gives the discrete-time survival estimate, the dashed line gives the discrete-time survival model adjusted for 
censoring round, the dashed and dotted line gives the discrete-time survival model adjusted for censoring round 
and screening round, and the dotted grey lines give the censoring bias estimates assuming 10% increased and 
decreased risk associated with each additional round attended.
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al model, and a number of alternatives have been suggested to account for dependent 
censoring. The appropriateness of these approaches varies by screening outcome and 
setting. Notably, the adjusted discrete-time survival approaches will substantially over-
estimate risk if the event of interest is among the causes of censoring. These approaches 
should never be used if the outcome of interest inherently terminates observation (e.g., 
cancer diagnosis). An uptick in empirical risk estimates in the last screening round prior 
to censoring, as observed for false-positive recall in the Nijmegen cohort, is an indication 
that this type of censoring may be at play. In this case, the censoring bias model is rec-
ommended. Investigating a range of values for the censoring bias parameter will provide 
bounds for the risk estimate.
Studies of the cumulative risk of false-positive mammography results using data from 
the US have used a variety of methods.4,6,14-17 A study of censoring bias using data from the 
BCSC estimated that risk was 4% lower for each additional screening round a woman at-
tended.17 Estimates of false-positive recall risk based on the discrete-time survival model 
adjusted for censoring round and screening round agreed well with a censoring bias esti-
mate assuming 10% decreased odds of a false-positive recall for each additional round an 
individual participated in. In the setting of screening mammography in the US, it appears 
that dependent censoring does play a small role and that either adjusted discrete-time 
survival models or censoring bias models can be used to obtain risk estimates accounting 
for dependent censoring in this setting.
A number of prior studies have estimated the cumulative risk of a false-positive 
screening mammography result using data from European population-based screen-
ing programs.7-9,12,20 Some of these studies have used discrete-time survival estimates7,12,20 
while others have used simpler approximations that assume independence of risk across 
screening rounds.8,9 In a recent comparison of the cumulative risk of false-positive results 
in Denmark using discrete-time survival methods with and without adjustment for depen-
dent censoring, little difference in estimates was found, suggesting that dependent cen-
soring plays little role in this setting.20 In general, dependent censoring may be less likely in 
European service screening programs where less patient choice is involved in the decision 
of starting and stopping ages and screening frequency compared to the US.
Similar to prior studies comparing screening in the US and Europe, we found substan-
tially higher risks of false-positive recall in the BCSC compared to Nijmegen, while risks 
of screen-detected cancer were similar.12,20,24 Possible explanations for these differences 
include the opportunistic nature of screening in the US, as compared to organized popu-
177
Statistical methods for estimating the cumulative risk of screening mammography outcomes 
using observational data
lation-based screening in Europe; differences in the medico-legal context; and differences 
in interpretive volumes required for radiologist accreditation. We also found that women 
in Nijmegen tended to discontinue screening after experiencing a false-positive recall, 
consistent with a prior study25, However, this result was not found in the BCSC. Previous 
research in the US found that women are more likely to continue screening after a false-
positive recall.26 
A few studies have used discrete-time survival models to estimate cumulative risks for 
outcomes other than false-positive results.19,27,28 These studies have not carried out adjust-
ment for dependent censoring. As we have demonstrated here, adjusting for dependent 
censoring using inappropriate methods in studies with cancer as the outcome leads to 
substantial overestimation of risk. However, the possibility of dependent censoring does 
exist in this context, and we recommend exploring its potential impact through sensitivity 
analyses using censoring bias models.
Estimating outcomes over the course of repeat screening examinations is increasingly 
common and important given the large number of population-based cancer screening 
programs and screening recommendations currently in existence. As new screening tests 
become available it will be important to evaluate their long-term outcomes across mul-
tiple rounds of screening. The considerations described in this paper can be applied to 
repeat screening tests of many kinds and should be used to ensure that appropriate sta-
tistical methodology is selected.
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ABSTRACT
Background: Trend studies investigating the impact of mammographic screening usually 
display age-specific mortality and incidence rates over time, resulting in an underestimate 
of the benefit of screening, mortality reduction, and an overestimate of its major harm, 
overdiagnosis. This study proposes a more appropriate way of analyzing trends.
Methods: Breast cancer mortality (1950-2009) and incidence data (1975-2009) were ob-
tained from Statistics Netherlands, ‘Stg. Medische registratie’ and the National Cancer 
Registry in the Netherlands for women aged 25-85. Data was visualized in age-birth co-
hort and age-period figures.
Results: Birth cohorts invited to participate in the mammographic screening programme 
showed a deflection in the breast cancer mortality rates within the first five years after 
invitation. Thereafter, the mortality rate increased, although less rapidly than in uninvit-
ed birth cohorts. Furthermore, invited birth cohorts showed a sharp increase in invasive 
breast cancer incidence rate during the first five years of invitation followed by a moder-
ate increase during the following screening years and a decline after passing the upper 
age limit.
Conclusion: When applying a trend study to estimate the impact of mammographic 
screening, we recommend using a birth cohort approach.
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INTRODUCTION
In a recent poll, a quarter of the European clinicians voted against recommending routine 
mammographic screening as they believed that the benefits of screening in terms of mor-
tality reduction did not outweigh the harms resulting from screening.1 This is remarkable, 
considering that most randomized controlled trials and observational studies have shown 
large mortality reductions since the introduction of mammographic screening.2 Trend 
studies are often executed to evaluate the impact of mammographic screening on breast 
cancer mortality. To this end, they  usually display age-specific rates of breast cancer death 
for calendar periods.3-5 The observed mortality decreases in these studies ranged between 
1 to 9% annually.6 These percentages are likely to be diluted because the effect of screen-
ing on breast cancer mortality is small shortly after women enter the mammographic 
screening programme and endures after women leave the screening programme.6 In 
other words, the effect of mammographic screening on mortality is not restricted to the 
screened age-range, but is dependent on whether or not women are screened. 
A similar condition applies to the effect of mammographic screening on the breast 
cancer incidence. Mammographic screening has immediate effects, such as the increased 
incidence directly following introduction, and delayed effects that can only be observed 
in women who have left the screening programme, such as the compensatory drop.7 In 
order to be able to make a reliable estimate of the main harm of screening, overdiagnosis, 
both immediate and delayed effects of mammographic screening on breast cancer inci-
dence should be taken into account.
This study aims to provide more insights into both the immediate and delayed effects 
of mammographic screening by visualizing trends in breast cancer mortality and incidence 
in ‘birth cohorts not invited’ and ‘birth cohorts invited’ to participate in the Dutch mam-
mographic screening programme. 
MATERIALS AND METHODS
The Dutch screening programme
In 1989, the implementation of the population-based biennial mammography screening 
programme in the Netherlands started, inviting all women aged 50-69. The geographic 
coverage of the screening programme increased from 11% in 1990, to 26% in 1991, 48% 
in 1992, 69% in 1993, 77% in 1994, 88% in 1995, and to its full capacity in 1996.8 The at-
tendance during this implementation period increased from 72.5% in 1990 to 80.1% in 
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1997, thereafter it remained  stable at around 80%.9 In 1997, the screening programme 
was extended to include women aged 70-74. The geographic coverage of the screening 
programme of the 70-74 age group increased from 26% in 1998, to 86% in 1999, 91% 
in 2000, and to its full coverage in 2001.8 Furthermore, the percentage of definite non-
participants, those who do not wish to receive further invitations to participate in the 
screening programme, has always been low (2.0-7.5%).10 From mid-2004 to 2010, there 
was a transition from screen-film mammography to digital mammography.10
Breast cancer mortality and incidence data
Data on the female population and on the number of breast cancer deaths were obtained 
per calendar year (1950-2010) in 5-year age groups from Statistics Netherlands.11 Data on 
invasive breast cancer incidence was obtained from the Stg. Medische Registratie (1975-
1988) and the website of the National Cancer Registry in the Netherlands (1989-2010).12 
We limited our analyses to invasive breast cancer because carcinoma in situ (CIS) inci-
dence was not registered before 1989. CIS represented 4.4% of all newly diagnosed breast 
cancers in 1989 and 13.1% in 2010. The exclusion of CIS resulted in this study results in an 
under-representation of the actual number of new breast cancer cases that are normally 
presented for the Netherlands. 
Crude breast cancer mortality and invasive breast cancer incidence rates were calcu-
lated per 100,000 women years using the female mid-population as denominator. Birth 
cohorts were computed by subtracting the age at breast cancer death or diagnosis from 
the calendar period. Because age was obtained in 5-year groups and calendar period was 
aggregated in 5-year groups, the birth cohorts cover 10 overlapping years and are indi-
cated by the five middle years. Figures were produced with Microsoft Excel (2007) using 
5-year averages in the age-birth cohort figures and 5-year moving averages in the age-
period figure to reduce large annual fluctuations.
RESULTS
Figure 9.1 displays the breast cancer mortality rates per birth cohort for cohorts of wom-
en that never participated in the national mammographic screening programme (A) and 
for cohorts of those women invited to participate in the screening programme (B). The 
birth cohorts not exposed to the national mammographic screening programme all show 
an increasing breast cancer mortality rate with age, which is similar for all birth cohorts. 
Younger birth cohorts also show a slightly higher breast cancer mortality rate than older 
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Figure 9.1 Breast cancer mortality rates per 100,000 women years for birth cohorts (A) uninvited and (B) invited to participate 
in the national mammography screening programme. Women born between 1923 and 1927 were 65 to 69 years old when 
invited to mammography screening for the first time. Women born between 1928-1932 were first invited aged 60 to 64, women 
born between 1933-1937 were first invited aged 55 to 59 and women born after 1938 were invited for the first time when they 
reached the age of 50.
birth cohorts. The birth cohorts not displayed in Figure 9.1A (to facilitate interpretation of 
trends) showed the same pattern.
In comparison, the invited birth cohorts (Figure 9.1B) show a deflection in the breast 
cancer mortality rate that starts within the first 5 years after receiving an invitation to par-
ticipate in the mammographic screening programme. After this initial deflection, the mor-
tality rate increases again, although, at a much lower rate in comparison to women of the 
same age in the uninvited birth cohorts. These effects are more prominent in those birth 
cohorts invited more often to participate in the mammographic screening programme.
Figure 9.1B also shows that the breast cancer mortality rate is lower in younger birth 
cohorts in both the age range where women are invited to participate in the national 
screening programme (older than 50) and the age range before women enter the national 
screening programme (younger than 50). 
Figure 9.2 presents age-specific breast cancer mortality rates over time. Overall, the 
breast cancer mortality increased from 1950 to 1990, which corresponds to the increasing 
mortality in younger uninvited birth cohorts (Figure 9.1A). After the implementation of 
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mammographic screening in 1990 for women aged 50-69,  breast cancer mortality starts 
to decline in women younger than 70, although very little at the start. From 1999 on-
wards, the breast cancer mortality also starts to decline in women aged 70-84. When 
taking the opportunity for screening into account, Figure 9.2 indicates that the mortality 
decline increases with increasing age. To facilitate comparison of Figure 9.2 with Figure 
9.1, three birth cohorts, indicated by their middle year, were added to Figure 9.2. The 
lines of the birth cohorts are fairly parallel before the implementation of mammographic 
screening and start to deviate from each other after the implementation of mammo-
graphic screening.
Figure 9.3 shows the invasive breast cancer incidence rates per birth cohort for co-
horts of women that never participated in the mammographic screening programme (A) 
and for cohorts of women  invited to participate in the screening programme (B and C). 
The uninvited birth cohorts show an increasing invasive breast cancer incidence rate with 
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Figure 9.2 Age-specific breast cancer mortality rates per 100,000 women years over time. Women born between 1908-1912 
were never invited for mammographic screening. Women born between 1923 and 1927 were first invited aged 65 to 69 and 
women born between 1938-1942 were first invited aged 50 to 54.
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increasing age, where the younger birth cohorts have a higher incidence than the older 
birth cohorts. The invited birth cohorts show a large peak in the invasive breast cancer 
incidence at the age of first invitation, which is followed by moderate increases in the 
birth cohorts of 1933-1937 and younger. The birth cohort 1923-1927 shows a drop in the 
invasive breast cancer rate in the 70-79 age group, when women in this birth cohort left 
the screening programme, and thereafter an increase in the invasive breast cancer rate. 
The 1928-1932  birth cohort shows a drop at the age 75-79 that is more prominent than 
the drop of the 1923-1927 birth cohort. 
Figure 9.3 A-C all show that the invasive breast cancer incidence rate is higher in 
younger birth cohorts, irrespective of their being invited to participate in the mammo-
graphic screening programme.
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Figure 9.3 Invasive breast cancer incidence rates per 100,000 women years for birth cohorts (A) uninvited, (B) invited at age 
55 or older and (C) invited since age 50 to participate in the national mammographic screening programme. Women born 
between 1923 and 1927 were 65 to 69 years old when invited to mammography screening for the first time, and are thereby 
the eldest birth cohort invited to screening. Women born between 1928-1932 were first invited aged 60 to 64, women born 
between 1933-1937 were first invited aged 55 to 59 and women born after 1938 were invited for the first time when they 
reached the age of 50.
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DISCUSSION 
Birth cohorts invited for mammographic screening had lower breast cancer mortality 
rates than uninvited birth cohorts; the breast cancer mortality rates in the invited and 
uninvited birth cohorts started to diverge shortly after the introduction of the mammo-
graphic screening programme and continued to diverge after the upper age limit of eligi-
bility was reached. In addition, birth cohorts invited for mammographic screening showed 
a sharp increase in the invasive breast cancer incidence at age of first invitation and a drop 
in the invasive breast cancer incidence after the upper age limit of eligibility was reached.
Trend studies evaluating the impact of mammographic screening have found a de-
creasing (age-specific) breast cancer mortality rate over time.6 The results of our study 
corresponds these findings, showing a decreasing age-specific breast cancer mortal-
ity rate over time after the introduction of mammographic screening, and a decreasing 
breast cancer mortality rate in birth cohort invited to participate in the mammographic 
screening programme.
Trend studies are often used to quantify the impact of mammographic screening on 
breast cancer mortality. So far, most studies have compared a screening period with a 
non-screening period, or screened age groups with pre- and post-screening age groups.6 
Some trend studies have also tried to take the delayed effects of mammographic screen-
ing into account by excluding women in the first five years of starting screening.6,8 Howev-
er, this study suggests that trends of birth cohorts are preferable to trends over time when 
studying the impact of mammographic screening on breast cancer mortality. Firstly, trend 
studies comparing a screening period with a non-screening period are likely to dilute the 
impact of mammographic screening, as this study shows that the breast cancer mortality 
increases slightly with birth cohort and over time. In addition, changes in other factors, 
such as therapy, make comparisons over time difficult. Secondly, trend studies comparing 
screened age groups with pre- and post-screening age groups are also likely to dilute the 
impact of mammographic screening, as this study shows that the breast cancer mortal-
ity rates in post-screening age groups are lower in invited birth cohorts than in uninvited 
birth cohorts. Lastly, exclusion of women in the first five years from the start of screening 
can partly limit dilution of the impact of mammographic screening, although, it cannot 
take into account that the impact of mammographic screening on breast cancer mortality 
is gradual. Therefore, we recommend studying the impact of mammographic screening 
in the same group of women, i.e. by comparing invited birth cohorts with uninvited birth 
cohorts.
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Even though birth cohorts can account for the gradual impact of mammographic 
screening on breast cancer mortality trends, it remains difficult to interpret mortality 
trends. This study shows that the breast cancer mortality rate decreases with successive 
birth cohorts after the implementation of mammographic screening regardless of being 
invited to participate in the mammographic screening programme. In the non-invited 
birth cohorts, the decreasing breast cancer mortality can be explained by, among oth-
ers, advances in breast cancer therapy and increased awareness, while it is likely to be 
caused by a combination of screening, therapy and other factors in the invited birth co-
horts. Some authors have analysed and estimated the individual effects of mammography 
screening and therapy on the mortality decrease in invited age groups, which has resulted 
in estimates varying from 20% to 72% for adjuvant systemic therapy and from 28% to 80% 
for mammography screening.13-16
The birth cohorts invited for mammographic screening showed a sharp short-term in-
crease in the invasive breast cancer incidence rate followed by more moderate increases. 
This is a well-known phenomenon which has been demonstrated in studies displaying 
age-cohort graphics17-19 or age-period graphics8,20,21. 
When invited birth cohorts exceed the upper age-limit of the screening programme, 
the invasive breast cancer incidence rate drops to a much lower level than would be ex-
pected at that age in a non-screening situation. This is in line with the prediction by Boer 
et. al.7 and the results of other studies.22 For a reliable calculation of the percentage of 
overdiagnosis, this drop in incidence after leaving the screening programme should be 
taken into account in addition to the extra incidence during the screening programme. 
Preferably, overdiagnosis should be calculated from the extra incidence and drop in one 
birth cohort of women, as our results suggest that the magnitude of the drop depends 
on how long the women were invited to participate in mammographic screening. Until 
now, only a few studies have used a cohort approach to study overdiagnosis, leading to 
estimates ranging from 1% to 5%.23,24
Younger birth cohorts show a higher invasive breast cancer incidence rate irrespective 
of being invited to participate into the mammographic screening programme. Other stud-
ies have also found an increasing breast cancer incidence rate with younger birth cohorts, 
even when adjusted for the introduction of mammographic screening.17,19,25 This increase 
in incidence might be explained by increasing risk factors17, such as age at first birth, and/
or changes in diagnostic practice.25 Although it is difficult to disentangle the combined ef-
fects, our study suggests that other forms of early detection play a role in the increasing 
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breast cancer incidence, because this coincides with a decreasing breast cancer mortality 
rate. Factors contributing to early detection of breast cancer in the Netherlands are  in-
creased awareness, increased use of opportunistic mammography and/or counselling and 
detection of high-risk families since the late 1990s.10
In this study, we chose to visualize trends in the breast cancer mortality and invasive 
breast cancer incidence in birth cohorts of women invited and not invited to participate 
in the mammographic screening programme. A major advantage of age-cohort graphics 
in comparison to the more common age-specific rates in time periods is that effects of 
changes, such as the introduction of mammographic screening, can be followed in one 
group of women over time, i.e. it displays both immediate and delayed effects. Further-
more, this approach is most suitable for visualizing the effects of mammographic screen-
ing on breast cancer incidence for other factors influencing  breast cancer incidence, e.g. 
risk factors, do not depend on the same age and cohort combination as mammographic 
screening. 
We chose not to estimate the effect of age, period and birth cohort as there is no 
unique parameterization of these three parameters, i.e. a ‘nonidentifiability’ problem, 
without making assumptions.26-29 Additionally, we believed that the message would be 
clearer by visualizing breast cancer mortality and incidence trends in birth cohorts rather 
than by quantifying the effects.
To conclude, mammographic screening has both immediate and delayed effects on 
the breast cancer mortality and incidence. A birth cohort approach prevents underestima-
tion of the mortality reduction by taking into account the effects of screening above the 
upper age limit for screening and by not including constant additions of women newly 
entering the screening programme. In addition, it prevents overestimation of overdiagno-
sis, because this can be calculated from the extra incidence and its associated compensa-
tory drop. Therefore, we recommend using a birth cohort approach when designing trend 
studies to estimate the impact of mammographic screening.
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ABSTRACT 
A drawback of early detection of breast cancer through mammographic screening is the 
diagnosis of breast cancers that would never have become clinically detected. This phe-
nomenon, called overdiagnosis, is ideally quantified from the breast cancer incidence of 
screened and unscreened cohorts of women with follow-up until death. Such cohorts do 
not exist, requiring other methods to estimate overdiagnosis. We are the first to quan-
tify overdiagnosis from invasive breast cancer and ductal carcinoma in situ (DCIS) in birth 
cohorts using an age-period-cohort-model (APC-model) including variables for the initial 
and subsequent screening rounds and a 5-year period after leaving screening. Data on 
the female population and breast cancer incidence were obtained from Statistics Neth-
erlands, ‘Stichting Medische registratie’ and the Dutch Cancer Registry for women aged 
0-99 years. Data on screening participation was obtained from the five regional screen-
ing organizations. Overdiagnosis was calculated from the excess breast cancer incidence 
in the screened group divided by the breast cancer incidence in presence of screening 
for women aged 20-99 years (population perspective) and for women in the screened-
age range (individual perspective). Overdiagnosis of invasive breast cancer was 11% from 
the population perspective and 17% from the invited women perspective in birth cohorts 
screened from age 49 to 74. For invasive breast cancer and DCIS together, overdiagnosis 
was 14% from population perspective and 22% from invited women perspective. A major 
strength of an APC-model including the different phases of screening is that it allows to 
estimate overdiagnosis in birth cohorts, thereby preventing overestimation.
  
199Overdiagnosis by mammographic screening for breast cancer studied in birth cohorts in the netherlands
INTRODUCTION
Mammographic screening reduces breast cancer mortality1 by detecting breast cancers at 
an early stage with better treatment outcomes.2 A drawback of early detection by mam-
mographic screening is, however, the detection of rather indolent breast cancers that 
would never have become clinically diagnosed during a woman’s lifetime. These indolent 
cancers are, so-called, ‘overdiagnosed’. Overdiagnosis is especially harmful when treat-
ment follows, which is referred to as overtreatment.
To date, there is much debate about the degree of overdiagnosis with estimates rang-
ing from 0 to 52%.3-8 The major reason for this wide range of overdiagnosis estimates is 
the difficulty in quantifying the true extent of overdiagnosis, because studies with ideal 
empirical data and follow up until death do not exist1, 5 and because there is no consensus 
about the optimal methodology to quantify overdiagnosis. Ideally, overdiagnosis is esti-
mated from the breast cancer incidence in a screened and unscreened cohort of women 
using the cumulative-incidence approach1, 9, 10, also called excess-incidence approach11, 12. 
For a valid comparison of the screened and unscreened cohort, the cohorts should have 
the same age distribution and risk of breast cancer1, and there should be no contami-
nation in the screened and unscreened group of women9, 13. Furthermore, the follow-up 
after the upper age-limit of the mammographic screening programme should be at least 
10-years to adjust for lead time14, but preferably longer1, 15. Unfortunately, there are no co-
hort studies fulfilling all of these criteria. An age-period-cohort (APC) model with variables 
for the different phases of screening is a good secondary approach as was suggested by 
Puliti et al13.
Until now, such an APC-model has been used only once to estimate overdiagnosis at a 
period in time.6, 16 Overdiagnosis estimates at a period in time have, however, as major dis-
advantage that they do not study the increase in breast cancer incidence during screening 
and the drop in incidence after leaving screening in the same women thereby overesti-
mating overdiagnosis.17 This disadvantage can be overcome by studying overdiagnosis in 
birth cohorts, i.e. following the same women over time. Therefore, the aim of this study is 
to quantify overdiagnosis of the Dutch mammographic screening programme in birth co-
horts using an APC-model including variables representing the initial round, subsequent 
rounds and a 5-year period after leaving screening.
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METHODS
Setting
From 1989 to 1996, the mammographic screening programme was implemented in the 
Netherlands, inviting women aged 50-69 years biennially. From 1997 onwards, women 
aged 70-74 years were invited also, with the programme reaching full coverage in 2001. In 
2004-2010, screen-film mammography was replaced by digital mammography.18
The mammographic screening programme in the Netherlands has always had high at-
tendance rates, ranging from 72% in 1990 to about 80% from 1997 onwards, and low per-
centages of definite non-participants (2.0-7.5%), consisting of women who do not wish to 
receive any further invitations to screening. Recall rates were 0.8% in the starting period 
and increased to 2.3% nowadays. Women receive an invitation for a subsequent screening 
exam on average 2 years after their screening exam. A small percentage (4.5%) of women 
has a screening interval longer than 2.5 years.18
Breast cancer incidence data
Stichting Medische Registratie provided data on the number of invasive breast cancer 
incident cases for the period 1975-1988. The website of the National Cancer Registry in 
the Netherlands19 provided data on the number of invasive breast cancer cases and ductal 
carcinoma in situ (DCIS) cases for the period 1989-2009. Statistics Netherlands20 provided 
data on the number of females aged 0-99 years living in the Netherlands per calendar year 
(1950-2009) in 5-year age groups. 
Because birth cohorts were calculated from 5-year age and period groups, each birth 
cohort consists of nine overlapping years indicated by the middle 5-years. Table 10.1 pres-
ents the absolute number of invasive breast cancer incidence, total breast cancer inci-
dence and person-years by birth cohort and age.
Screening participation
The number of women attending the mammographic screening programme after their 
initial and subsequent invitation was collected centrally from the screening organizations 
and categorized per calendar year in 5-year age groups. The proportion of women having 
their initial (SCREEN1) and subsequent screen (SCREEN2) was calculated as the number of 
women attending screening divided by the number of women-years. In order to calculate 
the proportion of women leaving the screening programme after 0-5 years (SCREEN3), we 
assumed that only women above age 75 left the programme, except for the period 1995-
201Overdiagnosis by mammographic screening for breast cancer studied in birth cohorts in the netherlands
1999 when women aged 70-74 years temporarily also left the screening programme. We 
further assumed the proportion of women that died from all causes between the ages 65-
94 was independent of screening. The proportions of SCREEN3 were calculated by subtract-
ing the proportion of women attending screening at age 70-74, 75-79 or 80-84 from the 
proportion of women attending screening at age 65-69, 70-74 or 75-79, respectively. For 
example, the proportion of women leaving screening after 0-5 years (SCREEN3) was 13.6 
for the age group 75-79 in the birth cohort 1923-1927. This was calculated by subtracting 
the proportion of women in this age groups that still attended screening (i.e. SCREEN2 
at age 75-79, which was 0.7) from the total proportion of women that were screened at 
age 70-74 (i.e. SCREEN1 and SCREEN2 at age 70-74, which were 2.5 and 11.8, respectively). 
Because the usual screening interval is two years in the Netherlands, all proportions were 
multiplied by two (Table 10.2). 
Statistical analysis
Statistical analyses were carried out with SAS (version 9.2). Negative binomial regression 
analysis was used to model first the invasive breast cancer incidence and second the in-
vasive breast cancer plus DCIS incidence between 1975 and 2009 in women aged 20-99 
years. The logarithm of the incidence rate is described as:
Log(IRRapc) = f(a) + g(c) + h(p) + S1* SCREEN1  + S2* SCREEN2  + S3* SCREEN3             (1)
In this regression formula, IRRapc is the relative (invasive) breast cancer incidence rate 
in age group a, cohort c and period p, f(a) are the age-specific rates, g(c) is the cohort 
component of cohort c, and h(p) is the period component of period p.21-23 S1, S2, and S3 
are the coefficients for the screening variables SCREEN1, SCREEN2 and SCREEN3, respec-
tively.24 Goodness of fit was evaluated by comparing the deviance (dev) with the degrees 
of freedom (df) of the model and overdispersion was measured by the ratio between the 
deviance and the degrees of freedom of the model. 
Overdiagnosis estimation
The full Poisson APC regression model including the screening variables was used to cal-
culate the expected number of new breast cancer cases in presence of screening. The 
expected number of new breast cancer cases in absence of screening was calculated by 
subtracting the screening variables multiplied by their coefficients from the full model. In 
order to calculate overdiagnosis in all birth cohorts, we assumed that the female popula-
tion would decline at the same pace in the forthcoming 20 years as in the past 5 years and 
that the period effect in the forthcoming 20 years is equal to the past 10 years. Further-
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Table 10.2 The percentage of women years attending (SCREEN1, SCREEN2) and leaving 
(SCREEN3) the mammographic screening programme 
 
 Cohort (c) Age (a) SCREEN1 SCREEN2 SCREEN3 
1918-1922 70-74 0.6 2.0 0.0 
  75-79 0.1 0.1 2.4 
  80-84 0.0 0.0 0.2 
  85-89 0.0 0.0 0.0 
  90-94 c 0.0 0.0 0.0 
1923-1927 65-69 16.1 14.4 0.0 
 
70-74 2.5 11.8 18.6 
 
75-79 0.0 0.7 13.6 
 
80-84 0.0 0.0 0.8 
 
85-89 c 0.0 0.0 0.0 
 
90-94 c 0.0 0.0 0.0 
1928-1932 60-64 19.7 18.5 0.0 
  65-69 7.4 54.1 0.0 
  70-74 1.4 65.5 0.0 
  75-79 0.0 0.8 66.2 
  80-84 c 0.0 0.0 0.8 
  85-89 c 0.0 0.0 0.0 
  90-94 c 0.0 0.0 0.0 
1933-1937 55-59 19.9 18.2 0.0 
 
60-64 9.7 65.7 0.0 
 
65-69 0.5 75.0 0.0 
 
70-74 0.2 70.1 0.0 
 
75-79 c 0.0 0.0 70.4 
 
80-84 c 0.0 0.0 0.0 
 
85-89 c 0.0 0.0 0.0 
1938-1942 50-54 23.0 15.2 0.0 
  55-59 9.5 65.0 0.0 
  60-64 0.7 76.5 0.0 
  65-69 0.3 74.2 0.0 
  70-74 c 0.0 70.2 0.0 
  75-79 c 0.0 0.0 70.2 
  80-84 c 0.0 0.0 0.0 
  85-89 c 0.0 0.0 0.0 
1943-1947 45-49 5.4 0.8 0.0 
 
50-54 23.6 49.8 0.0 
 
55-59 0.8 76.1 0.0 
 
60-64 0.4 74.6 0.0 
 
65-69 c 0.0 73.9 0.0 
 
70-74 c 0.0 69.7 0.0 
 
75-79 c 0.0 0.0 69.7 
 
80-84 c 0.0 0.0 0.0 
 
85-89 c 0.0 0.0 0.0 
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Table 10.2 The percentage of women years attending (SCREEN1, SCREEN2) and leaving 
(SCREEN3) the mammographic screening programme (CONTINUED) 
 
 
a No distinction was made between regular screening (interval <2.5 years) and irregular 
screening (interval ≥2.5 years) in subsequent screening examinations. 
b For the period 1990-1996 not all data were age- and round-specific (the percentage 
decreased from 29.9% in 1990 to 0.1% in 1996). Because these data came mainly from the 
regions Midden-Nederland and Nijmegen which have a history of screening, it is assumed that 
the screening rounds belong to the group of subsequent screens. The women concerned were 
percentaged to the age categories. 
c Extrapolation of the attendance percentage of the mammographic screening programme   
Cohort (c) Age (a) SCREEN1 SCREEN2 SCREEN3 
1948-1952 45-49 14.9 0.1 0.0 
  50-54 16.5 61.7 0.0 
  55-59 0.4 77.1 0.0 
  60-64 c 0.0 77.0 0.0 
  65-69 c 0.0 76.0 0.0 
  70-74 c 0.0 71.6 0.0 
  75-79 c 0.0 0.0 71.6 
  80-84 c 0.0 0.0 0.0 
  85-89 c 0.0 0.0 0.0 
1953-1957 45-49 15.7 0.0 0.0 
 
50-54 16.0 60.4 0.0 
 
55-59 c 0.0 76.8 0.0 
 
60-64 c 0.0 76.3 0.0 
 
65-69 c 0.0 75.2 0.0 
 
70-74 c 0.0 70.9 0.0 
 
75-79 c 0.0 0.0 70.9 
 
80-84 c 0.0 0.0 0.0 
 85-89 c 0.0 0.0 0.0 
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more, we assumed that screening attendance remained the same in the forthcoming 20 
years and no first screening examinations would take place after age 55. Overdiagnosis 
was calculated in birth cohorts using a formula similar to the formula proposed by the 
Independent UK panel on breast cancer screening1:
( ) Expected breast cancer incidence in presence of screening Expected breast cancer incidence in absence of screening Expected breast cancer incidence in presence of screening X 100% 
 Overdiagnosis was calculated from two perspectives: 1) from population perspective, 
presenting the overdiagnosed breast cancers as proportion of the expected incidence in 
absence of screening in women aged 20-99; and 2) from the perspective of a woman in-
vited to screening, presenting the overdiagnosed breast cancers as proportion of the ex-
pected incidence in absence of screening in women aged 45-74 years. Because there are 
less than 10 cases per year in women aged 0-2019, the estimate based on 20-99 approxi-
mates the percentage of overdiagnosis during a lifetime (0-99 years).
RESULTS
The APC-model with screening variables has a goodness of fit of 1.57 (dev=96.0, df=61) 
for invasive and a goodness of fit of 1.57 (dev=95.6, df=61)  for invasive breast cancer plus 
DCIS. In the full models of invasive and total breast cancer, the breast cancer incidence in-
creases with age (until 90 years), birth cohort and exposure to mammographic screening. 
The breast cancer incidence does not show an overall increase or decrease with period.
Table 10.3 presents the estimated relative risks of breast cancer for the initial screen-
ing exam, the subsequent screening exams and a five-year period after leaving the mam-
mographic screening programme for invasive and total breast cancer. The relative risk 
Table 10.3 Relative risks (RRs) of each screening variable 
 
  
  
RR (95% Confidence interval) 
Invasive breast cancer 
Invasive breast cancer and 
DCIS 
First screening exam 2.33 (2.00-2.73) 2.56 (2.20-2.99) 
Subsequent screening exam 1.38 (1.27-1.49) 1.49 (1.38-1.62) 
Leave screening (0-5 years) 0.65 (0.58-0.73) 0.68 (0.61-0.76) 
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(RR) of the first screening exam is 2.33 (95% Confidence interval (CI), 2.00-2.73) for inva-
sive breast cancer and 2.56 (95% CI, 2.20-2.99) for total breast cancer incidence. During 
the subsequent screening exams, the number of newly diagnosed breast cancers con-
tinued to increase, showing a RR of 1.38 (95% CI, 1.27-1.49) for invasive and 1.49 (95% 
CI, 1.38-1.62) for total breast cancer. When women leave the mammographic screening 
programme, the RR becomes lower than one. This indicates that the risk for breast cancer 
is  lower for women with a history of screening than for women without a screening his-
tory.  The RR for the five-year period after leaving screening is 0.65 (95% CI, 0.58-0.73) for 
invasive breast cancer and 0.68 (95% CI, 0.61-0.76) for invasive breast cancer and DCIS.
Figure 10.1 displays the observed and predicted invasive breast cancer and DCIS in-
cidence in presence and absence of mammographic screening for the birth cohorts (A) 
1923-1927 and (B) 1953-1957. The figure shows a good correspondence between the 
predicted and observed number of breast cancer cases. Furthermore, Figure 10.1A and 
B show that the predicted breast cancer incidence in the presence of screening increas-
es more during the screened ages (49-74 years) and decreases after women leave the 
screening programme (75 years and older) than the predicted incidence in the absence 
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Figure 10.1 The absolute number of invasive breast cancer and DCIS cases in the presence and absence of screening for the 
birth cohorts (A) 1923-1927 and (B) 1953-1957. The solid lines are based on predicted values and the dotted lines are based on 
extrapolation of women-years and participation in the Dutch screening programme. The observed and predicted breast cancer 
incidence of an unscreened birth cohort (1913-1917) is added as reference.
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of screening. Lastly, the figure indicates that the absolute number of new breast cancer 
cases is higher in the birth cohort 1953-1957 than in the birth cohort 1923-1927.
Table 10.4 presents overdiagnosis estimates in birth cohorts from the population per-
spective (20-99 years) and from the perspective of a woman invited to screening (45-74 
years) for invasive and total breast cancer. The overdiagnosis estimates of invasive and 
total breast cancer are negative in the oldest four and two birth cohorts, respectively. In 
the youngest three birth cohorts – which were screened from age 49 to 74 (birth cohort 
1943-1947 and younger) – overdiagnosis of invasive breast cancer is ranging between 
10.5-11.0% from population perspective and 16.3-17.1% from the perspective of a wom-
an invited to screening. Overdiagnosis from invasive breast cancer and DCIS is higher; 
13.8-14.4% from population perspective and 21.0-21.9% from the perspective of a wom-
an invited for screening in birth cohorts who were screened from age 49 to 74.
DISCUSSION
Breast cancer overdiagnosis is estimated at 14% from the population perspective and 22% 
from the perspective of a woman invited to screening in birth cohorts screened from age 
49 to 74 in the Dutch mammographic screening programme. Overdiagnosis of invasive 
breast cancer is estimated at 11% and 17%, respectively.  
Ideally, the extent of overdiagnosis is estimated from the difference between the 
Table 10.4 Overdiagnosis of breast cancer in birth cohorts 
 
  
% overdiagnosis from 
population perspective 
 
% overdiagnosis from an invited 
woman perspective 
Birth cohort Invasive 
Invasive and 
DCIS 
 
Invasive 
Invasive and 
DCIS 
1923-1927 1.3 2.0 
 
2.2 3.3 
1928-1932 5.1 7.1 
 
8.1 11.3 
1933-1937 7.8 10.5 
 
12.3 16.4 
1938-1942 9.7 12.8 
 
15.2 19.7 
1943-1947 10.5 13.8 
 
16.3 21.0 
1948-1952 11.0 14.4 
 
17.1 21.9 
1953-1957 10.9 14.2 
 
16.9 21.6 
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breast cancer incidence in a screened and an unscreened cohort that are comparable 
(e.g. age) and followed until death.1 Unfortunately, such studies do not exist1, requiring 
overdiagnosis to be estimated from imperfect empirical data or by modeling. This has led 
to a wide range of overdiagnosis estimates.1,5,25 Our overdiagnosis estimates are within the 
possible range of estimates.25 Differences between our estimate and other estimates may 
be explained by several factors, such as the methodological approach11, length of follow-
up14, population of analysis16, denominator25, and contextual factors (e.g. age range invited 
to the screening programme).11, 26 
Overdiagnosis can be estimated from empirical data, using the incidence-rate method 
or cumulative-incidence method, or from data appropriated by models using the disease 
transition to infer the lead time.9 Overdiagnosis estimates from models, i.e. the lead time 
approach, are generally lower than overdiagnosis estimates from the cumulative-inci-
dence approach11, also called the excess-incidence approach.11,12 This is also the case when 
we compare our overdiagnosis estimate, obtained by the cumulative-incidence approach, 
with another estimate from the Netherlands which was obtained by the lead time ap-
proach.25 So far, there is no consensus on which method is optimal and results in the most 
reliable estimate of overdiagnosis. Therefore, a comparison of the cumulative-incidence 
approach and the lead time approach is warranted.  
The cumulative-incidence approach in itself has also resulted in a wide range of over-
diagnosis estimates, ranging from 0%8 to 52%3. Most of the variation can probably be 
explained by data quality factors. Paramount factors are a too short follow-up period after 
screening14 and the method used to estimate the breast cancer incidence in absence of 
screening. The relevant length of follow-up is under continuous discussion with current 
recommendations amounting to periods of more than 10 years.15 We used a 5-year follow-
up period, because the RR of a 5-10 year period after leaving screening was based on few 
data and was unrealistically large; 0.35 for invasive breast cancer and 0.38 for invasive 
breast cancer plus DCIS. The use of a 5-year follow-up period may have led to an underes-
timation of the compensatory drop, thereby overestimating overdiagnosis. Furthermore, 
there are four main ways to obtain data on breast cancer incidence in absence of screen-
ing: 1) observations in a non-screened group, 2) observations in a non-attended group10,15, 
3) extrapolation from prescreening trends3,5,8,27,28, and 4) using an APC-model including 
variables for the different phases of screening.4,6,16 Randomized controlled trials are the 
only studies that can reliably observe the breast cancer incidence in absence of screen-
ing in a non-screened group, which is the ideal approach. However, previously executed 
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trials with overdiagnosis estimates of 11% from the population perspective were based 
on maximally 6 years of follow-up after screening.1 We used an APC-model to estimate 
the breast cancer incidence in absence of screening.  An advantage of this approach over 
observations in a non-attended group or extrapolation from prescreening trends is that 
no assumptions are required on self-selection or period trends, because the breast cancer 
incidence in absence of screening is calculated from the model based on the breast cancer 
incidence in presence of screening and the exposure to screening. To our knowledge, an 
APC-model including the different phases of screening is used only once before to esti-
mate overdiagnosis in a period in time. This study resulted in an overdiagnosis estimate 
of 11%6,16, which is comparable with our overdiagnosis estimate of 10-17% at a period in 
time (result not presented), i.e. 5-year periods. A major strength of our study is, however, 
that we estimated overdiagnosis in birth cohorts, thereby estimating overdiagnosis from 
the increase in breast cancer incidence during screening and the drop in incidence after 
leaving screening in the same women and preventing overestimation of overdiagnosis.17
Our study faces some other limitations, which may have influenced our overdiagno-
sis estimates. Firstly, the data we used for our analyses had some limitations. We based 
our analyses on aggregated data29 and had no data on the prevalence of opportunistic 
screening. Opportunistic screening in the age groups not yet invited to screening and 
the screened-age range is expected to have mainly an effect on the model fit. However, 
opportunistic screening in women who leave the screening programme (75+) will likely 
cause an overestimation of overdiagnosis, because the drop after leaving the screening 
programme cannot be measured adequately when women are still screened. Another 
limitation of the data was that DCIS incidence in the Netherlands was not registered be-
fore 1989. The absence of DCIS incidence before 1989 has probably had only a small im-
pact on the overdiagnosis estimates, since age-specific extrapolation of DCIS to 1975 only 
had a very small effect on our overdiagnosis estimates. Secondly, we needed to make 
some assumptions to calculate overdiagnosis in birth cohorts, namely that birth cohorts 
decline at the same pace and that screening attendance will remain the same. We believe 
that these assumptions are reasonable and that they have no or only a small impact on 
the overdiagnosis rate. Thirdly, the APC-model was not optimal. The APC-model including 
variables for the different phases of screening had a goodness of fit of 1.58 for invasive 
breast cancer and for invasive breast cancer plus DCIS, which indicates that not all vari-
ance in breast cancer incidence could be explained by the model. Besides, the RRs of our 
APC-model were on the higher end compared to estimated relative risks of other studies 
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using the same approach6,24,30,31 and were indirectly assumed to be stable. Because new 
technologies, e.g. digital mammography26,32, change the sensitivity of the mammographic 
screening programme, this assumption is likely to fail. 
Even though the estimates of overdiagnosis vary considerably in the literature, there 
is overall agreement that overdiagnosis is an inevitable effect of early detection that is 
harmful, especially when treatment follows. In order to be able to protect women from 
the harmful effect of overtreatment, it is important that women and physicians start to 
recognize the occurrence of the phenomenon overdiagnosis and its consequences.33 Two 
recent qualitative studies from England and Australia indicated that women would like to 
be informed about overdiagnosis34,35, even though this would have little impact on their at-
titude to attend mammographic screening if the estimates did not exceed 30%.34 In order 
to prevent overtreatment and to facilitate physicians and women in their treatment deci-
sion, more research will be needed to identify possibly overdiagnosed breast tumors1,36, 
especially for DCIS.
To conclude, an APC-model including variables for the different phases of screening 
seems to be a good method to estimate overdiagnosis in birth cohorts when the model 
is based on accurate data and has a perfect model fit. Our APC-model – based on quite 
accurate data and with a good model fit – indicates that overdiagnosis of invasive breast 
cancer plus DCIS in birth cohorts invited to participate to mammographic screening from 
age 49 to 74 is 14% from the population perspective and 22% from the perspective of a 
woman invited to mammographic screening in the Netherlands. Further research should 
try to find the most optimal method to quantify overdiagnosis and to explain differences 
in overdiagnosis estimates.
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ABSTRACT
Background: Overdiagnosis by mammographic screening is defined as the excess in breast 
cancer incidence in the presence of screening compared to the incidence in the absence 
of screening. The latter is often estimated by extrapolating the pre-screening incidence 
trend. The aim of this theoretical study is to investigate the impact of assumptions in ex-
trapolating the pre-screening incidence trend of invasive breast cancer on the estimated 
percentage of overdiagnosis. 
Methods: We extracted data on invasive breast cancer incidence and person-years by cal-
endar year (1975-2009) and 5-year age groups (0-85 years) from Dutch databases.  Differ-
ent combinations of assumptions for extrapolating the pre-screening period were investi-
gated, such as variations in the type of regression model, end of the pre-screening period, 
screened age range, post-screening age range and adjustment for a trend in women <45. 
This resulted in 69,120 estimates of the percentage of overdiagnosis, i.e. excess cancer 
incidence in the presence of screening as a proportion of the number of screen-detected 
and interval cancers. 
Results: Most overdiagnosis percentages are overestimated because of inadequate ad-
justment for lead time. The overdiagnosis estimates range between -7.1% and 65.1%, 
with a median of 33.6%. The choice of pre-screening period has the largest influence on 
the estimated percentage of overdiagnosis: the median estimate is 17.1% for extrapola-
tions using 1975-1986 as the pre-screening period and 44.7% for extrapolations using 
1975-1988 as the pre-screening period. 
Conclusion: The results of this theoretical study cover most likely the true overdiagnosis 
estimate, which is unknown, and may not necessarily represent the median overdiagno-
sis estimate. This study shows that overdiagnosis estimates heavily depend on the as-
sumptions made in extrapolating the incidence in the pre-screening period, especially on 
the choice of the pre-screening period. These limitations should be acknowledged when 
adopting this approach to estimate overdiagnosis. 
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INTRODUCTION
Mammographic screening benefits some women and harms a number of others.1,2 The 
major benefit of mammographic screening is the prevention of breast cancer deaths1 by 
detecting breast cancers at an early stage with better treatment outcomes.3 However, a 
major drawback of mammographic screening is the detection of cancers that would not 
be clinically detected during a woman’s lifetime if screening had not occurred, i.e. over-
diagnosed cancers. 
There is much debate on the extent of overdiagnosis in mammographic screening, 
with estimates ranging from 0 to 57%.4,5 According to Carter et al6, ecological and cohort 
studies are the most suitable method for estimating overdiagnosis. There is, however, 
a wide variability in the design of these studies, which are related to the methods used 
to adjust for lead time and the choice of the unscreened reference population.6 The un-
screened reference population is often obtained through extrapolating the incidence in 
the pre-screening period.5,7-10 However, studies utilize different assumptions in order to 
estimate the pre-screening incidence trend.11 Some studies apply linear regression to in-
cidence rates, while others apply poisson regression to absolute numbers. Furthermore, 
studies differ in the age groups modeled, choice of pre-screening period and whether to 
adjust for a trend in non-screened ages. 
The Independent UK Panel on Breast Cancer Screening11 estimated the absolute num-
ber of overdiagnosed cases in the UK National Health Service breast cancer screening 
program using several different assumptions. They showed that the estimated number of 
overdiagnosed cases depends on the specification of the model used for the estimation. 
Although this indicates that the choice of the model influences the estimated percentage 
of overdiagnosis, the panel only discussed the effects of a limited number of model as-
sumptions. Furthermore, the percentage of overdiagnosis does not only depend on the 
estimated number of overdiagnosed cases, but also on the number of cancers in the de-
nominator.12 Therefore, this theoretical study investigates the influence of a large number 
of assumptions in extrapolating pre-screening incidence trends on the estimated percent-
age of overdiagnosis by mammographic screening in the Netherlands.
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METHODS
Setting
In 1989, a biennial mammographic screening program was gradually implemented in the 
Netherlands, inviting women aged 50-69 years. Nationwide full coverage was reached in 
1997 and the upper age limit was gradually extended to age 75 in the period 1998-2001. 
Because women are invited per region and receive their first invitation in the year they 
turn 50, 51 or 52, women aged 49 can be screened. The attendance rates in the Dutch pro-
gram have always been high, ranging from 72% in 1990 to about 80% from 1997 onwards.13 
Until 2014, initial screens consisted of two view mammography and subsequent screens 
of one view, an oblique view, unless a second cranio-caudal view was required. From 2014 
onwards, two view mammography became the standard for subsequent screening. Mam-
mograms are independently read by two radiologists who decide in consensus on recall. 
Digital mammography was introduced in 2004 and reached full coverage in 2010.14
Because the incidence of ductal carcinoma in situ (DCIS) was not registered before 
1989, we limited our estimates of overdiagnosis to invasive breast cancer. Data on the 
number of invasive breast cancers were obtained from Stichting Medische Registratie for 
the period 1975-1988 (ages 0-85 years) and the website of the National Cancer Registry15 
in the Netherlands for the period 1989-2013 (ages 0-99 years). The number of screen-
detected breast cancers and interval cancers were collected centrally from the screening 
organizations (1975-2009)14 and the information on the number of women living in the 
Netherlands were obtained from Statistics Netherland (1975-2013)16. All data was provid-
ed by calendar year and 5-year age groups (0-85 years). Figure 11.1 presents the invasive 
breast cancer incidence rate per 100,000 women-years by calendar period and age group.
Percentage of overdiagnosis
The percentage of overdiagnosis was defined as ‘the percentage of cancers detected dur-
ing the screening period that would not present symptomatically during one’s lifetime 
in the absence of screening’, in line with previous work.17 The nominator is the absolute 
number of overdiagnosed cases estimated by subtracting the cumulative incidence in the 
absence of screening from the cumulative incidence in the presence of screening. In this 
study, the cumulative incidence in the presence of screening is the observed breast cancer 
incidence in the screened age group during the screening period. The cumulative inci-
dence in the absence of screening could not be observed and was estimated by extrapola-
tion of pre-screening incidence trends. This approach is called the cumulative incidence 
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method or excess-incidence method.18,19 The cumulative incidence approach needs to ful-
fill two conditions to adequately adjust for lead time: 1) the follow-up after screening ces-
sation should include the maximum length of lead time, and 2) the excess incidence dur-
ing screening and the compensatory drop after screening cessation should be estimated 
from women who had the same screening participation rates and experienced the same 
screening practice.20,21 In this study, we could not fulfill the last condition – and probably 
also not the first condition – because we estimated overdiagnosis in periods  with chang-
ing participation rates and screening practice rather than in birth cohorts.20 Knowing that 
the participation and detection rates increased over time, the overdiagnosis estimates are 
likely to be overestimated. Furthermore, the cumulative incidence approach can result in 
negative overdiagnosis estimates when the observed incidence in the presence of screen-
ing is lower than the expected incidence in the absence of screening. Overdiagnosis can, 
however, never be negative; therefore, values below zero are to be interpreted as overdi-
agnosis being non-existent (no overdiagnosis). For the denominator we used the number 
of cancers detected in women participating in the screening program, i.e. screen-detected 
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Figure 11.1 Invasive breast cancer incidence rate per 100,000 women-years by calendar period.
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breast cancers and interval cancers (i.e. breast cancers diagnosed in screened women dur-
ing the interval between two screening rounds).17
Models
We estimated overdiagnosis through extrapolating the pre-screening incidence trend, us-
ing 69,120 different combinations. These combinations varied with regards to the: type of 
regression model used, end of the pre-screening period, and the age-groups used to es-
timate the period trend (see Table 11.1). The percentage of overdiagnosis was estimated 
for different starting and stopping years of the screening period, screened age ranges, 
post-screening age groups, and with/without adjustment for a trend in women younger 
than 45. We adjusted for a trend in women younger than 45 years by dividing the ex-
pected incidence in the screened age range by the relative excess, i.e. the ratio between 
the expected and observed incidence, in women younger than 45.8 The percentage of 
overdiagnosis was calculated from absolute numbers and rates, regardless of the type of 
regression model used to estimate the pre-screening trend.
Table 11.1 Assumptions used to estimate the percentage of overdiagnosis 
 
Category Options 
Model 
 
 
Type of regression model poisson regression, linear regression 
 
End of pre-screening period 1984-1989 (the start of the pre-screening era is 
1975 for all analyses) 
 
Age groups to estimate period 
trend 
20-45, 45-49, 45-74, 50-69, 50-74, 70-74, 75-79, 
75-84, 80-84 
Calculation 
 
 
Screened age range 45-74, 50-74 
 
Post-screening age range 75-79, 75-84 
 
Starting year screening period 1990-2001 
 
Stopping year screening 
period 
2005-2009 
 
Numbers absolute, rates 
  Risk adjustment no, trend in women aged 20-45 
 
 
 
221
Extrapolation of pre-screening trends: impact of assumptions on overdiagnosis estimates by 
mammographic screening
RESULTS 
The percentage of overdiagnosis obtained by the different assumptions to estimate the 
pre-screening trend ranges from -7.1% to 65.1% (Figure 11.2). Figure 11.2 shows that 
the range of estimates form a multimodal distribution with peaks at 18%, 31%, 38% and 
48%. These peaks represent a group of small normal distributions, which are obtained 
when stratifying for pre-screening period, screened age range and adjustment for a trend 
in women below 45. Overall, the estimates are not normally distributed and the median 
estimated percentage of overdiagnosis is 33.6%.
Figure 11.2 Overdiagnosis estimates obtained from the extrapolation of pre-screening trends using different 
model specifications.
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Table 11.2 Median (quartile 1 - quartile 3) percentage of overdiagnosis unadjusted for a trend in women <45 
    Screened age range 
     45-75 50-75 Total 
Overall 43.0 (29.2-47.8) 35.0 (22.1-38.8) 37.0 (26.5-44.0) 
Type of regression 
   
 
Linear regression 42.6 (29.0-46.8) 34.1 (22.1-37.9) 36.5 (25.9-43.2) 
 
Poisson regression 44.2 (29.4-48.6) 36.1 (22.0-39.7) 37.4 (27.2-45.1) 
Calculation overdiagnosis 
   
 
Based on rates 42.1 (28.2-46.8) 34.1 (20.9-37.7) 35.9 (25.6-43.0) 
 
Based on absolute numbers 44.2 (30.3-48.8) 36.2 (22.9-39.8) 38.0 (27.8-45.1) 
End of pre-screening period 
   
 
1984 38.7 (36.7-40.9) 33.1 (31.0-35.4) 36.1 (33.0-39.0) 
 
1985 29.2 (27.5-30.9) 22.0 (19.8-24.9) 26.6 (22.0-29.4) 
 
1986 18.7 (17.1-20.3) 14.3 (12.2-16.9) 17.1 (14.2-19.2) 
 
1987 47.9 (46.3-49.4) 38.2 (36.3-40.6) 43.8 (38.2-47.9) 
 
1988 48.7 (47.1-50.2) 39.6 (37.7-41.7) 44.7 (39.6-48.7) 
 
1989 46.8 (45.3-48.3) 38.2 (36.3-40.2) 43.1 (38.2-46.8) 
Age groups to estimate period trend 
 
<45, 45-74, 75-79, 80-84 43.3 (28.3-47.2) 38.5 (26.5-41.8) 39.9 (37.4-44.6) 
 
<45, 45-74, 75-84 42.2 (27.5-46.4) 37.5 (25.8-40.9) 38.9 (26.6-43.7) 
 
<45, 45-49, 50-69, 70-74, 75-79, 80-84 44.9 (30.8-48.9) 35.0 (21.5-38.2) 36.8 (25.7-44.9) 
 
<45, 45-49, 50-69, 70-74, 75-84 43.8 (30.0-48.0) 34.0 (20.7-37.3) 35.8 (25.3-43.8) 
 
<45, 45-49, 50-74, 75-79, 80-84 43.8 (29.7-48.3) 34.2 (30.3-37.7) 36.3 (25.5-44.1) 
 
<45, 45-49, 50-74, 75-84 42.5 (28.9-47.4) 33.1 (19.7-36.7) 35.3 (24.6-42.8) 
Post-screening age group 
   
 
75-79 43.1 (29.5-47.8) 35.1 (22.3-38.8) 37.0 (26.8-44.0) 
 
75-84 43.0 (29.0-47.7) 34.9 (21.8-38.8) 36.9 (26.3-44.0) 
Starting year of screening era 
   
 
1990 45.2 (31.2-49.8) 37.5 (23.8-40.8) 39.0 (28.8-46.0) 
 
1991 44.9 (31.3-49.5) 37.2 (23.8-40.5) 38.8 (28.7-45.7) 
 
1992 44.6 (31.0-49.2) 36.8 (23.6-40.1) 38.5 (28.5-45.3) 
 
1993 43.9 (30.3-48.5) 36.0 (22.7-39.3) 37.7 (27.7-44.60 
 
1994 43.5 (29.9-48.1) 35.5 (22.3-39.3) 37.4 (27.1-44.7) 
 
1995 42.7 (28.9-47.3) 34.6 (21.6-38.1) 36.5 (26.4-43.4) 
 
1996 42.1 (28.5-46.9) 34.2 (20.7-37.5) 36.0 (25.9-42.8) 
 
1997 42.1 (28.5-46.9) 33.9 (20.2-37.6) 36.0 (25.6-42.9) 
 
1998 42.1 (28.4-46.9) 34.2 (20.5-37.5) 36.0 (25.8-42.9) 
 
1999 42.3 (28.5-47.2) 34.4 (20.7-37.8) 36.2 (25.9-43.1) 
 
2000 42.3 (28.3-47.1) 34.1 (20.7-37.7) 36.1 (25.6-43.0) 
 
2001 41.5 (27.2-46.5) 33.9 (20.7-38.5) 36.0 (24.9-43.1) 
Stopping year of screening era 
   
 
2005 44.7 (30.9-49.3) 36.9 (23.7-40.5) 38.7 (28.4-45.7) 
 
2006 43.6 (29.8-48.2) 35.5 (22.3-39.2) 37.4 (27.2-44.4) 
 
2007 43.1 (29.2-47.7) 35.0 (21.8-38.6) 36.9 (26.7-43.8) 
 
2008 42.5 (28.7-47.2) 34.6 (21.3-38.2) 36.5 (26.2-43.3) 
  2009 41.8 (27.9-46.5) 33.7 (20.5-37.4) 35.8 (25.3-42.6)  
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Table 11.2 presents the median percentages of overdiagnosis that were derived from 
34,560 model combinations without adjustment for a trend in women younger than 45 
for different assumptions. The table shows that the end of the pre-screening era has the 
largest influence on the percentage of overdiagnosis. For the screened age range 50-74, 
the median percentage of overdiagnosis is 14.3% for the estimates using 1975-1986 as 
the pre-screening period and 39.6% for estimates using 1975-1988 as the pre-screening 
period. Figure 11.1 gives an explanation for this difference: it shows a peak in the breast 
cancer incidence rate in 1986, which causes a higher trend and thus low overdiagnosis 
estimates, and a drop in the breast cancer incidence rate in 1987, which has an oppo-
site effect on the trend and overdiagnosis estimates. Table 11.2 also demonstrates that 
the overdiagnosis estimates are higher for the screened age range 45-74 than for the 
screened age range 50-74, which is caused by an increasing breast cancer incidence in 
women aged 45-49 (see Figure 11.1). 
Other model specifications, i.e. type of regression model, calculation method, age 
groups used to estimate period trend, selected post-screening age groups, and starting 
and stopping year of the screening period, also influence the percentage of overdiagnosis, 
but to a smaller extent. For example, overdiagnosis estimates decline with later starting 
and stopping years of the screening era. The effect of age groups in the model to estimate 
the period trend seems to depend on two factors, namely the number of groups and the 
specific age ranges in each group. If the number of age groups in the model is smaller and 
if the screened age range is grouped together (i.e. either 45-74 or 50-74), the overdiagno-
sis estimates are lower. The estimates of overdiagnosis are also slightly lower when linear 
regression is used instead of poisson regression, overdiagnosis is calculated based on rate 
ratios rather than absolute numbers and the post-screening age group was 75-84 years 
(10-year follow-up) rather than 75-79 years (5-year follow-up).
Table 11.3 presents the median overdiagnosis percentage of 34,560 model combina-
tions adjusted for a trend in women below 45. The adjusted overdiagnosis estimates are 
generally lower than the unadjusted overdiagnosis estimates (30.2% versus 37.0%). When 
comparing the results from Table 11.2 and 11.3, it becomes apparent that the effect of 
each model specification is similar for the unadjusted and adjusted estimates except for 
differences in the end of the specified pre-screening period and the calculation of over-
diagnosis. The adjusted overdiagnosis estimates from Table 11.3 are higher than the un-
adjusted estimates from Table 11.2 when the pre-screening period ends between 1984 
and 1986 and vice versa for the other pre-screening periods. Furthermore, in Table 11.2 
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Table 11.3 Median (quartile 1 - quartile 3) percentage of overdiagnosis adjusted for a trend in women <45 
 
    Screened age range   
    45-75 50-75 Total 
Overall 35.5 (20.6-40.6) 28.0 (16.2-33.4) 30.2 (18.4-37.9) 
Type of regression 
   
 
Linear regression 33.1 (30.4-39.6) 26.4 (15.7-31.9) 28.7 (18.0-36.3) 
 
Poisson regression 37.1 (30.7-41.8) 39.8 (16.6-34.7) 31.9 (18.9-39.2) 
Calculation overdiagnosis 
   
 
Based on rates 37.9 (29.2-40.7) 30.4 (22.1-33.6) 32.7 (26.3-38.3) 
 
Based on absolute numbers 26.5 (16.0-40.2) 20.1 (11.4-32.5) 23.6 (13.7-36.5) 
End of pre-screening period 
   
 
1984 43.7 (39.7-50.1) 37.2 (33.4-42.7) 40.8 (36.4-46.7) 
 
1985 31.6 (28.6-36.6) 24.8 (21.0-29.2) 28.8 (24.4-33.3) 
 
1986 23.9 (19.1-36.4) 20.6 (14.5-29.2) 22.2 (17.4-32.7) 
 
1987 32.7 (19.0-40.3) 26.4 (13.6-32.2) 37.7 (16.2-36.8) 
 
1988 29.2 (12.6-39.7) 24.5 (8.6-32.2) 25.4 (10.5-36.5) 
 
1989 30.5 (16.4-39.2) 25.5 (11.9-31.8) 26.8 (14.0-36.0) 
Age groups to estimate period trend 
 
<45, 45-74, 75-79, 80-84 35.2 (19.6-40.6) 31.6 (19.5-36.3) 32.4 (19.5-38.6) 
 
<45, 45-74, 75-84 34.1 (18.9-39.9) 30.6 (18.8-35.5) 31.5 (18.9-37.7) 
 
<45, 45-49, 50-69, 70-74, 75-79, 80-84 36.8 (21.8-41.4) 28.0 (14.9-32.6) 30.5 (18.9-38.3) 
 
<45, 45-49, 50-69, 70-74, 75-84 36.0 (21.1-40.6) 27.1 (14.3-31.8) 29.6 (18.1-37.4) 
 
<45, 45-49, 50-74, 75-79, 80-84 36.4 (20.9-40.9) 27.1 (14.2-32.1) 29.6 (18.0-37.8) 
 
<45, 45-49, 50-74, 75-84 35.4 (20.3-40.0) 26.1 (13.5-31.3) 28.6 (17.2-36.9) 
Post-screening age group 
   
 
75-79 35.5 (20.9-40.6) 28.1 (16.6-33.4) 30.3 (18.9-37.9) 
 
75-84 35.5 (20.1-40.6) 27.9 (15.6-33.3) 30.1 (18.0-37.8) 
Starting year of screening era 
   
 
1990 39.9 (23.8-44.3) 32.5 (19.7-36.8) 34.1 (22.0-41.9) 
 
1991 39.6 (23.9-43.8) 32.2 (19.8-36.4) 33.9 (22.1-41.5) 
 
1992 39.3 (23.7-43.5) 31.9 (19.6-36.0) 33.5 (21.9-41.2) 
 
1993 38.4 (22.5-42.5) 30.8 (18.2-34.9) 32.5 (20.8-40.3) 
 
1994 37.2 (20.8-41.4) 29.8 (16.7-33.9) 31.5 (19.2-39.1) 
 
1995 36.3 (19.6-40.4) 28.8 (15.1-32.7) 30.4 (18.1-38.1) 
 
1996 35.4 (18.6-39.4) 27.8 (13.8-32.0) 29.6 (17.2-37.3) 
 
1997 34.9 (18.1-38.9) 27.3 (13.2-31.5) 29.1 (16.8-36.8) 
 
1998 33.9 (17.0-38.2) 26.3 (12.0-31.3) 28.4 (15.5-36.3) 
 
1999 33.5 (16.7-38.4) 26.0 (12.3-31.5) 28.5 (14.9-36.0) 
 
2000 32.9 (15.9-37.6) 25.4 (11.1-30.8) 27.7 (14.0-35.5) 
 
2001 30.9 (13.9-37.1) 23.3 (9.1-29.9) 26.4 (10.9-33.9) 
Stopping year of screening era 
   
 
2005 37.5 (23.0-42.4) 30.1 (18.6-35.3) 31.9 (20.7-39.8) 
 
2006 36.2 (21.2-41.0) 28.5 (16.8-33.8) 30.5 (18.9-38.3) 
 
2007 35.8 (20.3-40.5) 28.1 (15.7-33.3) 30.1 (18.1-37.8) 
 
2008 35.3 (19.5-39.9) 27.7 (15.1-32.8) 29.7 (17.6-37.3) 
  2009 34.1 (18.6-39.0) 26.5 (14.1-31.7) 28.7 (16.6-36.3) 
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overdiagnosis estimates are higher when based on rate ratios rather than absolute num-
bers, but the opposite is true for the adjusted estimates in Table 11.3.
DISCUSSION
The percentage of overdiagnosis estimated through the extrapolation of pre-screening 
trends varies from -7.1% to 65.1% in this study. The period used to estimate the pre-
screening trend has the largest influence on the percentage of overdiagnosis, but the 
influence of other factors should not be neglected.
Comparision with other studies
Several studies estimated the percentage of overdiagnosis using the extrapolation of pre-
screening trends. The estimates of these studies vary from less than 0%9 to 57%5. Because 
each study uses a different denominator to estimate the percentage of overdiagnosis, 
comparison of our estimates with previously reported estimates is not straightforward. 
Our study, however, shows that a wide variation in overdiagnosis estimates can even 
solely be the result of using different assumptions for the extrapolation of pre-screening 
trends, regardless of the denominator used to estimate overdiagnosis. 
In addition, we showed that variation in overdiagnosis estimates based on extrapola-
tion of pre-screening trends depends on assumptions such as the pre-screening period, 
the age groups used to model the pre-screening trend, the screened age group, the start-
ing and stopping year of the screening era, adjustment for a trend in women below 45, 
and the method to calculate overdiagnosis (absolute numbers vs rates). The Independent 
UK panel estimated the absolute number of overdiagnosed cases using different models.11 
They found, similar to this study, that the number of overdiagnosed cases decreased with 
a smaller screened age range (50-64 vs 45-64), when the estimates were adjusted for 
a trend in women below 45, and when linear regression was used rather than poisson 
regression.11 Furthermore, the UK panel found an inverse relationship between length of 
pre-screening period and number of overdiagnosed cases, which was not observed in our 
study. Because this relation depends on the increase in the breast cancer incidence rates 
before the introduction of screening, it is likely to vary between countries. For example, 
in the Netherlands the breast cancer incidence peaks at 1986 and drops in 1987 causing 
the lowest and highest overdiagnosis estimates, when using these years as the end of the 
pre-screening period. Unfortunately, it is unknown whether this sudden fluctuation is real 
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or due to data errors (i.e. registration issues). Our study also showed that overdiagnosis 
is influenced by the age groups included in the model and shows the impact of each as-
sumption in perspective. Unlike estimates for absolute numbers of overdiagnosed cases, 
estimates for percentage of overdiagnosis are not dependent on the number of women 
screened and illustrate the impact of each assumption in a standardized way. 
Limitations of utilizing pre-screening trends
The overdiagnosis estimates in this theoretical study range from -7.1% to 65.1% and will 
therefore most likely cover the true overdiagnosis estimate. The true overdiagnosis esti-
mate however remains unknown and is necessarily represented by the median overdi-
agnosis estimate of this study. The use of extrapolation of pre-screening trends has two 
important assumptions when it comes to estimating overdiagnosis. Firstly, this method 
assumes a constant trend in the (breast) cancer incidence rate after the pre-screening 
period ends.11  The validity of this assumption can be questioned because it requires that 
all risk factors for (breast) cancer, both birth cohort and period related, cause a constant 
increase in the (breast) cancer incidence rate by calendar year. Besides the validity of this 
assumption, this study showed that the magnitude of the constant increase is not a set 
value and is highly dependent on the choice of the pre-screening period. Secondly, the 
use of extrapolation of pre-screening trends assumes that the quality of case ascertain-
ment remains the same.11 This is unlikely given the improvements in diagnostic proce-
dures over the last decades. 
In addition to the assumptions required to extrapolate pre-screening trends, an ad-
justment for a trend in women younger than 45 assumes that the breast cancer incidence 
rate increases  at the same pace in women in the screened age range and below 45. In 
other words, the risk factors for pre- and postmenopausal breast cancers are assumed 
to be similar or at least cause a similar proportional increase in breast cancer incidence 
in each age group. This assumption can be questioned, because some risk factors, i.e. 
hormone-replacement therapy, only have an effect on post-menopausal breast cancers. 
Adjustment for a trend in women younger than 45 may however be useful when the 
unadjusted and adjusted trends are compared. Similar overdiagnosis estimates for un-
adjusted and adjusted trends may indicate the more reliable trends and therefore more 
reliable overdiagnosis estimates. Another way to obtain more reliable and stable trends is 
the utilization of 5-year smoothed averages. 
Another limitation of using of pre-screening trends is that it can often only be used 
to estimate overdiagnosis from invasive cancer. DCIS is more likely to be overdiagnosed 
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than invasive breast cancer. However, in most countries DCIS was not registered before 
the introduction of mammographic screening and can therefore not be included in the 
overdiagnosis estimate. This leads to an underestimation of overdiagnosis. 
Limitations of the current study
Besides the limitations of the assumptions needed to extrapolate pre-screening trends, 
other factors may cause an overestimation of the range of overdiagnosis estimates provid-
ed in this study. We estimated overdiagnosis in a population that is still screened, which 
leads to an inadequate adjustment for lead time. In order to adequately adjust for lead 
time and obtain a reliable estimate of overdiagnosis using a cumulative incidence ap-
proach, overdiagnosis should be estimated in a population in which screening has ceased 
and is followed up until the maximum length of lead time after screening has ceased. Such 
a population can be obtained either by measuring overdiagnosis in birth cohorts that stop 
screening at a certain age20 or by measuring overdiagnosis in countries that once screened 
for (breast) cancer but have ceased screening. Because we could not adequately adjust 
for lead time in this study, the overdiagnosis estimates are most likely overestimated. This 
is also reflected by the decreasing percentage of overdiagnosis with later starting and 
stopping years of the screening period: overdiagnosis is expected to increase within this 
period based on advances in technology (i.e. digital mammography22). However, this does 
not occur because the compensatory drop starts to compensate the excess cases from 
about 2002 onwards in the age group 75-79 and even later in the age group 80-84.  Other 
overdiagnosis estimates from the Netherlands with a more adequate adjustment for lead 
time have also reported estimates towards the lower end of the range of estimates pre-
sented here and also included DCIS.12,23
Another limitation of this study is that we analyzed the data for the whole population 
of the Netherlands rather than per region, even though screening was implemented in 
different years in different regions/municipalities. Incidence trends per region will prevent 
dilution and show a more pronounced shift in the breast cancer incidence after intro-
duction of mammographic screening.24 The effect of such analyses on the overdiagnosis 
estimate is not straightforward, because the compensatory drop may also be more pro-
nounced and the denominator depends – just as the number of overdiagnosed cases – on 
the implementation. Analyses per region are, however, likely to result in more accurate 
overdiagnosis estimates.
Furthermore, we would like to point out that we used the cumulative incidence meth-
od18, also called excess incidence method19, to estimate the percentage of overdiagnosis. 
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Extrapolation of pre-screening trends is also used to create a reference population for 
estimating overdiagnosis25,26 and to estimate the percentage of overdiagnosis using the 
lead time approach27,28. It can be expected that the influence of the pre-screening trends 
on the percentage of overdiagnosis in such studies is smaller than the range of estimates 
presented here25, because the current estimates are also affected by an inadequately 
measured drop after leaving screening.
Conclusion
To conclude, extrapolation of pre-screening trends are commonly used to estimate the 
percentage of overdiagnosis. This study shows that overdiagnosis estimates are heavily 
dependent on the assumptions made, especially those for the pre-screening period. Re-
searchers should acknowledge the limitations of extrapolation of pre-screening trends 
and adjust adequately for lead time.
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CHAPTER 12
Quantifying overdiagnosis in cancer screening: 
evaluation of study designs
T.M. Ripping, K. ten Haaf, A.L.M. Verbeek, N.T. van Ravesteyn, M.J.M. Broeders
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ABSTRACT
Objectives:  To evaluate existing approaches to estimate the magnitude of overdiagnosis 
in breast cancer screening in order to gain insight into the strengths and limitations of 
these designs and to provide researchers with guidance to obtain a reliable estimate of 
overdiagnosis in cancer screening.
Methods: We conducted a systematic review to identify primary research studies quan-
tifying overdiagnosis in breast cancer screening. From the studies we extracted the ap-
proach to adjust for lead time and the approach to obtain an unscreened reference popu-
lation. For each approach, we gave an overview of the data required, assumptions made, 
limitations and strengths.
Results: 40 studies met the inclusion criteria. We grouped the approaches to adjust for 
lead time in two main categories: the lead time approach and the excess incidence ap-
proach. The lead time approach was further subdivided into the mean lead time approach, 
lead time distribution approach and modeling. The excess incidence approach was subdi-
vided into the cumulative incidence approach and early versus late stage approach. The 
approaches used to obtain an unscreened reference population were grouped into the 
categories: control group of a randomized controlled trial, non-attenders, control region, 
extrapolation of a pre-screening trend, uninvited groups, adjustment for the effect of 
screening, and modeling.
Conclusion: Each approach to adjust for lead time and obtain an unscreened reference 
population has its own strengths and limitations, which should be taken into consider-
ation when estimating overdiagnosis. 
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INTRODUCTION
Cancer screening programs aim to detect cancer pre-cursors or cancers at an early stage 
in order to prevent cancer death. Early detection is beneficial when cancer incidence or 
death is prevented, but can also be harmful when the cancer pre-cursor or cancer would 
not have become symptomatic  during an individual’s lifetime. This is called overdiagnosis. 
Overdiagnosis is harmful because it transforms women into cancer patients and usually 
leads to overtreatment.
It is difficult to quantify overdiagnosis in cancer screening programs1 which explains 
the wide range of estimates (0-57%)1 and discussion about the optimal methodology.2,3 
Carter et al concluded in their review that the optimal method to quantify and monitor 
overdiagnosis in cancer screening programs is ‘ecological and cohort studies’.1 However, 
ecological and cohort studies do not represent a single design, but multiple study designs. 
This review aims to evaluate existing designs and appraoches to estimate overdiagnosis 
by breast cancer screening in order to gain insight in the strengths and limitations of each 
design and provide researchers with guidance to obtain reliable estimates of overdiagno-
sis in cancer screening.
METHODS
We executed a systematic review to identify studies on overdiagnosis in cancer screening. 
Although overdiagnosis has been quantified for other cancer screening programs, previ-
ous research has shown that most studies quantifying overdiagnosis in cancer screening 
focused on breast cancer screening. In addition, the studies available for breast cancer 
screening cover all considered approaches to estimate overdiagnosis with the exception 
of autopsy studies and pathological and imaging studies.1 These studies were not of in-
terest for the current review. Besides, pathological and imaging studies tend to oversim-
plify overdiagnosis, because they do not include overdiagnosis resulting from compet-
ing mortality in their estimate.1 Therefore, we limited ourselves to studies investigating 
overdiagnosis in breast cancer screening. We used the query “(breast neoplasms[MeSH 
Terms] OR (breast[All Fields] AND cancer[All Fields]) OR breast cancer[All Fields]) AND 
(overdiagnosis[All Fields] OR over-diagnosis[All Fields] OR overdetection[All Fields] OR 
over-detection[All Fields])” to search for relevant articles in Pubmed. We only included 
primary studies in English that estimated overdiagnosis in breast cancer screening. Be-
cause adjustment for lead time and comparison to an unscreened reference population 
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are essential for the estimation of overdiagnosis, we did not include studies missing at 
least one of these items.4 This resulted in the inclusion of 40 studies (see Figure 12.1). 
From each study, we extracted the study population, type of data, method to adjust for 
lead time, method to obtain the unscreened reference population, the reported method-
ological limitations and strengths and the outcome (measure, type of data, percentage of 
overdiagnosis) (see Supplement).  
RESULTS
Approaches to adjust for lead time
Most cancer screening programs aim to detect cancers in a pre-clinical stage with better 
treatment options in order to prevent cancer death. A certain proportion of the cancer 
precursors and cancers detected in the pre-clinical phase would have become symptom-
atic if screening had not occurred. For these non-overdiagnosed cancers, only the time of 
diagnosis is advanced; this time period between the detection by screening and when the 
cancer would have been clinically diagnosed is known as the lead time (see Figure 12.2). 
However, screening also detects cancers in a pre-clinical phase that would never have 
Records identified through 
datatbase searching (n=441) 
Records after removal of duplicates (n=442) 
Records screened for relevance (n=442) 
Full text articles accessed for eligibility (n=42) 
Records excluded (n=400) 
Full text articles excluded (n=2) 
- No unscreened reference population (n=1) 
- Not in English (n=1) 
Studies included in the qualitative synthesis (n=40) 
Records identified through 
other sources (n=1) 
Figure 12.1 Studies
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become symptomatic during an individual’s lifetime, i.e. overdiagnosed cancers (Figure 
12.2). When estimating the number of cancers that are overdiagnosed by screening, it is 
necessary to distinguish between cancers which are only detected early and would have 
become symptomatic if screening had not occurred and cancers that are overdiagnosed. 
In other words, it is necessary to correct for the lead time of cancers that would have 
been clinically detected without screening. There are several methods to adjust for lead 
time, which are usually divided into two groups: the lead time approach and the excess-
incidence approach.2,5 
Lead time approach
The lead time approach is based on a direct adjustment for lead time. Basically, overdiag-
nosis is calculated by comparing the cancer incidence in an unscreened population with 
the cancer incidence in a screened population adjusted for lead time. There are, however, 
several different approaches to adjust for lead time, which range from simple to more 
sophisticated: the average lead time approach, the lead time distribution approach and 
modeling (see Table 12.1). 
The first two approaches, the average lead time and lead time distribution approach, 
NO DETECTABLE CANCER  PRE-CLINICAL DETECTABLE CANCER  SYMPTOMATIC CANCER  
Sojourn time 
OVERDIAGNOSIS 
NO OVERDIAGNOSIS 
Lead time 
Cancer detected 
by screening 
Cancer detected 
by screening 
Cancer would have 
been detected due 
to symptoms 
Cancer would have 
been detected due 
to symptoms 
Figure 12.1 Lead time
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both require an estimate of the mean lead time in order to adjust the cancer incidence in 
a screened population for lead time. The natural history and lead time of a cancer is unfor-
tunately unobservable. There are several approaches to estimate the mean lead time. For 
breast cancer, the most common methods to estimate the mean lead time is the method 
of Day & Walter.6-9 
The average lead time approach, also called the incidence rate approach10 or rate shift 
approach7, uses the estimated mean lead time to shift the cancer incidence rate: the can-
cer incidence in the unscreened reference population is compared with the cancer in-
cidence in the screened population a few years earlier (i.e. the length of the mean lead 
time). Because the number of latent cases is the highest at the first screening examination, 
the first screening examination is often excluded from analyses to allow the estimation of 
overdiagnosis in a steady state of screening. Most authors do, however, not exclude all 
first screens, but estimate overdiagnosis from a steady state period where the number 
of persons having their first screen is small. Until now, this approach has been applied six 
times to estimate overdiagnosis.11-16 The main limitation of this approach is that it needs 
to exclude the first screening round (i.e. prevalent round), resulting in an underestimation 
of overdiagnosis. 
The second approach, the lead time distribution approach, uses the mean lead time 
not as a fixed value, but combines it with a chance to estimate the number of screen-de-
tected breast cancers that would have become symptomatic if screening would not have 
occurred (i.e. a lead time distribution). The number of screen-detected cancers that would 
have become symptomatic can then be added to the cancer incidence in the unscreened 
reference population7 or subtracted from the number of screen-detected cancers.8,9 Ei-
ther way, the cancer incidence will be adjusted for lead time and the cancer incidence in 
the screened and unscreened population can be compared to estimate overdiagnosis. So 
far, this approach has been applied three times to estimate overdiagnosis.7-9 The major 
limitation of this approach is that the natural history and lead time of cancers cannot be 
observed, requiring assumptions to estimate lead time and thus overdiagnosis. 
The last approach to adjust directly for lead time is mathematical modeling.17-26 Each 
type of model requires slightly different input data and assumptions, which goes beyond 
the scope of the current review. Generally, models require background information on 
cancer incidence and mortality, clinical data (e.g. age and stage by mode of detection, 
including  data from a non-screened population), and screening data (i.e. detection rates 
by age, stage and round, interval cancers). In case of (micro)simulation models, this data 
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is used to simulate the reality: under certain assumptions the model should give the same 
outcomes (e.g. cancer incidence and mortality) as observed. If this is the case, the model 
is ‘well-calibrated’ or ‘well-fitted’. Overall, the main limitation of models is that different 
combinations of assumptions can give the same model fit and it is not possible to verify 
which combination of parameter values is the most appropriate. 
In general, the lead time approach is a useful method to estimate overdiagnosis di-
rectly, because it does not require a long period of follow-up after screening cessation. 
But at the same time, it also requires a number of assumptions on the natural history of 
cancer to estimate lead time and calculate overdiagnosis. Inadequate estimates of lead 
time will result in biased estimates.27
Excess incidence approach
The excess incidence approach adjusts for the consequences of early detection by screen-
ing (i.e. lead time) on cancer incidence. As shown in Figure 12.3, cancers that are detected 
early and would have become symptomatic if screening had not occurred (i.e. non over-
diagnosed cancers) will cause an increase in the cancer incidence during screening and a 
No overdiagnosis Overdiagnosis
Non -overdiagnosed cancers that ared
diagnosed earlier (lead time) cause an excess
incidenc during screening that is completely
compensated for after screening cessation
Overdiagnosed cancers cause an excess
incidence during screening that is not
compensated for after screening cessation
Age Age
Ca
nc
er
 in
ci
de
nc
e
Ca
nc
er
 in
ci
de
nc
e
Screened
age range
Screened
age range
Figure 12.3 Estimated overdiagnosis
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drop in the incidence after screening cessation compared to a no screening situation, until 
the end of the lead-time. However, overdiagnosed cancers cause an increased incidence 
during screening that is not compensated for by a drop after screening cessation. In a 
screening setting, the extra cancer incidence during screening is thus caused by a com-
bination of non-overdiagnosed and overdiagnosed cancers, which will lead to an incom-
plete compensatory drop after screening cessation. Currently, there are two approaches 
to distinguish the extra incidence from non-overdiagnosed cancers and overdiagnosed 
cancers: the cumulative incidence approach and the early versus late stage cancer ap-
proach.
The first approach, i.e. the cumulative incidence approach, is the most common ap-
proach and has been applied in 21 studies to estimate overdiagnosis.4,14,17,28-47 This approach 
uses the effect displayed in Figure 12.3 to estimate overdiagnosis: it estimates the cumu-
lative incidence in a screened population (both during screening and after cessation of 
screening) and compares this with the cumulative incidence in an unscreened population. 
The difference in incidence between the two populations then represents the number of 
overdiagnosed cases, under the condition that the analysis is carried out appropriately. 
There are, however, three important conditions that need to be fulfilled for adequate 
estimation: 1) screened individuals need to cease screening, 2) the follow-up after cessa-
tion of screening needs to be as long as the longest lead time, and 3) the cancer incidence 
during screening and after screening cessation needs to be estimated  from the individu-
als with a similar cancer risk and screening participation rates.48,49 The second condition 
simply requires a long follow-up period; conditions one and three can both be fulfilled 
by estimating overdiagnosis in birth cohorts rather than in time periods. The main limita-
tion of the cumulative incidence approach is directly related to the conditions needed for 
adequate estimation: it requires a long period of follow-up and needs to estimate overdi-
agnosis in birth cohorts.
The second excess incidence approach is the early versus late stage approach. This ap-
proach has only been used once to estimate overdiagnosis by mammographic screening50 
and has received much criticism.51-53 The basic idea of this approach is that early detec-
tion by screening will increase the incidence of early stage cancers, which comprises both 
overdiagnosed cancers and non-overdiagnosed cancers. As a consequence, the increase 
in early stage cancers that is not compensated by a decrease in symptomatic cancers (i.e. 
reflected by late stage cancers) represents the number of overdiagnosed cancers. But, 
once again, there are a number of conditions that need to be fulfilled to arrive at a reliable 
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estimate of overdiagnosis, the most important being: 1) an unambiguous cut-off point to 
group cancers either as pre-clinical (i.e. early stage) and symptomateous (i.e. ‘late’ stage), 
and 2) an adjustment for the shift in age and calendar period caused by early detection 
(i.e. lead time). The last condition can be fulfilled by estimating the increase in early stage 
and decrease in late stage in a birth cohort that stops screening and is followed until there 
is no decrease in late stage cancers anymore. As for the cumulative incidence approach, 
the main limitations of the early versus late stage approach are also directly related to 
the conditions needed for adequate estimation, namely: no unambiguous cut-off point to 
distinguish early and late stage cancers and need for a long follow-up period after screen-
ing cessation. 
Generally, the excess incidence approach is theoretically a robust method that does 
not require assumptions on lead time. However, it requires good data and a proper execu-
tion, which is seldom reached in studies that have used this approach.
Approaches to obtain an unscreened reference population
Overdiagnosed cancers are cancers that are not detected in absence of screening. Thus, to 
estimate the number of overdiagnosed cancers, the cancer incidence in a screened popu-
lation should be compared with the cancer incidence in a comparable unscreened popula-
tion with follow-up until death.54 Until now, seven methods have been used to estimate 
the breast cancer incidence in an unscreened population: a control group of a random-
ized controlled trial (RCT), non-attenders, control region, extrapolation of a pre-screening 
trend, uninvited groups, adjustment for the effect of screening, and modeling. Table 12.2 
presents the seven methods to estimate the cancer incidence in the absence of screen-
ing and gives an overview of the required data, assumptions and the major strengths and 
limitations.
Randomized controlled trial
In an RCT, participants are randomly assigned to a screened intervention group and an un-
screened control group. This is the best approach to obtain a screened and an unscreened 
population with similar underlying cancer risks. In the last decades, eight RCTs have been 
executed to estimate the (additional37) effect of mammographic screening on breast can-
cer mortality.36,38 These RCTs provide individual-level data that can be used to estimate 
overdiagnosis using the cumulative-incidence approach37,45 or a lead time approach30,45. If 
perfectly executed, RCTs control for different types of bias including self-selection bias 
and contamination. However, most RCTs are not perfect: some individuals in the interven-
243Quantifying overdiagnosis in cancer screening: evaluation of study designs
tion group will not adhere to the intervention and some individuals in the control group 
will have opportunistic screening. This contamination causes a dilution in the overdiag-
nosis estimate. Furthermore, most RCTs cannot be used to estimate overdiagnosis since 
they have severe limitations, such as inadequate randomization38, screening of the con-
trol group at the end of the trial36, physical examination in the control group37, long-term 
follow-up in which a national screening program was implemented37,39,45. These limitations 
are not restricted to mammography RCTs.55 Besides the limitations of RCTs, the generaliz-
ability of overdiagnosis estimates obtained from RCTs may be limited, because current 
screening programs differ in screening modality, intensity, invited age range among other 
things.38 
Non-attenders 
Individuals invited to participate in a population-based screening program (Europe and 
Australia) or recommended to have a mammogram (US) can chose to adhere, i.e. so-
called attenders, or to non-adhere, i.e. so-called non-attenders. The cancer incidence of 
the attenders and non-attenders can be compared to calculate the number of overdiag-
nosed cancers. Until now, five studies have used this approach to estimate overdiagnosis 
by mammographic screening.28,29,31,35,41 The exact method to calculate overdiagnosis differs 
slightly between the studies, but the underlying idea is the same. The individuals selected 
for the study, either from a database29, cohort31,35,41 or case-control study28, are divided into 
two groups: ever-attended versus never-attended. The ever- and never-attinding groups 
can be further subdivided into screening phase, including prevalent screening, subsequent 
screening and a period after leaving the screening program.31 For each group, incidence 
rates are calculated and the incidence rate ratio can be used to compare the breast can-
cer incidence in attenders and non-attenders. The evaluated studies differ mainly in the 
way they calculate overdiagnosis: one study used the difference in standardized incidence 
rates29, one used the incidence rate ratio41 and two studies used the absolute difference in 
the cancer incidence28,31.
The main strength of the non-attenders approach is the use of individual data, which 
allows one to estimate overdiagnosis in women actually screened rather than women who 
have the opportunity to screening. This prevents dilution of the overdiagnosis estimates 
and provides estimates that are more informative to women planning to participate in 
screening. There are, however, a number of limitations associated with the non-attenders 
approach, including self-selection bias, small non-adjustable lead time bias, misclassifica-
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tion of exposure and difficulty in estimating the number of overdiagnosed cases. Firstly, 
the choices of individuals to become attenders or non-attenders may be correlated with 
differences in the baseline risk of cancer, so-called self-selection bias. Self-selection bias 
may cause an overestimation or underestimation of overdiagnosis, depending on the 
direction of the self-selection.56,57 Secondly, comparison of incidence rates of attenders 
and non-attenders will introduce a small lead time bias, because screening advances the 
time of diagnosis (i.e. lead time) and attenders with a screen-detected cancer will there-
fore on average contribute less person-years than non-attenders with cancer. Thirdly, the 
exposure for irregular attenders may be misclassified, because the attenders and non-
attenders are simply classified as either ever attended or never attended. This may result 
in an underestimation of overdiagnosis. Finally, the calculation of overdiagnosis is not 
straightforward for this approach, because the cancer incidence in non-attenders cannot 
be adjusted for risk factors or needs another reference population, for example extrapola-
tion of pre-screening trends28,31, to estimate overdiagnosis.
Control region
A geographically distinct region with no (organized) cancer screening program or cancer 
screening recommendations can also serve as an unscreened reference population. Until 
now, this approach has been used five times to estimate overdiagnosis by mammographic 
screening in the Netherlands40, Sweden12, Norway14 and Denmark16,34,39. With the exception 
of two studies,16,39 most studies used data at the population level.12,14,34,40 
Compared with other ecological designs to obtain an unscreened reference population 
(i.e. uninvited groups and extrapolation of pre-screening trends), the strength of a control 
region is that it does not require assumptions with regards to incidence over time or age 
groups. However, it does need the assumption that the screened and unscreened region 
are comparable with respect to the underlying risk of cancer, cancer detection (when 
screening does not occur) and registration of cancer diagnosis. Most studies estimating 
overdiagnosis by mammographic screening acknowledge that the screened region and 
unscreened control region may differ in their risk of breast cancer, and therefore, they 
adjusted for differences in breast cancer incidence trends between both regions.12 14 34,39 
Overdiagnosis can, however, still be affected by other differences between both regions, 
such as opportunistic screening.34 Another limitation of this approach is that it can no 
longer be executed in most countries, because most countries implemented a population 
based screening program (Europe and Australia) or provided the entire population with 
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screening recommendations (North America). 
Extrapolation of a pre-screening trend
The cancer incidence in absence of screening can also be obtained by extrapolating the 
observed pre-screening cancer incidence trend to the screened period. This approach has 
been used eleven times and is thereby the most common approach to estimate overdiag-
nosis by mammographic screening using observational data.7-9,11,13,29,30,33,36,42,46,50 The basic idea 
of this approach is simple: select a period before the introduction of screening and esti-
mate the trend in the cancer incidence using either linear regression on rates or Poisson 
regression on counts. Then, the trend in cancer incidence is extrapolated to the current 
screening era to obtain an unscreened reference population.
The major strength of this approach is its simplicity and the fact that it can be executed 
in most countries. Extrapolation of pre-screening trends requires, however, at least two 
assumptions that are not always fulfilled. First, extrapolation requires that the cancer inci-
dence trend would remain the same if screening was not introduced. Second, it assumes 
that case ascertainment and other factors related to cancer diagnosis remain the same, 
which is unlikely knowing that diagnostic procedures and systems have evolved over the 
last decades. Third, an extra assumption is required when the pre-screening trend is ad-
justed for a trend in a non-screened age group, namely that the change in the cancer 
incidence in the screened and non-screened age group is similar. Besides the fact that 
the assumptions made to extrapolate pre-screening trends are not likely to be fulfilled, it 
has been shown that there is strong statistical uncertainty surrounding the pre-screening 
trend. Overdiagnosis estimates depend heavily on the assumptions made to extrapolate 
the trend, especially on the choice of the pre-screening period.36
Uninvited groups 
Groups that are not invited to cancer screening, i.e. uninvited birth cohorts or uninvit-
ed age ranges, may also serve as unscreened reference populations. To obtain the un-
screened reference population, this approach does not just use the observed values in 
the uninvited group, but adjusts the cancer incidence in the uninvited age group for differ-
ences between the invited and uninvited group. Until now, this approach has been used 
twice to obtain an estimate of overdiagnosis.11,32 One study used the cancer incidence in 
uninvited age ranges (≤40 years and ≥80 years) to estimate the incidence in the screened 
age range by assuming a linear increase in incidence with age.11 The other study used 
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the cancer incidence in an uninvited birth cohort (1930-1934) and adjusted the cancer 
incidence for the model based birth cohort effect to obtain a comparable unscreened 
reference population.32
In comparison to the other ecological study designs, the strength of using uninvited 
groups to obtain an unscreened population is that it does not require assumptions on 
trends over time or on equality between two regions with respect to factors influencing 
the cancer incidence. However, this approach does require a different set of assumptions. 
For example, interpolation of cancer incidence from uninvited age groups assumes a lin-
ear increase in incidence with age, which is not likely to hold for breast cancer (e.g. Clem-
menson’s hook in the perimenopausal age range). Furthermore, this approach assumes 
no opportunistic screening in the uninvited age groups. Although this ‘no (opportunistic) 
screening’ assumption applies to more designs, it is more likely to fail for uninvited age 
groups or birth cohorts that are directly followed by screened age groups or birth cohorts 
because these groups may unintentionally be invited for screening. 
Adjust for the effect of screening
An unscreened reference population can also be obtained by adjusting the cancer in-
cidence in a screened population for the effect of screening. The incidence in the un-
screened population is thus not observed, as was the case with the previous designs, 
but it is calculated from the model. Currently, this approach has been used four times to 
calculate overdiagnosis by mammographic screening.15,32,43,44 The approach uses a Poisson 
regression model or Negative Binomial regression model to explain the cancer incidence 
based on factors like age, period, cohort and screening uptake. Then, the effect of screen-
ing on the cancer incidence is removed to obtain the cancer incidence in an unscreened 
population. The existing models differ slightly in the factors used to explain the cancer 
incidence: some incorporate several risk factors15,44 and some stratify the effect of screen-
ing by type of screening examination (e.g. first and subsequent).43,44
Compared to previous approaches using the observed cancer incidence in an un-
screened population, the main strength of using statistical adjustment for the effect of 
screening to obtain the unscreened population is that it does not require assumptions 
about the equality of the screened and unscreened population. Because the screened 
and unscreened population are obtained from the same model that only differs in the 
effect of screening, both populations are equal. Besides, this approach may be favoured 
over more complex models, because it is rather simple and requires less assumptions. 
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However, the simplicity of the model may also be its pitfall: the model may sometimes 
be too simplistic. The model does, for example, indirectly assumes that the effect of (the 
different phases of) screening on the cancer incidence is constant, which does not reflect 
changes in screening practice. Furthermore, it explains the cancer incidence using a lim-
ited number of parameters that may not result in an adequate model fit, although this is 
seldom reported.43  
Modeling
The last approach to obtain an unscreened reference population is modeling. The effect 
of modeling on overdiagnosis is not restricted to the unscreened population alone, but 
is also directly related to the specification of the natural history of the disease and the 
effects of screening. Because the main limitations of modeling are related to its underly-
ing assumptions, which are more closely related to lead time than unscreened reference 
population, we already discussed modeling under the lead time approach. Besides the 
limitations related to the assumptions required to estimate a model, modeling is mainly 
useful to obtain an unscreened reference population: the unscreened population is ex-
actly the same as the screened population except for exposure to screening.
DISCUSSION
This review classified the methods to estimate overdiagnosis according to two important 
characteristics: adjustment for lead time and the specification of the unscreened refer-
ence population. There were two main approaches to adjust for lead time and seven dif-
ferent approaches to obtain an unscreened references population. For each approach, we 
gave an overview of the required data, the assumptions needed and the major strengths 
and limitations.
Adjustment for lead time
The two main methods to adjust for lead time were the lead time approach and the excess 
incidence approach. Although this grouping of methods to adjust for lead time is well-
known,5 there is much debate about the optimal method to adjust for lead time.3,58,59 Some 
authors explicitly prefer the excess incidence approach over the lead time approach, be-
cause the latter relies on lead time assumptions that may be false.58 However, the excess 
incidence approach has drawbacks as well, which are mainly related to the data and the 
prerequisites for adequate estimation of overdiagnosis. Therefore, one approach cannot 
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simply be preferred over the other. In contrast, using both approaches and recognizing 
their limitations may help to achieve consensus on accurately estimating overdiagnosis.2
In this review, we also subdivided the main methods to adjust for lead time. The lead 
time approach was subdivided into three groups, which ranged from simple to complex: 
mean lead time, lead time distribution and modeling. Overall, there is a direct relation-
ship between the complexity of the method and the number of assumptions required: 
the more complex the approach, the higher the number of assumptions. When using the 
lead time approach, it is therefore important to make a balanced decision on the number 
of assumptions and the reliability of the estimate. For example, the simplest method (i.e. 
mean lead time) requires only a few assumptions, but will always underestimate over-
diagnosis because it excludes the ‘prevalent round’. On the other hand, modeling can 
estimate overdiagnosis for all screening rounds or exams, but requires more assumptions 
The excess incidence approach was further subdivided into two groups: the cumulative in-
cidence approach and early versus late stage approach. We showed that both approaches 
need to fulfil different conditions for adequate estimation of overdiagnosis, which are 
rarely fulfilled in existing studies. 
Unscreened reference population
Although most (review) studies so far focused on the adjustment for lead time, this review 
also included the choice of the unscreened reference population as one of the major char-
acteristics influencing overdiagnosis estimates. We showed that there are seven differ-
ent approaches to obtain an unscreened reference population: a control group of a RCT, 
non-attenders, control region, extrapolation of a pre-screening trend, uninvited groups, 
adjustment for the effect of screening, and modeling. 
All approaches to obtain an unscreened reference population have limitations and 
strengths, which we discussed in this review. Nevertheless, some approaches can be fa-
voured above others. To this end, researchers can use general guidelines, such as the 
well-known hierarchy of study designs (from high to low: RCTs, cohort studies, case-con-
trol studies, and ecological studies) and guidelines on the type of data (individual data is 
favoured over population level data60), to choose the optimal design. Nevertheless, judge-
ment of the reliability of overdiagnosis estimates based on these guidelines alone is not 
appropriate. This requires a careful examination of all strengths and limitations of both 
the study design used to obtain the unscreened reference population and the approach 
to adjust for lead time. A high-evidence design with a poor adjustment for lead time can 
thus give poorer estimates than an evidence design of poorer quality and better adjust-
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ment for lead time.
Focus review
This review did not focus on the judgment of overdiagnosis estimates, but rather on the 
evaluations of the strengths and limitations of the methods used to quantify overdiagno-
sis by mammographic screening. As a consequence, we did not provide an estimate or 
range of estimates for overdiagnosis by mammographic screening. Other reviews have 
judged overdiagnosis estimates and provided a range of the most reliable overdiagnosis 
estimates, which differs between the reviews.1,10,61 However, our review indicates it is not 
straightforward to give a range of  reliable estimates of overdiagnosis, because many stud-
ies suffer from severe limitations and overdiagnosis is often not defined in an uniform way 
(see Supplement).
Furthermore, we focused on studies quantifying overdiagnosis by mammographic 
screening to evaluate the limitations and strengths of lead time adjustment and choice 
of unscreened reference population. There are also studies quantifying overdiagnosis in 
screening for prostate cancer, lung cancer and colon cancer.1 However, overdiagnosis is 
most commonly studied in breast cancer screening and covers the widest variation in 
designs. As a consequence, the presented approaches cover all approaches available to 
estimate overdiagnosis in cancer screening. However, some approaches will not be suit-
able for all cancer screening programs: overdiagnosis in cancer screening programs that 
focus on detecting cancer pre-cursors (e.g. cervix and colon cancer) and screening for can-
cers with no trial or implemented screening program can only be estimated by modelling.
Final conclusion
To conclude, overdiagnosis can be estimated using different study designs. There are 
two main methods to adjust for lead time and seven different approaches to obtain an 
unscreened reference population. Each approach has its own strengths and limitations, 
which should be taken into consideration to determine the most suitable approach to 
estimate overdiagnosis in a specific setting.
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ABSTRACT
It is widely accepted that overdiagnosis is a major harm of screening, but its extent is 
still topic of controversy. This is partly the result of incomparable overdiagnosis estimates 
in scientific literature, as a variety of denominators are used to calculate the percent-
age of overdiagnosis in cancer screening. We propose to use the following denominator 
to calculate the percentage of overdiagnosis: ‘all cancers detected during the screening 
period, both interval and screen-detected, in participants of a screening program’. This 
denominator is more appropriate than existing denominators because it presents over-
diagnosis as a real percentage, is unaffected by attendance percentages, is applicable to 
all observational study designs, and can be easily recalculated to absolute numbers. To 
conclude, this denominator can be widely applied and increase comparability between 
overdiagnosis estimates, which is needed to correctly present the balance between the 
benefits and harms of screening.
269Overdiagnosis in cancer screening: the need for a standardized denominator
It is widely accepted that overdiagnosis is a major harm of cancer screening. However, 
the discussion continues as to whether the benefit of screening (i.e. cancer mortality re-
duction) outweighs the harm of overdiagnosis at population level, because there is so 
much uncertainty about the extent of overdiagnosis. One important factor influencing 
this uncertainty is the incomparability of overdiagnosis estimates: some studies express 
overdiagnosis as a percentage of cancers detected in absence of screening1,2, while other 
studies use the cancers detected in presence of screening as denominator3. In order to in-
crease the comparability of overdiagnosis estimates in the scientific literature, we need a 
single denominator to express the percentage of overdiagnosis. This denominator should 
present overdiagnosis as a real percentage, be unaffected by attendance percentages, be 
applicable to all study designs, and be easily translated to relevant risks and numbers. In 
this viewpoint, we propose a new denominator that fulfils all these requirements and is 
therefore a strong candidate for replacing existing denominators.
A crucial first step, that is often forgotten, is the need to establish an agreed defini-
tion of the percentage of overdiagnosis in cancer screening. We define the percentage of 
overdiagnosis as: ‘the percentage of cancers detected during the screening period that 
would not present symptomatically during one’s lifetime, in the absence of screening’. 
The numerator is the absolute number of overdiagnosed cases, i.e. ‘the detection of can-
cers that, in the absence of screening, would not present symptomatically during one’s 
lifetime’. The corresponding denominator is ‘all cancers detected during the screening 
period, both interval and screen-detected, in participants of a screening program’. The 
formula (1) to calculate overdiagnosis is therefore 
where y is the percentage of overdiagnosis, x is the absolute number of overdiagnosed 
cancers, SD is the number of screen-detected cancers, and I is the number of interval 
cancers.
The numerator can be calculated by a number of study designs, including randomized 
trials, modeling and observational studies. Most observational studies use the cumula-
tive incidence approach1, which uses the difference in the cumulative cancer incidence 
in presence (Cs ) and absence (Cns) of screening to calculate the absolute number of over-
diagnosed cases: x = Cs – Cns. In all study designs apart from randomized trials Cns is un-
𝑦𝑦𝑦𝑦 = � xSD + I� ∗ 100% 
 
270 Chapter 13
Part 4
Ch
ap
te
r 
13
known, therefore, most studies estimate Cns from pre-screening trends4, control regions5, 
non-attenders6 or trends adjusted for screening.7
 The denominator comprises all breast cancers detected in participants of the 
screening program and is therefore a strong candidate for replacing existing denomina-
tors. 
Firstly, this denominator and definition express overdiagnosis as a real percentage, 
which is not the case for all denominators. For example, Biesheuvel et al.1 proposed di-
viding the number of overdiagnosed breast cancer cases by the number of breast cancer 
cases in absence of screening. This is not a percentage. The definition of a percentage is 
‘a part of a whole’. Since overdiagnosed cases are not detected in absence of screening, 
they form  no part of Biesheuvel’s denominator. So, Biesheuvel’s denominator does not 
result in a real percentage. In contrast, our proposed definition uses the breast cancers in 
presence of screening as denominator, and therefore forms a true percentage. 
Secondly, the proposed denominator can be used to compare overdiagnosis between 
countries with different attendance percentages. Attendance percentages influence both 
the number of overdiagnosed cases and the total number of breast cancer cases. The nu-
merator (i.e. overdiagnosed cases) depends on the number of women attending screen-
ing. The denominator needs to be corrected for attendance. This only occurs if the can-
cers in women participating in screening are used instead of cancers in women invited to 
screening, as was, for example, proposed by the UK panel.3
 Thirdly, our proposed denominator can calculate overdiagnosis for all existing 
study designs, thereby increasing the comparability of overdiagnosis estimates between 
studies. In some studies in countries with a population-based screening program4,6,7, it 
is unknown which breast cancers are detected in screening participants (i.e. screen-de-
tected) and which are detected in an interval, and in non-participants, so, the proposed 
denominator and denominators using only screen-detected cancers would be unknown. 
The percentage of overdiagnosis can, however, be calculated according to the proposed 
definition using an adapted formula (formula 2):
In this formula, y is the percentage of overdiagnosis, Cs and Cns are the number of cancers 
detected in presence and absence of screening respectively, and p is the proportion of 
𝑦𝑦𝑦𝑦 = � Cs − CnsCns ∗ p + Cs − Cns� ∗ 100% 
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individuals participating in the screening program (see Box 13.1 for the derivation of this 
formula). 
Lastly, the percentage of overdiagnosis obtained by the proposed denominator is rel-
evant to some constituencies and can easily be transformed to other relevant risks and 
numbers for other constituencies. The most appropriate way to express overdiagnosis 
depends on who is interested in the percentage of overdiagnosis. Persons detected with 
cancer during screening and cancer scientists are most likely interested in the chance 
that screen-detected cancer is overdiagnosed. In contrast, a person invited to screening is 
most likely interested in the absolute risk of an overdiagnosed cancer using the number 
of participants as denominator. The absolute risk of overdiagnosis can be obtained by 
multiplying the percentage of overdiagnosis with the cumulative risk of screen-detected 
and interval cancers or by dividing the absolute number of overdiagnosed cases by the 
population at risk of overdiagnosis. Some constituencies (i.e. governments) may be inter-
ested in the absolute number of overdiagnosed cases to calculate the health care costs of 
overdiagnosis among others. The absolute number of overdiagnosed cancers (x) can be 
recalculated from the percentage of overdiagnosis using the reverse of formula 1 or by 
the reverse of formula 2, i.e.: 
This formula was derived from formula 2 by replacing the numerator for x and Cns in the 
denominator for x-Cs. Then, the function was divided by x and rewritten as a function of x. 
The only data required for this formula is the percentage of overdiagnosis (y), total num-
ber of cancers in a screened population (Cs) and the attendance proportion (p).’
  To balance the benefits and harms of screening, agreement must be reached 
about the percentage of overdiagnosis. A crucial step towards achieving agreement is the 
standardization of the percentage of overdiagnosis. Our proposed definition for the per-
centage overdiagnosis, which expresses overdiagnosis as a real percentage, is not depen-
dent on attendance, and is applicable to all study designs. Furthermore, the percentage 
overdiagnosis can easily be recalculated to other relevant numbers and risks.
x = Cs ∗ pp − 1 +  100𝑦𝑦𝑦𝑦  
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Box 13.1 Derivation of formula 2.  
𝑦𝑦𝑦𝑦 = �Cs − Cnsb + c � ∗ 100% 
𝑦𝑦𝑦𝑦 = � Cs − CnsCns ∗ p + c� ∗ 100% 
𝑦𝑦𝑦𝑦 = � Cs − CnsCns ∗ p + Cs − Cns� ∗ 100% 
Imagine a population with a population-based screening program where only a certain 
proportion of the population (p) participates in the screening program. The total number 
of cancers in this population in presence of screening (Cs) consist of three groups of 
cancers: 
a. Cancers detected in individuals not participating in the screening program 
b. Cancers detected in individuals participating in the screening program that 
would also be detected without the screening program, i.e. non-
overdiagnosed cancers. 
c. Cancers detected in individuals participating in the screening program that 
would not be detected without the screening program, i.e. overdiagnosed 
cancers. 
 
Overdiagnosis in this population can be calculated, even though we do not have the 
number of screen-detected (SD) and interval (I) cancers. Together, SD + I are all cancers 
detected in individuals participating in the screening program, and therefore, SD + I 
equals b + c. As a consequence, the formula for the percentage of overdiagnosis can be 
written as: 
 
 
In absence of screening, the total number of cancer cases (Cns) would be equal to a + b, 
even though all cancers would be detected as ‘a’. The number of cancers detected in 
individuals participating in screening depends on the attendance proportion p, i.e. b = 
Cns*p . This leads to  
 
Since ‘c’ is the number of number of overdiagnosed cases, i.e. cancers in presence of 
screening minus cancers in absence of screening (Cs – Cns), the formula can be written as 
in formula 2: 
 
 
In comparison to the original formula (formula 1), this formula more heavily depends on 
the assumption that the underlying incidence is the same in presence and absence of 
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Mammographic screening benefits and harms a number of women. There is much de-
bate about the benefit-harm balance, which is best reflected in the number of reviews 
investigating the benefits and harms of screening. In Chapter 2, we compared six reviews 
balancing the benefit, i.e. breast cancer mortality reduction, and harms, i.e. mainly over-
diagnosis and false-positives, of screening. We showed that these reviews differ in their 
estimates of the benefit and harms and we tried to explain these differences. It is, how-
ever, no matter of dispute that mammographic screening does good and harm at the 
same time in different women. Therefore, there is room for improvement: optimize the 
benefit-harm ratio.
BENEFITS AND HARMS STRATIFIED BY RISK FACTORS
The balance between the benefits and harms of mammographic screening may be op-
timized by risk-based screening, where a woman’s screening regimen is tailored to her 
breast cancer risk.1,2 A key assumption to risk-based screening is that the benefits and 
harms of breast cancer screening vary by breast cancer risk. In this context, we investi-
gated the benefits, i.e. (a proxy for the) breast cancer mortality reduction, and harms, i.e. 
cumulative risk of false-positives and interval cancers, of mammographic screening for 
four (risk) factors: a first-degree family history of breast cancer, socio-economic status 
(SES), co-morbidity and breast density (See Figure 14.1). We did not estimate the extent 
of overdiagnosis stratified by these factors, because there is still much uncertainty about 
the optimal method to estimate overdiagnosis (See section on overdiagnosis).
Family history
Women with a first-degree relative with a history of breast cancer have about a two-fold 
risk of breast cancer and a higher risk to die from breast cancer.4 Therefore, women with a 
family history are expected to have a greater absolute benefit from screening than wom-
en without breast cancer. Previous research has, however, also indicated that women with 
a family history have a higher risk of screening harms, i.e. false-positives5-7 and interval 
cancer8, which may influence the overall benefit-harm balance.
In chapter 6, we estimated the cumulative risks of favorable (small invasive screen-
detected breast cancer) and unfavorable (false-positives and interval cancer) screening 
outcomes for women with and without a family history of breast cancer. We showed that 
women with a first-degree family history of breast cancer have about a 1.6 increased 
risk of small invasive screen-detected breast cancers (diameter <15 mm) compared to 
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women without a family history. This indicates that the benefit of screening in terms of 
breast cancer mortality reduction is likely larger for women with a family history, because 
the life-expectancy of women diagnosed with small invasive breast cancers is similar to 
women without breast cancer.9 We also found that the cumulative risk of interval cancers 
and false-positives were 1.7 and 1.5 times greater for women with a family history than 
for those without (See Figure 14.1 for absolute numbers).  
A group of special interest for risk-based screening is formed by women aged 40-49 
with a family history of breast cancer, because their breast cancer risk is two times higher10 
and their benefit-harm balance is likely to equal the balance of average risk women aged 
50.11 In Chapter 6, we showed that biennial screen-film mammography mainly increased 
the risk of false-positives and intervals cancers, i.e. the harms, but not the risk of screen-
detected breast cancer, which can offer benefit. This seems to contrast previous research 
and may be outdated, because today’s screening (digital) is more accurate than screening 
in the eighties (screen-film) for premenopausal women.12,13 Annual digital mammography 
can detect more breast cancers by screening in women aged 40-4914 and can offer a higher 
breast cancer mortality reduction and survival in women with a family history.15,16 
Based on our results and available evidence, we are not yet able to provide an over-
view of the benefits and harms stratified by family history subgroup (see Figure 14.1). To 
complete the benefit-harm balance and allow individuals to make an informed decision, 
the breast cancer mortality reduction and overdiagnosis should be estimated by family 
history subgroups of all ages. Nevertheless, current evidence indicates that family history 
is a useful factor for risk-based screening because it results in a more favorable benefit-
harm and benefit-cost balance.11,17,18
Socio-economic status
Socio-economic status is associated with a number of breast cancer risk factors including 
reproductive factors and health behavior. Overall, women with high SES have a higher 
breast cancer incidence and mortality. As a consequence, women with high SES may have 
a higher number of breast cancers prevented by mammographic screening than women 
with low SES. However, knowing that high SES is associated with breast density, which 
can mask tumors on mammograms, it is uncertain whether the absolute benefit of mam-
mographic screening is indeed greater in women with high SES. Furthermore, it can be 
expected that women with high SES also have more harms of mammographic screening 
due to its association with breast density.
In Chapter 3, we found no statistically significant difference in the relative effect of 
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Figure 14.1 The benefit-harm balance over a screening lifetime (50-75) stratified by family history, socio-economic 
status, co-morbidity and breast density.
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mammographic screening on breast cancer mortality in women with high and low SES. 
Because women with high SES have a higher breast cancer mortality, this indicates that 
the absolute number of breast cancer deaths prevented by screening is also likely high-
er in women with high SES. Furthermore, Chapter 7 shows that the harms of mammo-
graphic screening, i.e. false-positives and interval cancers, are also higher for women with 
high SES than for women with low SES (see Figure 14.1). However, compared to the total 
number of cancers and total number of recalls, the cumulative risks of interval cancer 
and false-positives are not disproportionally higher in women with high SES: in both SES 
groups, interval cancers are 23-24% of all cancers and false-positives are 66-72% of all 
recalls (depending on the invited age range). 
With the exception of the above mentioned studies, SES has not been investigated in 
the context of risk-based breast cancer screening and its use in risk-based screening may 
well be unacceptable to policy-makers and women. However, these results can still con-
tribute to risk-based screening. We showed that the benefit and harm are likely to differ 
by SES (see Figure 14.1). As a consequence, risk factors underlying SES, e.g. reproductive 
factors and health behavior, may be useful targets for risk-based screening. More research 
will be needed to confirm this.
Co-morbidity
Women with co-morbidity have a higher risk to die from breast cancer or any other cause 
of death, even when breast cancers are detected early.19,20 As a consequence, women with 
co-morbid conditions are likely to benefit less from mammographic screening, although 
direct supporting evidence remains limited. Because the main issues surrounding screen-
ing women with co-morbidities are breast cancer mortality reduction and overdiagnosis, 
the cumulative risks of false-positives and interval cancers are seldom studied.21
We focused on the benefit of screening and investigated the effectiveness of mammo-
graphic screening in women with and without co-morbidities aged 50 to 75 (Chapter 4). 
We showed that the effectiveness of mammographic screening on breast cancer mortal-
ity differed not statistically significant for women without or with one or more co-morbid 
conditions reported in the Charlson Co-morbidity Index22. However, the absolute benefit 
of mammographic screening is likely to be smaller due to decreased survival.18,19 
The harm of overdiagnosis is also likely to be greater for women with co-morbidities, 
because these women have a decreased life-expectancy.23 However, the other two harms 
of mammographic screening, i.e. false-positives and interval cancers, are likely not af-
fected by co-morbidity status. For false-positives, this has been shown in older women 
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(66-89)21, but supporting evidence is lacking for interval cancers. When assuming an equal 
cumulative risk of false-positives21 and interval cancers, it is expected that the overall ben-
efit-harm balance is less favorable for women with than without co-morbidities, which is 
supported by modeling studies.24,25  
Even though there is agreement that presence of a co-morbid condition is likely to re-
sult in a less favorable benefit-harm balance for breast cancer screening (see Figure 14.1), 
more research will be needed before co-morbidity can be used in risk-based screening 
programs. In order to define which women will not benefit as much from screening and 
may need to quit screening at a younger age, it is necessary to know the life-expectancy 
in relation to individual co-morbid diseases26 and whether there is an interaction between 
breast cancer (treatment) and (treatment of) the co-morbid disease, among other things. 
Breast density
Breast density is a risk factor for breast cancer and can mask tumors on a mammogram. 
As a consequence of the latter, tumors in women with dense breasts are more likely to be 
detected at a later stage or during a screening interval27, which will result in a lower effect 
of mammographic screening on breast cancer mortality. Also, the risk of a false-positive 
result may be increased in women with dense breasts, because of reduced screening per-
formance.28
In Chapter 5, we investigated the effect of (screen-film) mammographic screening on 
breast cancer mortality by breast density. We showed that the effect of mammographic 
screening was smaller in women with dense than non-dense breasts. This indicates that 
mammographic screening alone offers less benefit to women with dense breasts com-
pared to women with non-dense breasts. Furthermore, we showed that high breast den-
sity decreased the sensitivity and (most often) the positive predictive value. So propor-
tionally to the number of screen-detected cancers, the number of interval cancers and 
false-positives are higher in women with dense breasts, which reflects a greater harm 
of screening in these women. So, women with dense breasts experience a smaller rela-
tive benefit from mammographic screening and a higher risk of interval cancer and false-
positive results (see Figure 14.1).
Because breast density affects both breast cancer risk and mammographic screening 
performance, it is a complex factor for personalized screening. Based on risk alone, some 
modeling studies have suggested that women aged 40-49 with dense breasts may have 
similar benefit-harm ratios for biennial mammographic screening as average risk women 
aged 50-74.11 In contrast, due to the limited performance of mammographic screening in 
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women with dense breasts, multiple states in the US have adopted a Breast Density Law, 
which requires that women are  informed about their breast density and allow supple-
mental screening for women with dense breasts. Supplemental screening for women with 
dense breasts does, however, add not much benefit, but it does increase the number of 
ultrasounds and costs enormously.29 This indicates that breast density alone is not suit-
able to allow for increased mammography or supplemental screening. Rather, risk-based 
screening programs using breast density should take both the effect on breast cancer 
risk and mammography performance into account.30 (See also the section on personalized 
screening)
METHODOLOGICAL ISSUES IN ESTIMATING THE HARMS OF 
SCREENING
The extent of the benefits and harms of mammographic screening can only be quantified 
when appropriate methodology and good data are available. Nowadays, there are good 
methods and datasets available to estimate the relative (and absolute) effect of mammo-
graphic screening on breast cancer mortality.31 There are, of course, still drawbacks related 
to each method, e.g. self-selection in case-control studies32. Some drawbacks can also be 
prevented by analyzing the data differently, e.g. visualization of trends in birth cohorts 
rather than over time periods. Overall, most of these drawbacks are known rather than 
concealed as is the case for the harms of screening. Observational study designs to esti-
mate the percentage of overdiagnosis and cumulative risks of false-positives and interval 
cancers are still in their infancy. Therefore, we devoted part of this thesis to the develop-
ment of methodology to quantify these harms.
Trend studies
Trend studies are often used to evaluate the impact of mammographic screening on 
breast cancer mortality and incidence.33,34 Generally, age-specific mortality and incidence 
rates are displayed over time. Besides the fact that trend studies cannot disentangle the 
effect of treatment and mammographic screening on breast cancer mortality, trends over 
time will dilute the effect of screening on the breast cancer mortality reduction33 and over-
estimate overdiagnosis.
In Chapter 9, we visualized breast cancer mortality and incidence in birth cohorts that 
were uninvited and invited to mammographic screening in the Netherlands. We showed 
that the breast cancer mortality rate starts to increase at a lower rate within the first 
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five years after the implementation of mammographic screening which continues at least 
until the age of 85 years. This indicates that mammographic screening has a direct and 
delayed effect on breast cancer mortality. Furthermore, we showed that the breast cancer 
incidence increases sharply after the introduction of mammographic screening, but drops 
when women leave the screening program at age 75. We also showed that the drop after 
leaving screening, i.e. the so-called compensatory drop, depends on the length women 
were screened. As a consequence, we recommended to calculate overdiagnosis from the 
excess incidence during screening in the same women as the drop in incidence after ceas-
ing screening, i.e. from one birth cohort. 
Although trend studies have more limitations when it comes to estimating the effec-
tiveness of mammographic screening on breast cancer mortality33, trends in birth cohorts 
provide a better visualization of the effect of screening and treatment on breast cancer 
mortality than trends over time. Similarly, trends in birth cohorts cannot adjust for effects 
other than screening, but they will provide better insight in the short and long-term ef-
fects of screening on the breast cancer incidence and give more reliable overdiagnosis 
estimates than trends over time periods.35
Overdiagnosis
There is much uncertainty about the percentage of overdiagnosis by mammographic 
screening, which is reflected in the estimates varying from 0% to 57%34,36 (or even 75%37). 
There are two main drivers for this uncertainty: 1) unavailability of good data and meth-
odology to estimate overdiagnosis and 2) lack of agreement on the definition of the over-
diagnosis percentage38. In this thesis, we investigated both issues.
First, the method to estimate overdiagnosis. Internationally, there is agreement on 
the best approach to estimate overdiagnosis by mammographic screening: comparison 
of the breast cancer incidence in a screened population with the breast cancer incidence 
in a comparable unscreened population with follow-up until death.39 In other words, a 
randomized-controlled trial (RCT) with follow-up until death. Unfortunately, such perfect 
RCTs are not available and other methods, including observational designs and modeling, 
are used to estimate overdiagnosis.40 In Chapter 10 and 11, we estimated overdiagno-
sis using two different designs: adjustment for the effect of screening in birth cohorts 
(Chapter 10) and extrapolation of pre-screening trends (Chapter 11). Both chapters have 
a methodological focus: in Chapter 10 we introduced a new methodology to estimate 
the breast cancer incidence in the absence of screening, i.e. adjustment for the effect of 
screening, and in Chapter 11 we show the influence of assumptions and inadequate ad-
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justment of lead time on overdiagnosis estimates based on extrapolation of pre-screening 
trends. Because in both chapters the follow-up after ceasing screening is too short to ad-
just completely for lead time, the overdiagnosis percentages are most likely overestimat-
ed. In Chapter 12, we continued evaluating the methodology to estimate overdiagnosis 
and performed a review. In this review, we focused on two important aspects needed to 
estimate overdiagnosis, namely the correction for lead time and the use of an unscreened 
reference population. We concluded that the data to estimate overdiagnosis are currently 
limited and that the overdiagnosis estimates of all methods will be subject to some bias. 
Therefore, the best approach to get an indication of the percentage of overdiagnosis is to 
use a combination of several approaches – either over- or underestimating overdiagnosis 
– that will together provide a range of the most likely percentage of overdiagnosis. 
The second driver of the uncertainty surrounding the percentage of overdiagnosis is 
the lack of agreement on its definition. There is agreement on the definition of an over-
diagnosed case, i.e. the detection of a breast cancer that, in the absence of screening, 
would not present symptomatically during one’s lifetime. However, to calculate the per-
centage of overdiagnosis, one needs a nominator, i.e. number of overdiagnosed cases, 
and a denominator. In Chapter 13, we proposed a denominator to calculate the percent-
age of overdiagnosis: all breast cancers detected during the screening period, both inter-
val and screen-detected, in participants of a screening program. Although this denomina-
tor may seem irrelevant, i.e. overdiagnosed cancers are always screen-detected breast 
cancers and never interval cancers, we showed that it can contribute to comparability 
between studies for it is applicable to all study designs. Furthermore, we showed that this 
denominator is a real percentage and unaffected by attendance percentages, and there-
fore, is comparable between studies and countries. In order to calculate numbers that are 
relevant for different stakeholders, the obtained percentages can be easily translated to 
other percentages and absolute values.
To conclude, we contributed to the methodology to estimate overdiagnosis and the 
definition of the percentage of overdiagnosis. There is, however, still discussion about the 
extent of the percentage of overdiagnosis by mammographic screening, which is likely 
to diminish over time when the quality of studies increase (e.g. better assessment of the 
compensatory drop) and when the discussion about overdiagnosis becomes less polar-
ized. 
False-positives and interval cancers
The main benefit (breast cancer deaths prevented) and harm (overdiagnosis) of mam-
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mographic screening are estimated over a lifetime of screening, e.g. 50-75 years in the 
Netherlands. To increase comparability between all effects of screening, false-positives 
and interval cancers should also be estimated over a screening lifetime. It is, however, not 
straightforward to estimate the life-time or cumulative risk of false-positives and interval 
cancers. Previous research has shown that the risk of false-positives differs by age and 
screening round and women are seldom followed from the starting to stopping age of 
screening. Furthermore, women can quit screening or choose not to participate. This may 
cause a bias in the estimates of the cumulative risks, because women who participate in 
less rounds may have a different risk of false-positives (and possibly also of interval can-
cers) than women participating more rounds, i.e. dependent censoring.41  
Previously, different methods have been proposed to estimate the cumulative risk of 
false-positives with and without adjustment for dependent censoring.42,43 Unfortunately, 
not all these methods are adequate for all screening outcomes and all screening situa-
tions. For example, adjustment for dependent censoring using the total number of rounds 
participated is only useful when the screening outcome, e.g. false-positive, does not in-
fluence re-attendance. This is the case for the US, but not for the Netherlands44 and oth-
er European countries45 and certainly not for interval cancer or screen-detected cancer. 
Therefore, we evaluated the appropriateness of each method per screening outcome and 
cause of censoring in Chapter 8. We explained among other things that discrete survival 
models are preferred when the event of interest causes women to quit screening, i.e. 
cancer detection, and no dependent censoring is suspected. In case dependent censoring 
is suspected and the event of interest results in censoring of some individuals – as is the 
case with false-positives in the Netherlands – we proposed to use a censoring bias model. 
A censoring bias model includes a correction factor, which is independent of the censoring 
time. In Chapter 6 and 7 we used an adjusted and unadjusted discrete survival model in 
order to estimate the cumulative risks of the main screening outcomes stratified by family 
history and SES.
MORE ON THE BENEFIT-HARM BALANCE
In this thesis, we focused on the benefits and harms of mammographic screening strati-
fied by four risk factors. There are however more benefits and harms of screening, more 
risk factors and possible interactions between risk factors. Furthermore, the benefits and 
harms of screening should be weighed to make risk-based screening decisions. 
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More benefits and harms
We focused on the quantification of breast cancer deaths prevented, overdiagnos is, false-
positives and interval cancers. Mammographic screening has, however, more benefits and 
harms. Table 14.1 gives an overview of all benefits and harms of mammographic screen-
ing, presenting the benefits and harms quantified in this thesis in Italics. 
The benefits of screening that we did not quantify in this thesis are stage migration (or 
down-staging) and less invasive treatment (e.g. fewer mastectomies, chemotherapy and/
or hormonal therapy).46  These benefits are directly related to the breast cancer mortal-
ity reduction, because a reduction in the breast cancer mortality by screening can only 
be achieved when breast cancers are detected at an earlier stage with better treatment 
options.47 Also some of the additional harms of mammographic screening are related to 
the harms of screening quantified in this thesis, including anxiety from additional testing 
which is related to false-positive test results and false-reassurance48, i.e. delayed symptom 
presentation due to screening participation, which has the same origin as interval cancers. 
In addition, there are harms that are not directly related to the harms quantified in 
this thesis, such as discomfort and pain49, radiation-induced breast cancer and radiation-
induced breast cancer death.50,51 These harms are likely to vary by screening modality and 
personal characteristics. For example, mammographic screening causes discomfort and 
pain because the breasts are placed between two plates that are pressed together. The 
discomfort and pain will depend on the method used for breast imaging, e.g. pressure ver-
sus force-standardization52, and on personal characteristics. Similar for radiation-induced 
breast cancer and breast cancer death, the radiation dose that induces breast cancers dif-
fers between screening modalities53,54 and may also be related to personal characteristics.
Table 14.1 Benefits and harms of mammographic screening 
 
Benefits Harms 
Breast cancer deaths prevented Overdiagnosis  
Stage migration False-positives 
Less invasive treatment Interval cancers 
 Anxiety 
 False reassurance 
 Discomfort and pain 
 Radiation  
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When weighing the benefits and harms of screening, it may be useful to include not 
only the most commonly estimated benefits and harms, i.e. breast cancer deaths averted, 
overdiagnosis and false-positives, but also the other benefits and harms. Although their 
effect may be smaller, they are also likely to vary between screening modalities (e.g. ra-
diation exposure, pain and discomfort) and with personal characteristics. Therefore, it is 
relevant to take into account all benefits and harms of screening when creating a benefit-
harm balance for risk-based screening. 
More factors and their interaction
In this thesis, we studied the benefits and harms of mammographic screening for four risk 
factors, i.e. family history of breast cancer, SES, co-morbidity and breast density. There 
are, however, more (risk) factors that may affect the benefits and/or harms of mammo-
graphic screening and may be relevant for risk-based screening. For example, modeling 
studies have shown that a previous breast biopsy and genetic variants are also useful fac-
tors for risk-based screening.17,18,55 
Furthermore, we only studied the benefits and harms of screening for each individual 
(risk) factor. A woman does, however, always have a combination of different (risk) factors 
for breast cancer that are likely to interact and influence the overall benefit-harm balance 
of mammographic screening. As mentioned before, SES and breast density share risk fac-
tors for breast cancer, e.g. parity and alcohol consumption56, and are therefore associ-
ated.57 There is also indication that the relation between breast density and breast cancer 
risk is modified by a first-degree relative with a history of breast cancer.58 This may be 
influenced by shared genetic variants, which may make the interaction between several 
risk factors for breast cancer even more complicated. 
Quantification and balancing of the benefits and harms of risk-based, or ‘personal-
ized’, screening is therefore not straightforward. A benefit-harm balance for individual 
women should include all relevant risk factors and their interaction (See section on per-
sonalized screening).
Weighing the benefits and harms
This thesis focused on the quantification of the benefits and harms of mammographic 
screening by risk factors, but did not consider quantitative weighing of the benefits and 
harms to create a benefit-harm balance. To provide risk-based screening recommenda-
tions it is, however, necessary to weigh the benefits and harms. Generally, there are two 
different ways to weigh the benefits and harms: ‘objectively’ and ‘subjectively’ or, in other 
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words, from the perspective of a population or an individual, respectively.
The first approach weighs the benefits and harms of mammographic screening ‘ob-
jectively’ for populations using quality-adjusted life years (QALYs). Over the years, QALYs 
have been estimated for various diseases and conditions.59 This allows us to express the 
benefits, i.e. breast cancer death averted, as numbers of life-years gained and the harms 
as a reduction in the quality of life years. In this way, the benefits and harms of screen-
ing are expressed in the same entity and can be weighed. Modeling studies use this ap-
proach to weigh the benefits and harms of screening11 or to weigh the benefits and cost 
of screening17,18,55, i.e. cost-effectiveness analysis. The second approach is more subjective: 
individual women are offered information about their risk of benefit and harm and are 
asked to make an informed choice on whether to participate in screening or not. This 
preference-sensitive informed decision making at individual level can be facilitated by the 
use of decision aids.60,61 
European countries with a population-based screening program will need a combina-
tion of both approaches to weigh the benefits and harms of screening. In order to de-
cide whether risk-based screening offers more benefit to a population than the current 
‘one-size-fits-all’ screening programs, cost-effectiveness analyses are useful. However, to 
support women in deciding whether to adhere to their risk-based screening regimen, de-
cision aids including their individual breast cancer risk and their associated benefit-harm 
balance of breast cancer screening are more useful.
THE FUTURE OF BREAST CANCER SCREENING
Medicine is shifting from a ‘one-size-fits-all’ approach towards a personalized approach, 
where healthcare is tailored to individuals. Also breast cancer prevention is moving to a 
personalized approach, where the preventive intervention is tailored to a woman’s breast 
cancer risk (see Figure 14.2 for a hypothetical situation). Women with an extremely high 
breast cancer risk, e.g. BRCA mutation carriers, may benefit from preventive surgery and 
the whole female population may benefit from lifestyle advice to reduce their breast can-
cer risk.3 Currently, it is possible to identify women with an extremely high breast cancer 
risk, but tools are limited to stratify women in the middle part of the pyramid who have 
an average risk of breast cancer and may benefit from screening. As indicated before, 
stratification of women with average breast cancer risk may result in a more favorable 
benefit-harm balance of screening for each woman and the society in general. Further-
more, to diminish the harm of overdiagnosis and prevent more deaths from breast cancer, 
291General discussion
personalized treatment of (screen-detected) breast cancers is of utmost importance.
Personalized screening
Personalized or risk-based screening aims to provide women with a screening regimen 
– which includes the starting and stopping age, interval, and modality – that offers the 
optimal benefit-harm balance of breast cancer screening for their breast cancer risk. This 
requires an understanding of which risk factors can reliably predict a woman’s breast can-
cer risk (and for what type)62, which screening modality is most suitable for certain groups 
of women and which other personal factors affecting the benefit-harm balance should be 
taken into account.  
First, in order to screen women according to their breast cancer risk, it is important to 
predict a woman’s risk of breast cancer correctly. Currently, there are a number of models 
predicting individual breast cancer risk, including the Gail model, BOADICEA model and 
Tyrer-Cuzick model. These models include different breast cancer risk factors, such as age, 
PREVENTIVE SURGERY
PREVENTIVE THERAPY
RISK-BASED SCREENING
LIFESTYLE ADVISE
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Figure 14.2  Hypothetical pyramid for personalized breast cancer prevention (based on Pruthi et al.3). Women 
with an extremely high risk of breast cancer (BRCA mutation carriers) are in the top of the pyramid and they 
may benefit from preventive surgery. The second layer of the pyramid is formed by women with a high risk of 
breast cancer who may benefit from preventive therapy (e.g. selective estrogen modulators). In the middle of 
the pyramid (layer three to six) are women with an average risk of breast cancer who may benefit from breast 
cancer screening. The different layers for women with an average breast cancer risk represent variation in breast 
cancer risk and thereby variation in the risk-based screening regimens. The lowest layer covers women who 
have a low risk of breast cancer and are not (yet) helped by screening, but can reduce their breast cancer risk 
by lifestyle advice.
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age at menarche, age at first birth, history of biopsy, first-degree family history, breast den-
sity, and multiple genes.63 These models have, however, low predictive power and there is 
a need for risk models with better discriminatory accuracy that can identify persons at all 
risk levels.1  Therefore, a number of large cohort studies – including PRISMA64, PROCAS65, 
KARMA66, ATHENA67 and PROSPR68,69  – are initiated to increase the discriminatory accuracy 
of breast cancer risk prediction models and to stratify all women according to their breast 
cancer risk. Ideally, risk prediction models do not only predict the risk of breast cancer, but 
also the type of breast cancer in order to prevent at least some overdiagnosis.70
Second, the choice of the most optimal screening modality or modalities does not 
only depend on breast cancer risk, but also on the performance of the screening modal-
ity used to a woman. Women with certain breast characteristics (e.g. dense breasts) may 
benefit less from mammographic screening alone and may – dependent on their breast 
cancer risk30 – benefit from supplemental screening. There are various modalities that can 
potentially be used to screen women for breast cancer, including digital mammography, 
computer-aided-detection in combination with an imaging modality, magnetic resonance 
imaging (MRI) and tomosynthesis.71 Each modality may improve screening performance in 
some women, but most likely not in all women. Therefore, women should be assigned to 
one or more screening modalities based on a combination of breast cancer risk and breast 
characteristics in order to obtain the most favorable benefit-harm balance.68,72
Last, more factors can influence the benefit-harm balance of breast cancer screening, 
even though they are not directly related to breast cancer risk or screening performance. 
For example, the effect of co-morbidity on the benefits and harms of mammographic 
screening is not likely to be mediated through a decreased breast cancer risk or screening 
performance, but mainly due to a decreased breast cancer specific and overall survival 
(Chapter 4).20,21 This will most likely influence the screening regimen (e.g. women with 
co-morbidities may benefit from stopping screening at a younger age24) and may be com-
bined with breast cancer risk and breast characteristics. Therefore, personal factors, such 
as co-morbidity, need to be taken into account when developing screening regimens.  
To conclude, more research needs to be done to allow stratification of average to high-
risk women in risk groups and provide them with a screening regimen resulting in the op-
timal benefit-harm balance. Breast cancer risk, breast characteristics and personal factors 
unrelated to risk or screening performance need to be taken into account when assigning 
women to a screening regimen or recommending women. Meanwhile, more research is 
also needed to assess whether implementation of a risk-based screening program is fea-
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sible and acceptable.
Personalized treatment
Personalized treatment is about providing each woman with the optimal treatment after 
detection of breast cancer (by screening). This is a broad concept and we will only focus 
on the parts of breast cancer treatment that are related to the benefits and harms of 
screenings: overtreatment and optimal treatment of (early diagnosed) breast cancers. In 
order to prevent, or at least diminish, the harmful effect of overtreatment due to over-
diagnosis, it is necessary to distinguish significant from minimal-risk cancers (prognostic 
markers). Furthermore, understanding how a specific breast cancer subtype is treated 
optimally can help to reduce breast cancer death further.
First, to understand whether a breast cancer should be treated, it is necessary to 
distinguish between significant breast cancers that are life-threatening and minimal risk 
breast cancers that are likely to be overdiagnosed. Breast cancers with a high- and low-
risk of causing breast cancer death can already be partly distinguished based on some 
prognostic factors73-75 and ongoing research tries to identify more characteristics to dis-
tinguish these breast cancers. Furthermore, there is growing support to rename ductal 
carcinoma in situ (DCIS), a precursor lesion with variable malignant potential, to a non-
cancer term.73,76,77 Renaming of DCIS may increase women’s willingness to abstain from 
direct treatment and choose watchful waiting.78 Currently, there is, however, no evidence 
that women with (certain types of) DCIS benefit more or equally from watchful waiting 
than treatment, but two trials are under way to provide evidence. In these two trials, the 
effectiveness of watchful waiting, also called active surveillance, is compared with direct 
treatment for low grade DCIS79,80, a lesion that is likely to be overdiagnosed for it remains 
indolent or progresses mainly to low grade invasive breast cancer.81 
Second, to provide each woman who needs treatment with the optimal treatment, it 
is necessary to understand how a woman will react to treatment. Ideally, we do not only 
want to know whether a woman responds well to treatment, but also get information on 
the expected side-effects of a given treatment.82 Breast cancer can be divided in a number 
of molecular subtypes with clinical implications, including hormone receptor (estrogen 
(ER) and progesterone (PR)) positive subtypes and HER2 (human epidermal growth fac-
tor receptor 2) positive subtype.82 These subtypes can help to make treatment decisions, 
for example: a positive HER2 status is a strong predictor for response to trastuzumab.82,83 
However, more research is needed to test new predictive factors and further personal-
ize breast cancer treatment. Besides, side effects of treatment, such an increased risk of 
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cardiovascular disease as a result of radiation84 and systemic treatment for breast cancer, 
should be taken into account when making treatment decisions.85
To conclude, more research is needed to identify and validate prognostic and predic-
tive markers in order to reduce the harm of overtreatment and increase the breast cancer 
survival. Besides, decision aids can help women to choose their treatment in circumstanc-
es where there is ambiguity on the most optimal treatment.
MAIN CONCLUSIONS
• Risk-based screening has the potential to optimize the benefit-harm balance for 
women with an average risk of breast cancer.
• A first-degree relative with a history of breast cancer is a risk factor for breast can-
cer and affects the benefit-harm balance of mammographic screening. As such, it 
may be a relevant factor for risk-based screening.
• SES covers a number of risk factors for breast cancer and most likely affects the 
benefit-harm balance of mammographic screening. Risk factors underlying SES, 
e.g. reproductive factors and health behavior, may therefore be useful in personal-
ized screening, although more research is needed to confirm this.
• Co-morbidity affects the breast cancer and all-cause mortality and thereby de-
creases the benefit of mammographic screening. As a consequence, co-morbidity 
is a relevant factor for risk-based screening, even though it is not a risk factor for 
breast cancer.
• Breast density affects both breast cancer risk and mammographic screening per-
formance. Both aspects of breast density should be taken into account when using 
breast density in risk-based screening.
• As long as methodology and data are limited to quantify overdiagnosis, research-
ers should aim to obtain a rough estimate of (the range of) overdiagnosis using 
several different approaches that either over- or underestimate the real percent-
age of overdiagnosis.
• Agreement on the definition of the percentage of overdiagnosis is needed among 
researchers in order to increase the comparability between overdiagnosis esti-
mates and reach agreement on the extent of the overdiagnosis percentage.
• Overdiagnosis should be estimated in birth cohorts when using the excess-inci-
dence approach.
295General discussion
• The best approach to estimate the cumulative risk of a screening outcome (e.g. 
screen-detected breast cancer, false-positive results or interval cancer) depends on 
the screening outcome and the screening setting.
• Trends in birth cohorts show both the immediate and delayed effects of mam-
mographic screening and should therefore be preferred over trends over calendar 
years.
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Currently, mammographic screening is still topic of intensive debate which is centralized 
around the question: ‘do the benefits of screening outweigh its harms?’. Several reviews 
have weighed the benefit, i.e. breast cancer mortality reduction, and two major harms of 
mammographic screening, i.e. overdiagnosis and false-positive results. Their conclusions 
and recommendations do, however, vary widely. We showed that the choice of study 
design, screening setting, measurement method and reference population can explain at 
least part of the variation between the outcomes of the reviews (Chapter 2). Although dis-
cussion on the extent of the benefits and harms of mammographic screening continues, 
new efforts are undertaken to optimize the benefit-harm balance of breast cancer screen-
ing.  One of these efforts explores the potential of risk-based screening, which aims to 
stratify women to a screening regimen that is tailored the woman’s individual risk profile.
RISK-BASED SCREENING
We estimated the benefits and harms of mammographic screening by the four (risk) fac-
tors listed below. The estimated benefit is (a proxy of) breast cancer mortality reduction 
and the estimated harms are false-positives and interval cancers.
First-degree family history of breast cancer
A first-degree family history of breast cancer, or in short ‘family history’, indicates that 
a woman has one or more first-degree family members (i.e. mother, sister(s) and/or 
daughter(s)) who have been diagnosed with breast cancer. Women with a family history 
of breast cancer are twice as likely to develop breast cancer than women without such 
family history. Therefore, women with a family history of breast cancer may benefit more 
from screening. We calculated the cumulative risk of screening outcomes over a screen-
ing lifetime (50-75 years and 40-75 years) and showed that women with a family history 
indeed have a higher risk of breast cancer and may be more likely to benefit from screen-
ing (Chapter 6). However, women with a family history also have an increased risk to 
be harmed by screening: they have a higher cumulative risk of false-positive results and 
interval cancers.
Socio-economic status
Socio-economic status (SES) reflects the social and economic position of an individual in 
the society and is associated with a number of risk factors for breast cancer (reproduc-
tive factors and health behaviour). As such, women with high SES (measured by income, 
unemployment and education) have an increased risk of breast cancer diagnosis and mor-
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tality and may therefore benefit more from mammographic screening. We executed a 
case-control study to estimate the effect of mammographic screening on breast cancer 
mortality by SES. We showed that there was no significant difference in the relative ef-
fectiveness of mammographic screening on breast cancer mortality by SES (Chapter 3). 
This indicates that women with high SES may indeed have a greater absolute benefit from 
mammographic screening than women with low SES. Furthermore, the cumulative risk 
of false-positive results and interval cancers were higher for women with high SES, which 
reflects a greater harm of screening in these women (Chapter 7). Even though SES may be 
unacceptable for risk-based screening programs, our results show that the benefit-harm 
balance is likely to differ by SES and risk factors underlying SES may be useful targets for 
risk-based screening.
Co-morbidity
Co-morbidity is the co-existence of one or multiple chronic diseases next to an index 
disease in one individual. The presence of a co-morbid disease next to breast cancer is 
known to influence all-cause mortality and breast cancer mortality, even when breast 
cancers are diagnosed in an early stage. As a consequence, it is likely that the effect of 
mammographic screening on breast cancer mortality is smaller for women with a chronic 
disease. We conducted a case-control study to investigate the effect of mammographic 
screening on breast cancer mortality in women with and without (co-)morbidity (Chapter 
4). This study showed no statistically significant difference in the effectiveness of screen-
ing on breast cancer mortality by co-morbidity. However, the absolute benefit of mammo-
graphic screening is likely to be smaller for women with co-morbidities due to decreased 
survival. If co-morbidity does not affect the performance of mammographic screening, 
the benefit-harm balance of mammographic screening will be less favourable for women 
with a chronic life-threatening disease. Therefore, co-morbidity is a useful factor for risk-
based screening.
Breast density
Breast density is a mammographic feature that describes the tissue of the breast. Over-
all, women with dense breasts (i.e. much glandular and connective tissue and less fatty 
tissue) have a higher risk of breast cancer than women with non-dense tissue. Breast 
density is, however, not only a risk factor for breast cancer, but also interacts with the 
performance of mammographic screening. We showed that the effectiveness of mammo-
graphic screening on breast cancer mortality is reduced for women with dense breasts, 
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while the number of false-positive results and interval cancers are higher proportionally 
to the number of screen-detected breast cancers (Chapter 5). Because the benefit-harm 
balance differs by breast density, breast density is a useful factor for risk-based screening. 
If breast density is used for risk-based screening, it should combine both the effect on 
breast cancer risk and on screening performance. 
METHODOLOGICAL ISSUES
Trend studies
Trend studies are used to evaluate the impact of mammographic screening on the breast 
cancer mortality and incidence, even though they cannot disentangle the effect of screen-
ing from other effects over time (e.g. improved treatment and changes in risk factor 
prevalence). Trends over calendar periods will also dilute the effect of mammographic 
screening on breast cancer mortality reduction and overestimate overdiagnosis, because 
they only present the short-term effects of screening. We displayed breast cancer mor-
tality and incidence trends in birth cohorts as opposed to trends over calendar periods. 
We showed that mammographic screening has both immediate and delayed effects on 
mortality and incidence (Chapter 9). In order to take into account both immediate and 
delayed effects, we recommend to use birth cohorts to display breast cancer incidence 
and mortality trends and estimate overdiagnosis.
Overdiagnosis
Overdiagnosis is the detection of cancers that would not present symptomatically during 
a woman’s lifetime in the absence of screening. There is much debate on the extent of 
overdiagnosis by mammographic screening, which is reflected in estimates varying from 
0% to 57% (or even 75%). The main drivers for the uncertainty around the magnitude of 
overdiagnosis are the lack of good data and methodology to estimate overdiagnosis and 
the lack of agreement on the definition of the percentage of overdiagnosis. We dealt with 
both issues in this thesis. First, we investigated two designs to estimate overdiagnosis, i.e. 
adjustment for the effect of screening and extrapolation of pre-screening trends (Chap-
ters 10 and 11), and critically evaluated the study designs used to estimate overdiagnosis 
by mammographic screening (chapter 12). Second, we proposed a denominator to calcu-
late the percentage of overdiagnosis, i.e. all breast cancers detected during the screen-
ing period, both interval and screen-detected, in participants of the screening program 
(Chapter 13). This denominator can contribute to comparability between overdiagnosis 
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estimates, because it is applicable to all study designs, is unaffected by attendance rate, 
and results in a real percentage.
False-positives and interval cancer
False-positive results (i.e. the recall of women without breast cancer for further diagnos-
tic follow-up) and interval cancers (i.e. breast cancer detected between two subsequent 
screening examinations) are two harms of screening that can be measured per screening 
round. However, to balance the benefits and harms of mammographic screening, all ben-
efits and harms should be expressed over a screening lifetime (age 50-75 or 40-75). It is, 
however, not straightforward to calculate the so-called cumulative risk of false-positive re-
sults and interval cancers because of dependent censoring, i.e. the possibility that women 
who participate in less rounds have a different risk of screening outcomes than women 
who participate in more rounds. We evaluated the appropriateness of several methods to 
adjust for cause of censoring per screening outcome and provided recommendations for 
researchers estimating cumulative risks (Chapter 8). 
CONCLUSION
To conclude, the benefit-harm balance of mammographic screening is likely to differ be-
tween women with and without the presence of certain risk factors. As such, risk-based 
screening has potential when it combines 1) breast cancer risk (e.g. family history, risk 
factors underlying SES, and breast density) with  2) breast characteristics affecting screen-
ing performance (e.g. breast density) and 3) personal factors influencing the benefit-harm 
balance via other routes than risk (e.g. co-morbidity). Furthermore, agreement on the 
percentage of overdiagnosis in both the current target population of screening as in risk 
groups is required to complete the benefit-harm balance.  
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Het bevolkingsonderzoek naar borstkanker heeft zowel voor- als nadelen (hoofdstuk 1). 
Het voordeel van borstonderzoek met behulp van mammografie is dat borstkankers eerder 
gevonden kunnen worden, waardoor ze beter kunnen worden behandeld en borstkank-
ersterfte kan worden voorkomen. Daar staat echter tegenover dat sommige borstkank-
ers die weliswaar vroeg gevonden worden nooit klinisch relevant zouden zijn geworden 
zonder die screening (overdiagnose). Een ander nadeel van mammografie is dat sommige 
vrouwen worden doorverwezen naar het ziekenhuis voor nader onderzoek terwijl ze geen 
borstkanker hebben (een fout-positieve bevinding). Daarnaast is het (huidige) bevolking-
sonderzoek naar borstkanker niet in staat om alle borstkankers te detecteren, waardoor 
er nog steeds borstkankers klinisch ontdekt worden tussen twee screeningsrondes in, de 
zogenoemde intervalkankers.
In de wetenschappelijke wereld en maatschappij zijn al jaren discussies aan de gang 
over de omvang en balans tussen de voor- en nadelen van bevolkingsonderzoek naar 
borstkanker. Oftewel, is het bevolkingsonderzoek naar borstkanker (of simpeler: borst-
kankerscreening) over het algemeen nu goed voor de doelgroep van het bevolkingsonder-
zoek of niet? Grote wetenschappelijke onderzoeken, de zogenoemde reviews, die deze 
vraag stelden kwamen tot verschillende resultaten. In hoofdstuk 2 lieten we zien dat deze 
verschillen ten minste deels verklaard kunnen worden door de specifieke onderzoeken 
die in de reviews werden meegenomen. Zo verschilden de onderzoeken in de gebruikte 
onderzoeksmethode, de uitvoering van screening (onder andere de leeftijd van de doel-
groep en de duur van het screeningsinterval), de betekenis van de percentages en de 
vertaling naar absolute aantallen. Terwijl de discussie over de voor- en nadelen van het 
huidige bevolkingsonderzoek naar borstkanker doorgaat, worden er ook nieuwe stappen 
genomen om te kijken of de screening te optimaliseren is. Een potentiële manier voor 
deze optimalisatie is het afstemmen van het borstkankerscreeningsprogramma  op het 
borstkankerrisico van vrouwen, het zogenaamde risicoprofiel. Het idee is dat vrouwen een 
gepersonaliseerd screeningsprogramma krijgen op basis van hun risicoprofiel, waarmee 
de voordelen van screening worden vergroot ten opzichte van de nadelen. 
SCREENING OP BASIS VAN RISICOFACTOREN
In dit proefschrift hebben we de voor- en nadelen van de borstkankerscreening onder-
zocht voor verschillende groepen vrouwen. Deze groepen werden gevormd aan de hand 
van onderstaande (risico)factoren voor borstkanker. We hebben niet alle bovengenoemde 
nadelen meegenomen, omdat het schatten van overdiagnose zelfs voor de hele populatie 
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methodologisch nog lastig is. 
Borstkanker bij één of meer eerstegraads familieleden
In de medische wereld vallen de moeder, zus(sen) en dochter(s) onder eerstegraads (vrou-
welijke) bloedverwanten. Als één van deze vrouwen borstkanker heeft (gehad), dan wordt 
er gesproken van een (eerstegraads) familiegeschiedenis van borstkanker. Vrouwen met 
zo’n familiegeschiedenis hebben een twee keer zo grote kans om borstkanker te krijgen en 
hebben daarom mogelijk ook meer profijt van mammografisch borstonderzoek. In hoofd-
stuk 6 hebben wij de kans berekend op het ontdekken van borstkanker tijdens screen-
ing (van leeftijd 50 tot 75 jaar en van 40 tot 75) en dat voor een vrouw met en zonder 
familiegeschiedenis van borstkanker. We zagen dat vrouwen met een familiegeschiedenis 
inderdaad een grotere kans hebben op detectie van borstkanker door screening en daar-
mee mogelijk ook een grotere kans dat borstkankersterfte wordt voorkomen. Daar staat 
echter tegenover dat vrouwen met een familiegeschiedenis ook een grotere kans hebben 
op een fout-positieve bevinding en intervalkanker.
Sociaaleconomische status
De sociale en economische positie van individuen is te beschrijven met de sociaalecon-
omische status (SES) score. SES is gerelateerd aan meerdere risicofactoren voor borst-
kanker, zoals reproductie en levensstijl. Over het algemeen hebben vrouwen met een 
hoge SES meer nadelige risicofactoren voor borstkanker en daardoor hebben zij weer 
een hogere kans om borstkanker te krijgen en/of eraan te overlijden. Als het gunstige ef-
fect van screening niet met  SES samenhangt, dan is het absolute voordeel van screening 
groter voor vrouwen met een hoge SES.  In hoofdstuk 3 hebben wij de effectiviteit van 
het bevolkingsonderzoek naar borstkanker onderzocht – met behulp van een patiënt-con-
troleonderzoek – voor vrouwen met een hoge en lage SES. Als we kijken naar de relatieve 
vermindering van het borstkankersterftecijfer door screening, dan zien we geen signifi-
cant verschil tussen vrouwen met een lage SES en vrouwen met een hoge SES. Dit sug-
gereert dat vrouwen met een hogere SES (omdat ze een hoger borstkankersterftecijfer 
hebben) in absolute zin meer baat hebben bij screening. Aan de andere kant zagen we in 
hoofdstuk 7 dat het risico op fout-positieve uitkomsten en intervalkanker ook groter was 
voor vrouwen met een hoge SES. Ons onderzoek laat dus zien dat de balans tussen de 
voor- en nadelen van borstkankerscreening waarschijnlijk verschilt tussen vrouwen met 
een hoge en vrouwen met een lage SES. Echter, SES is waarschijnlijk onacceptabel om te 
gaan gebruiken voor screenen op basis van risicofactoren. Toch is deze studie relevant, 
313
omdat het laat zien dat risicofactoren voor borstkanker die gerelateerd zijn aan SES  –re-
productie en levensstijl – interessant kunnen zijn om mee te nemen in een risicoprofiel.
Co-morbiditeit
Als een individu meerdere chronische aandoeningen tegelijkertijd heeft naast een 
specifieke ziekte, dan spreken we van co-morbiditeit. In onze situatie is co-morbiditeit 
gedefinieerd als de aanwezigheid van een of meerdere ziektes naast borstkanker. Co-
morbiditeit beïnvloedt de totale sterfte en de borstkankerspecifieke sterfte, wat zelfs 
het geval is als borstkanker in een vroeg stadium wordt gedetecteerd. Het is daarom te 
verwachten dat borstkankerscreening bij vrouwen met een of meer chronische ziektes 
een minder gunstig effect heeft op de borstkankersterfte. In hoofdstuk 4 hebben wij een 
patiënt-controleonderzoek uitgevoerd waarin we het effect van borstkankerscreening op 
de borstkankersterfte hebben onderzocht voor vrouwen met en zonder co-morbiditeit. 
We zagen geen significant verschil in het relatieve effect van screening tussen vrouwen 
met en zonder co-morbiditeit. Het is echter aannemelijk dat het absolute voordeel van 
borstkankerscreening kleiner is voor vrouwen met co-morbiditeit, omdat deze vrouwen 
minder oud worden dan vrouwen zonder co-morbiditeit. Als co-morbiditeit geen invloed 
heeft op de kwaliteit van screening (en dus op de fout-positieven en intervalkankers), dan 
zal de balans tussen voor- en nadelen van screening minder voordelig zijn voor vrouwen 
met andere levensbedreigende aandoeningen dan voor vrouwen zonder andere aan-
doeningen. Co-morbiditeit is daarom een relevante factor voor screening op basis van 
risicoprofielen.
Borstdensiteit
Borstdensiteit is een term die de samenstelling van borstweefsel beschrijft zoals dat op 
een mammogram te zien is. Als vrouwen relatief veel melkklierweefsel en bindweefsel 
hebben ten opzichte van de hoeveelheid vet in hun borsten, dan spreken we van een hoge 
borstdensiteit. Borstdensiteit is een risicofactor voor borstkanker: vrouwen met veel van 
dit borstweefsel hebben een grotere kans op borstkanker dan vrouwen met veel vetweef-
sel. Daarnaast is het lastig om borstkanker te vinden in borsten met hoge densiteit, omdat 
borstkankers en dit type borstweefsel beide wit kleuren op een mammogram. In hoofd-
stuk 5 lieten we zien dat borstkankerscreening minder effectief is bij vrouwen met een 
hoge borstdensiteit dan bij vrouwen met een lage borstdensiteit.  Het aantal fout-posi-
tieven en intervalkankers (ten opzichte van het aantal kankers gedetecteerd door screen-
ing) is echter hoger bij vrouwen met een hoge borstdensiteit. Borstdensiteit beïnvloedt 
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dus de balans tussen de voor- en nadelen van borstkankerscreening en is daarom nuttig 
om te gebruiken voor screening op basis van risicoprofielen. Het is echter wel belangrijk 
om hierbij zowel het effect van borstdensiteit op borstkankerrisico mee te nemen als het 
effect van borstdensiteit op de kwaliteit van de screeningstest.
METHODOLOGIE
Trendanalyses
Het effect van borstkankerscreening op de borstkankersterfte en –incidentie wordt regel-
matig bestudeerd met behulp van zogenoemde ‘trendanalyses’. Over het algemeen wordt 
bij een trendanalyse de borstkankersterfte en/of –incidentie bestudeerd over tijd heen, 
uitgedrukt in kalenderjaren. Een nadeel van trendanalyse is dat het niet heel geschikt is 
om het effect van borstkankerscreening te bestuderen, omdat de effecten van screening 
niet los te koppelen zijn van andere effecten, zoals verbeteringen in behandeling en ve-
randeringen in het risico voor borstkanker. Daarnaast verdunnen trends over de kalender-
jaren heen het effect van borstkankerscreening op de borstkankersterfte en overschatten 
ze de omvang van overdiagnose, omdat ze alleen de korte termijneffecten van screening 
meenemen. In hoofdstuk 9 deden wij een trendanalyse waarbij we niet naar trends over 
kalenderjaren keken zoals de meeste onderzoeken, maar naar trends die in geboorte-
cohorten optreden. Oftewel, trends over tijd in groepen vrouwen die in hetzelfde jaar 
(of een langere period) zijn geboren. Hierdoor zagen we dat borstkankerscreening zowel 
korte als lange termijneffecten heeft. We bevelen daarom aan om trends in geboorteco-
horten te bestuderen zowel om de (gunstige) veranderingen in de borstkankersterfte te 
zien als de ontwikkelingen in de incidentie en de mate van overdiagnose te schatten. 
Overdiagnose
Overdiagnose is de detectie van borstkankers die zonder screening nooit klinisch relevant 
zouden zijn geworden. Dit is een nadeel van screening, omdat de ‘over-gediagnosticeerde 
borstkankers’ nooit zouden zijn ontdekt en behandeld zonder borstkankerscreening. 
Over de omvang van overdiagnose bij borstkankerscreening is veel discussie. Momenteel 
variëren de schattingen ten aanzien van de omvang van overdiagnose van 0% tot 57% 
(of zelfs 75%). Er zijn meerdere redenen waarom de overdiagnoseschattingen zo sterk 
variëren. De twee belangrijkste zijn: 1) het gebrek aan goede data en statistische meth-
oden en 2) de onenigheid over de definitie van het percentage overdiagnose. In dit proef-
schrift hebben we ons met beide zaken bezig gehouden. We hebben twee verschillende 
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methoden uitgeprobeerd om de borstkankerincidentie zonder screening te schatten en zo 
overdiagnose te berekenen, namelijk het effect van screening weghalen en het extrapole-
ren van incidentietrends voor de introductie van screening screening begon (hoofdstuk 
10 en 11). Vervolgens hebben we alle huidige methoden om overdiagnose te schatten 
geëvalueerd (hoofdstuk 12). Om meer overeenstemming te krijgen over het percentage 
overdiagnose hebben we een voorstel gedaan voor de definitie van het percentage over-
diagnose, namelijk: het percentage  borstkankers dat tijdens screening wordt gediagnos-
ticeerd (zowel tijdens als in het  screeningsinterval), maar nooit klinisch relevant zouden 
zijn geworden zonder screening (hoofdstuk 13). Deze definitie voor het percentage over-
diagnose is breed toepasbaar, is onafhankelijk van de opkomst bij screening en resulteert 
in een echt percentage. Daardoor kan het bijdragen aan meer overeenstemming over het 
percentage overdiagnose.
Fout-positieven en intervalkankers
We spreken van een fout-positief resultaat als een vrouw naar aanleiding van borstkank-
erscreening poliklinisch onderzoek moet ondergaan om uit te sluiten dat de vrouw borst-
kanker heeft. Bij een intervalkanker gaat het om de diagnose van borstkanker tussen twee 
screeningsrondes in. Dit zijn nadelen van screening die per screeningsronde gemeten kun-
nen worden. Om voor- en nadelen zinvol uit te drukken is het handiger om dit over het 
hele ‘screeningsleven’ te doen (bijvoorbeeld voor screening van 40 tot 75 jaar of, zoals 
in Nederland, voor screening van 50 tot 75 jaar). Foutpositieve screeningsuitkomsten en 
intervalkanker kunnen niet zomaar opgeteld worden voor alle screeningsrondes, omdat 
het mogelijk is dat vrouwen die minder vaak aan screening meedoen een ander risico op 
die factoren hebben dan vrouwen die vaker meedoen. In hoofdstuk 8 hebben we daarom 
verschillende methodes om hier rekening mee te houden geëvalueerd en aanbevelingen 
gedaan om het cumulatieve risico goed te onderzoeken.
CONCLUSIE
De voor- en nadelen van borstkankerscreening verschillen tussen vrouwen en kunnen mo-
gelijk gerelateerd worden aan risicofactoren voor borstkanker. Screening met behulp van 
een risicoprofiel heeft daarom potentie als het de volgende factoren combineert: 1) borst-
kankerrisico (familiegeschiedenis, risicofactoren die bepalend zijn voor SES en borstdens-
iteit), 2) borstkarakteristieken die de kwaliteit van de screeningstest beïnvloeden (zoals 
borstdensiteit) en 3) persoonlijke factoren die de voor- en nadelen van screening niet via 
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risico beïnvloeden (zoals co-morbiditeit). Het is daarnaast noodzakelijk om overeenstem-
ming te krijgen over het schatten van het percentage overdiagnose voor zowel de huidige 
screeningsprogramma’s als voor toekomstige screening op basis van risicoprofielen. Op 
deze manier kan de balans tussen de voor- en nadelen van borstkankerscreening com-
pleet gemaakt worden. 
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gen lagen vaak onder de mijne en de zin ‘neem de tijd (voor jezelf)’ was jullie ook niet 
onbekend. Het heeft ervoor gezorgd dat ik relaxter ging werken en heeft uiteindelijk het 
resultaat, dit boekje, ook goed gedaan! 
André, ik heb genoten van jouw optimisme, jouw enthousiasme, het samen ‘hobbyen’, je 
‘relax and take it easy’-houding en je toegankelijkheid. Het is erg fijn om een promotor te 
hebben die methodologisch goed is onderlegd en je elke keer weer uitdaagt om het ‘sim-
pel’ te houden. Want ja, een proefschrift in 1,000 woorden beschrijven is soms moeilijker 
dan het honderdvoudige. Het zorgt ervoor dat je bij de kern komt. Bedankt daarvoor!
Mireille, ik ben onder de indruk hoeveel ballen jij tegelijk omhoog houdt en hoe goed je 
ook alles doet! Je hebt altijd een volle agenda, maar bent toch ook heel erg betrokken. Je 
las mijn stukken, gaf feedback en had ook altijd tijd om te praten als dat nodig was! Ik heb 
dat enorm gewaardeerd. Ik waardeer ook je doelgerichte, strategische en open houding: 
je hield de grote lijn in de gaten en gaf toegang tot je netwerk. Voor dit proefschrift is dat 
van onschatbare waarde geweest! Het bijzondere is dat je naast de grote lijnen ook op 
detail niveau meedacht. Bedankt voor je onuitputtelijke taalverbeteringen! Ik hoop dat ik 
ooit zelf een keer automatisch de bijvoeglijke naamwoorden en werkwoorden in de goede 
volgorde zet…
Mijn manuscriptcommissie – bestaande uit Evert van Leeuwen, Ellen Kampman en Sabine 
Siesling – wil ik ook (alvast) heel erg bedanken. Ik ben blij dat jullie in mijn manuscriptcom-
324 Appendices
missie vormen. Bedankt voor het doorlezen (en goedkeuren!) van dit boekje en het werk 
wat jullie nog zullen doen ter voorbereiding van mijn verdediging. Ik zie er naar uit! Evert 
van Leeuwen, jou wil ik graag in het bijzonder bedanken, omdat jij zowel inhoudelijk als 
persoonlijk betrokken bent geweest. Ik vond het heel fijn dat je mijn mentor was: bedankt 
voor je open houding, luisterende oren en goede adviezen. 
Een groep mensen die ik ook heel erg dankbaar ben zijn al mijn coauteurs! Jullie hebben 
enorm veel bijgedragen aan alle stukken in dit boekje: van het uitdenken van de eerste 
ideeën tot de puntjes op i. De eerste samenwerking begon al bij mijn eerste artikel. Het 
was een artikel vanuit de LETB. LETB-ers, bedankt dat jullie meedachten en ik aanwezig 
mocht zijn op de vergaderingen. Ik vond dit erg waardevol: ik kreeg beter beeld van het 
bevolkingsonderzoek naar borstkanker in Nederland en de zaken die speelden (maar niet 
op papier te lezen waren). 
Één van de grootste externe bijdragen – uitgedrukt in aantal artikelen – wordt gevormd 
door de ‘Rotterdammers’ (ook al woont misschien maar een enkeling daarvan daad-
werkelijk in Rotterdam). Ik vond het erg fijn om met jullie samen te werken. Ik heb jul-
lie werkhouding erg gewaardeerd: jullie zijn persoonlijk betrokken en inhoudelijk sterk. 
Bedankt daarvoor! Jacques, bedankt voor alle data die ik mocht gebruiken. Nicolien, be-
dankt  voor het fijne laagdrempelige contact, je meedenken en nuttige feedback. Jouw 
bijdrage is erg waardevol geweest voor een aantal stukken uit dit boekje: zonder jou bij-
drage zouden ze er óf niet zijn geweest óf in een inferieure staat. Kevin, jou heb ik relatief 
laat leren kennen, maar je bijdrage is desondanks groot geweest. Ik vond het fijn dat we 
samen naar Amerika konden en waardeer je snelle feedback en oog voor detail.
Daarnaast heeft Rebecca ook enorm veel bijgedragen! Ik ben Mireille nog steeds dank-
baar dat ze mij in contact bracht met Rebecca, nadat we een jaar hadden geploeterd 
met de cumulatieve kansen. Dear Rebecca, thank you for your statistical help and your 
patience. You are a wonderful teacher! I am really thankful for our effective communica-
tion (via e-mail) and all your statistical help. I am also thankful that you managed to write 
down our struggle in a nice article, which will hopefully help other researchers to calculate 
the cumulative risk of screening outcomes in an ‘easy’ and reliable manner.
Gelukkig zaten niet al mijn coauteurs ver weg. Waling, José, Marion en Pim van de eerste-
lijnsgeneeskunde wil ik ook erg bedanken voor hun bijdrage. Waling en José, het was fijn 
om met jullie samen te werken en samen uit te zoeken hoe we onze data ‘probalistisch’ 
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konden koppelen. Dit heeft geleid tot een waardevol anoniem dataset! Marion, ook be-
dankt voor jouw inhoudelijke bijdrage.
Last, but not least: de coauteurs van de screeningsgroep van de afdeling for Health Evi-
dence: Hans, Daniëlle en Linda. Het was gezellig, informeel, opbouwend en leerzaam. 
Bedankt daarvoor! Hans, dank je wel dat jij mij hebt ingewijd in de data en dat jouw deur 
altijd voor mijn vragen open stond! Je bent een man van detail! Daniëlle, waar zal ik eens 
beginnen met jou te bedanken? We begonnen ongeveer tegelijk aan onze promotie en 
hebben lang gelijk op gelopen. Jouw bijdrage aan dit boekje is ook meer geweest dan voor 
het oog zichtbaar is. Je hielp me als ik vast zat en even wilde sparren. Je dacht mee als 
ik na een dag nog steeds niet wist hoe ik mijn syntax moest schrijven. En soms (of moet 
ik zeggen vaak?) was het gewoon gezellig kletsen! Delen van vreugde/baal/verdriet-mo-
mentjes. Ik heb je oog voor detail, je goede methodologische basis en de precisie waar-
mee je werkt gewaardeerd. Bedankt voor alles wat je al hebt gedaan en nog gaat doen. Ik 
zie ernaar uit dat je naast me zal staan tijdens mijn verdediging als paranimf! Een ECHTE 
paranimf! En dat samen met Linda, nog zo’n echte paranimf. Linda, het is maf om te besef-
fen dat wij eigenlijk nog niet eens een jaar collega’s zijn geweest, want het voelt langer. Ik 
was erg blij met jouw werk als stagiaire (ja, echt!) en ik vond het ook erg leuk om met je 
samen te werken. Bedankt voor je open en dienstbare houding, de leuke gesprekken en 
natuurlijk je werk! Ik had je graag langer als collega willen hebben!
Ik mag mezelf gelukkig prijzen dat de screeningsgroep niet alleen uit onderzoekers be-
stond, maar ook uit een aantal toegewijde databeheerders: Erik, Monique (en ook Hans 
met zijn dubbelrol). Zonder jullie was veel van het onderzoek niet eens mogelijk geweest! 
Erik, bedankt dat ik af en toe gewoon met je mee mocht kijken en je werk mocht versto-
ren met vragen SAS- en datavragen. En als ik een databestandje nodig had, dan zorgde 
jij er altijd voor dat ik het in no-time had. Bedankt! En dan Monique, die veel data heeft 
bijgewerkt en ondertussen ook op mijn kleine irritante vragen heel liefdevol en geduldig 
antwoord gaf. Jij hebt zoveel meer gedaan dan ik heb kunnen zien en ik ben je daarvoor 
erg dankbaar! Het was leuk en gezellig om met je samen te werken.
Tja, dan denk je bijna aan het eind te zijn gekomen van alle mensen die inhoudelijk heb-
ben bijgedragen, maar niks is minder waar! Er zijn zoveel meer mensen geweest die on-
misbare rol hebben gespeeld in dit onderzoek en ik graag wil bedanken: de vrouwen, de 
screeningsorganisaties, de reviewers, de mensen met wie ik sprak op congressen (miss-
chien nog wel het meeste de ‘screeningsopponenten’) en vele anderen die ik omwille van 
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het leesplezier hier niet allemaal zal noemen. Bedankt allemaal!
En naast al die zichtbare bijdrages zijn er natuurlijk ook nog tal van mensen die onzichtbaar 
hebben bijgedragen aan dit boekje en mijn vorming als echte wetenschapper. Allereerst 
mijn kamergenoten. Ik begon ooit als groentje bij de toen net-gepromoveerde Marleen 
met d’r lekkere snoeppot. Vervolgens moest ik verhuizen en kwam ik bij Anne. Erg gezellig 
en leerzaam zo’n ‘oudere’ PhD-er. Gelukkig was ik toen degene die mocht blijven zitten 
en kwamen anderen bij mij op de kamer: Richelle, René en Tamara (gelukkig niet allemaal 
tegelijk!). Ik kan oprecht zeggen dat onze kamer de leukste en vrolijkste van de afdeling 
was: altijd versierd (en ik heb er bij deze weer een vlaggetje bij!!) met eigen bezittingen 
(is mijn naam al doorgekruist?). En als het kerst was hadden we onze eigen kersboom met 
een ‘zwarte pieten’-engel en kortsluiting. Het was feest! Ik ga dat zeker missen… Richelle, 
ik heb genoten van je gezelligheid en alle gekkigheid. Je bent echt super sociaal en staat 
voor mensen klaar, wat al heel snel leidde tot vele spontane bezoekjes van de halve afdel-
ing. In sommige opzichten zijn we echte tegenpolen, maar dat heeft mij goed gedaan. 
Ik heb veel van je kunnen leren. Bedankt en ik zal je missen! René, het was leuk (en ook 
handig) om je op onze kamer erbij te hebben, zodat Richelle met jou gek kon doen en ik 
rustig kon werken (gelukkig weet Richelle dat ze dit met een knipoog moet lezen). Ik heb 
je relaxte en behulpzame houding gewaardeerd! Hopelijk zul je nog wat langer op de 
afdeling rondlopen… En dan Tamara! Mijn laatste kamergenoot. Ik heb onze filosofische 
gesprekken erg leuk gevonden: wij waren volgens mij al binnen drie zinnen off-topic en 
konden daar nog wel uren over doorpraten als we niks moesten doen. Het was gezellig! 
Na twaalf namen van de afdeling verder te zijn heb ik er nog negentig (?) te gaan... Wim, 
bedankt voor je vriendelijke ‘goedemorgens’ en open deur voor SAS-vragen (‘omdat ik 
bij de groep van André zit’). Ton en Rogier, bedankt voor jullie statistische hulp. Sandra, 
bedankt dat je zoveel van jouw PhD-ervaring en documenten met me deelde. Jacqueline, 
bedankt voor de leuke gesprekken en het feit dat ik in jou een mede-mama-promovendus 
had. Alina, bedankt voor de gezellige treinreizen die helaas ophielden na jullie verhuizing. 
Peep, bedankt voor je aanwezigheid bij de RIP-meetings, je feedback, de gesprekken en 
de mails. Bart, bedankt voor … Nee, ik zal het niemand aandoen om al mijn afdelingsge-
noten persoonlijk te bedanken. Bij deze wil ik al mijn slimme, leuke, interessante, sociale, 
lieve en gedreven collega’s bedanken. Het was mij een waar genoegen.
En nu hoor ik ook nog alle vrienden en familieleden te noemen die van de zijlijn meekek-
en en mij regelmatig vroegen hoe het met mijn PhD (of simpel: werk) ging. Ik ben blij 
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dat jullie er waren en nog zijn! Het is zeker geen straf om jullie te mogen noemen in dit 
dankwoord! Jullie belangstelling heeft me erg goed gedaan en onze gesprekken maakten 
soms dat ik alles even in een ander licht ging zien. Daarnaast heb ik het ook als een groot 
voordeel ervaren dat ik werkte aan een onderwerp waar de meesten van jullie direct of 
indirect mee te maken hadden. Door jullie persoonlijke ervaring en vragen met mij te 
delen ging ik breder nadenken. En gelukkig, gingen onze gespreken niet alleen over dit 
boekje, maar ook over hele andere levenszaken! Bedankt (schoon)familie, Vineyard-ers, 
Eldad-ers, Ichthianen, reisgenoten en een ieder die niet onder één van deze groepen thuis 
valt maar zich wel aangesproken voelt. 
De directe familie wil ik nog in het bijzonder bedanken. Schoonfamilie, wat ben ik blij dat 
jullie onderdeel van mijn leven zijn en ik daardoor nog wat meer promoverende fami-
lieleden heb. Al ligt dit volgens Florian aan de ‘slimme’ aanhang. Iets waar ik overigens 
anders over denk. En dan mijn eigen ouders, broer en zusje. Papa en mama: bedankt dat 
jullie er altijd voor ons zijn! (iets wat overigens ook voor mijn schoonouders geldt). Ik ben 
zo dankbaar dat jullie te hulp schieten als het nodig is en de kinderen regelmatig bij jullie 
mogen logeren (wat ze overigens geweldig vinden!). Het heeft ons en dit boekje (hele-
maal de laatste loodjes) erg goed gedaan! En broer, bedankt voor de mooie voorkant van 
dit boekje! Je hebt het weer voor elkaar: jouw uitwerking is altijd mooier dan het originele 
idee! En zus(je), jij ook bedankt!!
Een dankwoord van een proefschrift wordt vrijwel altijd geëindigd met het bedanken van 
het thuisfront. Ik vraag me altijd af of dat komt doordat deze groep het minste heeft bi-
jgedragen. Dat is sowieso niet het geval voor mijn thuisfront. Florian, jij hebt enorm veel 
bijgedragen: jij verbeterde mijn eerste tekst, je herschreef een formule voor me (want 
daar zijn de Hoeves nou eenmaal beter in), jij haalde me op van Schiphol, jij zorgde goed 
voor de kinderen, jij ruimde het huis op als ik ’s avond moe was, jij masseerde mijn ges-
pannen schouders… kortom: je was er voor mij en de kinderen! Ik hou van je! En Rachel, 
Jefta, Salomé en Kaleb: jullie zorgden voor de nodige afleiding, vreugde, gezelligheid en 
liefde. Jullie zijn elk een ‘twinkle in my eye’ en ik geniet ervan om nu meer tijd met jullie 
door te brengen. 
Bedankt!
- Dorien 
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Towards Risk-Based 
Benefits and Harms
Benefits and harm
s
In virtually all European mammographic screening programs, age is the only risk factor to 
deﬁne the target group for population-based mammographic screening programs. This is 
also true for the Netherlands, where women aged 50 to 75 are invited for biennial mammo-
graphic screening. Age is one of the strongest risk factors for breast cancer, but not the only 
risk factor. Incorporation of additional risk factors to deﬁne and stratify the target group can 
potentially optimize breast cancer screening: more beneﬁts with less or the same harms. 
During her doctoral research Theodora Maria Ripping evaluated the beneﬁts and harms of 
mammographic screening stratiﬁed for multiple risk factors: socio-economic status (SES), 
family history of breast cancer, co-morbidity and breast density. In this thesis, she shows that 
the investigated risk factors aﬀect the risk of averting breast cancer death (beneﬁt) and/or 
the risk of false-positive screening outcomes and interval cancer (harms). Furthermore, she 
presents her search for the optimal method to quantify the extent of overdiagnosis and to 
express the percentage of overdiagnosis. 
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